Doneer nu
Alzheimercentrum Amsterdam

Publicaties

Via het overzicht hiernaast kunt u door de wetenschappelijke publicaties van het Alzheimercentrum zoeken.

Publicaties 2019

  1. Albani D, Marizzoni M, Ferrari C, Fusco F, Boeri L, Raimondi I, Jovicich J, Babiloni C, Soricelli A, Lizio R, Galluzzi S, Cavaliere L, Didic M, Schönknecht P, Molinuevo JL, Nobili F, Parnetti L, Payoux P, Bocchio L, Salvatore M, Rossini PM, Tsolaki M, Visser PJ, Richardson JC, Wiltfang J, Bordet R, Blin O, Forloni G, Frisoni GB; PharmaCog Consortium. Plasma Aβ42 as a Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. J Alzheimers Dis. 2019;69(1):37-48. doi: 10.3233/JAD-180321. PubMed PMID: 30149449.
  2. Altomare D, Ferrari C, Caroli A, Galluzzi S, Prestia A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen CE, Wall A, Carter SF, Schöll M, Choo ILH, Grimmer T, Redolfi A, Nordberg A, Scheltens P, Drzezga A, Frisoni GB; Alzheimer’s Disease Neuroimaging Initiative. Prognostic value of Alzheimer’s  biomarkers in mild cognitive impairment: the effect of age at onset. J Neurol. 2019 Jul 2. doi: 10.1007/s00415-019-09441-7. PubMed PMID: 31267207.
  3. Babapour Mofrad R, van der Flier WM. Nature and implications of seks differences in AD pathology. Nat Rev Neurol. 2019 Jan;15(1):6-8. doi: 10.1038/s41582-018-0115-7. PubMed PMID: 30542072.
  4. Babapour Mofrad R, Visser LNC, Fruijtier AD, Scheltens P, Smets EEMA, van der Flier WM, Teunissen CE. Cerebrospinal fluid collection: An informative animation  video for patients and caregivers. Alzheimers Dement (Amst). 2019 Jun 12;11:435-438. doi: 10.1016/j.dadm.2019.04.005. eCollection 2019 Dec. PubMed PMID: 31211216; PubMed Central PMCID: PMC6562320.
  5. Babapour Mofrad R, Schoonenboom NSM, Tijms BM, Scheltens P, Visser PJ, van der Flier WM, Teunissen CE. Decision tree supports the interpretation of CSF biomarkers in Alzheimer’s disease. Alzheimers Dement (Amst). 2018 Nov 12;11:1-9.  doi: 10.1016/j.dadm.2018.10.004. eCollection 2019 Dec. PubMed PMID: 30569013; PubMed Central PMCID: PMC6287084.
  6. Beker N, Sikkes SAM, Hulsman M, Schmand B, Scheltens P, Holstege H. Neuropsychological Test Performance of Cognitively Healthy Centenarians: Normative Data From the Dutch 100-Plus Study. J Am Geriatr Soc. 2019 Apr;67(4):759-767. doi: 10.1111/jgs.15729. Epub 2018 Dec 27. PubMed PMID: 30592018.
  7. Boelaarts L, Meyer SRA, Scheltens P, de Jonghe JFM. Testing Episodic Memory in Elderly Subjects: Not as Simple as It Looks. Dement Geriatr Cogn Dis Extra. 2019  Jun 18;9(2):207-216. doi: 10.1159/000499836. eCollection 2019 May-Aug. PubMed PMID: 31275346; PubMed Central PMCID: PMC6600035.
  8. Boomsma JMF, Exalto LG, Barkhof F, van den Berg E, de Bresser J, Heinen R, Leeuwis AE, Prins ND, Scheltens P, Weinstein HC, van der Flier WM, Biessels GJ; behalf of the TRACE-VCI study group. How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study. J  Alzheimers Dis. 2019;68(3):1273-1286. doi: 10.3233/JAD-180696. PubMed PMID: 30909212.
  9. Bos I, Vos SJB, Schindler SE, Hassenstab J, Xiong C, Grant E, Verhey F, Morris JC, Visser PJ, Fagan AM. Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer’s disease. Alzheimers Dement. 2019 Aug 1. pii: S1552-5260(19)30122-0. doi: 10.1016/j.jalz.2019.04.015. PubMed PMID: 31378575.
  10. Bos I, Vos S, Verhey F, Scheltens P, Teunissen C, Engelborghs S, Sleegers K, Frisoni G, Blin O, Richardson JC, Bordet R, Tsolaki M, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Lleó A, Johannsen P, Freund-Levi Y, Frölich L, Vandenberghe R, Westwood S, Dobricic V, Barkhof F, Legido-Quigley C, Bertram L, Lovestone S, Streffer J, Andreasson U, Blennow K, Zetterberg H, Visser PJ. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer’s disease spectrum. Alzheimers Dement. 2019 May;15(5):644-654. doi: 10.1016/j.jalz.2019.01.004. Epub  2019 Mar 8. PubMed PMID: 30853464.
  11. Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL  Group, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig  S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild  EJ. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurol. 2019 Jun 17. doi:  10.1001/jamaneurol.2019.1534. PubMed PMID: 31206160; PubMed Central PMCID: PMC6580449.
  12. Brugnolo A, De Carli F, Pagani M, Morbelli S, Jonsson C, Chincarini A, Frisoni GB, Galluzzi S, Perneczky R, Drzezga A, van Berckel BNM, Ossenkoppele R, Didic M, Guedj E, Arnaldi D, Massa F, Grazzini M, Pardini M, Mecocci P, Dottorini ME, Bauckneht M, Sambuceti G, Nobili F. Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer’s Disease. J Alzheimers Dis. 2019;68(1):383-394. doi: 10.3233/JAD-181022. PubMed PMID: 30776000.
  13. Bruun M, Frederiksen KS, Rhodius-Meester HFM, Baroni M, Gjerum L, Koikkalainen J, Urhemaa T, Tolonen A, van Gils M, Rueckert D, Dyremose N, Andersen BB, Lemstra AW, Hallikainen M, Kurl S, Herukka SK, Remes AM, Waldemar G, Soininen H, Mecocci  P, van der Flier WM, Lötjönen J, Hasselbalch SG. Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective  validation study. Alzheimers Res Ther. 2019 Mar 20;11(1):25. doi:10.1186/s13195-019-0482-3. PubMed PMID: 30894218; PubMed Central PMCID: PMC6425602.
  14. Bruun M, Koikkalainen J, Rhodius-Meester HFM, Baroni M, Gjerum L, van Gils M, Soininen H, Remes AM, Hartikainen P, Waldemar G, Mecocci P, Barkhof F, Pijnenburg Y, van der Flier WM, Hasselbalch SG, Lötjönen J, Frederiksen KS. Detecting frontotemporal dementia syndromes using MRI biomarkers. Neuroimage Clin. 2019;22:101711. doi: 10.1016/j.nicl.2019.101711. Epub 2019 Feb 4. PubMed PMID: 30743135; PubMed Central PMCID: PMC6369219.
  15. Bruun M, Frederiksen KS, Rhodius-Meester HFM, Baroni M, Gjerum L, Koikkalainen J, Urhemaa T, Tolonen A, van Gils M, Tong T, Guerrero R, Rueckert D, Dyremose N, Andersen BB, Simonsen AH, Lemstra A, Hallikainen M, Kurl S, Herukka SK, Remes AM, Waldemar G, Soininen H, Mecocci P, van der Flier WM, Lötjönen J, Hasselbalch SG. Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study. Curr Alzheimer Res. 2019;16(2):91-101. doi: 10.2174/1567205016666190103152425. PubMed PMID: 30605060.
  16. Cha, D.S., Carmona, N.E., Cha, R.H., Zhou, A.J., Subramanipillai, M., Mansur, R.B., Lee, Y., Le, J.H., Lee, J.G., Alageel, A., Rosenblat, J.D., Shekotikhina, M., Rong, C., Harrison, J.E., McIntyre, R.S. Perceived sleep quality predicts cognitive function in adults with major depressive disorder independent of depression severity. Annals of Clinical Psychiatry. 2019:31(1):17-26.
  17. Collij LE, Konijnenberg E, Reimand J, Kate MT, Braber AD, Alves IL, Zwan M, Yaqub M, van Assema DME, Wink AM, Lammertsma AA, Scheltens P, Visser PJ, Barkhof  F, van Berckel BNM. Assessing Amyloid Pathology in Cognitively Normal Subjects Using (18)F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. J  Nucl Med. 2019 Apr;60(4):541-547. doi: 10.2967/jnumed.118.211532. Epub 2018 Oct 12. PubMed PMID: 30315145; PubMed Central PMCID: PMC6448465.
  18. Collorone S, Prados F, Hagens MH, Tur C, Kanber B, Sudre CH, Lukas C, Gasperini C, Oreja-Guevara C, Andelova M, Ciccarelli O, Wattjes MP, Ourselin S, Altmann DR, Tijms BM, Barkhof F, Toosy AT; MAGNIMS Study Group. Single-subject structural cortical networks in clinically isolated syndrome. Mult Scler. 2019 Jul 24:1352458519865739. doi: 10.1177/1352458519865739. PubMed PMID: 31339446.
  19. den Haan J, Csinscik L, Parker T, Paterson RW, Slattery CF, Foulkes A, Bouwman FH, Verbraak FD, Scheltens P, Peto T, Lengyel I, Schott JM, Crutch SJ, Shakespeare TJ, Yong KXX. Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer’s disease. Alzheimers Res Ther. 2019 Jul 18;11(1):62. doi: 10.1186/s13195-019-0516-x. PubMed PMID: 31319885; PubMed Central PMCID: PMC6639972.
  20. Dicks E, Vermunt L, van der Flier WM, Visser PJ, Barkhof F, Scheltens P, Tijms BM; Alzheimer’s Disease Neuroimaging Initiative. Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer’s disease. Neuroimage Clin. 2019;22:101786. doi: 10.1016/j.nicl.2019.101786. Epub 2019 Mar 19. PubMed PMID: 30921610; PubMed Central PMCID: PMC6439228.
  21. Doorduijn AS, Visser M, van de Rest O, Kester MI, de Leeuw FA, Boesveldt S, Fieldhouse JLP, van den Heuvel EGHM, Teunissen CE, Scheltens P, van der Flier WM, de van der Schueren MAE. Associations of AD Biomarkers and Cognitive Performance  with Nutritional Status: The NUDAD Project. Nutrients. 2019 May 23;11(5). pii: E1161. doi: 10.3390/nu11051161. PubMed PMID: 31126170; PubMed Central PMCID: PMC6566264.
  22. Doorduijn AS, van de Rest O, van der Flier WM, Visser M, de van der Schueren MAE. Energy and Protein Intake of Alzheimer’s Disease Patients Compared to Cognitively Normal Controls: Systematic Review. J Am Med Dir Assoc. 2019 Jan;20(1):14-21. doi: 10.1016/j.jamda.2018.06.019. Epub 2018 Aug 9. Review. PubMed PMID: 30100233.
  23. Eikelboom WS, Singleton E, van den Berg E, Coesmans M, Mattace Raso F, van Bruchem RL, Goudzwaard JA, de Jong FJ, Koopmanschap M, den Heijer T, Driesen JJM, Vroegindeweij LJHM, Thomeer EC, Hoogers SE, Dijkstra AA, Zuidema SU, Pijnenburg YAL, Scheltens P, van Swieten JC, Ossenkoppele R, Papma JM. Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer’s disease: protocol of the BEAT-IT study. Alzheimers Res Ther. 2019 May 24;11(1):48. doi: 10.1186/s13195-019-0503-2. PubMed PMID: 31122267; PubMedCentral PMCID: PMC6533693.
  24. Fathy YY, Hoogers SE, Berendse HW, van der Werf YD, Visser PJ, de Jong FJ, van de Berg WDJ. Differential insular cortex sub-regional atrophy in neurodegenerative diseases: a systematic review and meta-analysis. Brain Imaging  Behav. 2019 Apr 23. doi: 10.1007/s11682-019-00099-3. Review. PubMed PMID: 31011951.
  25. Femminella, G.D., Harrison, J.E. et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study). BMC Trials. 2019; 20:191.
  26. Ferro DA, van den Brink H, Exalto LG, Boomsma JMF, Barkhof F, Prins ND, van der Flier WM, Biessels GJ; TRACE-VCI study group. Clinical relevance of acute  cerebral microinfarcts in vascular cognitive impairment. Neurology. 2019 Apr 2;92(14):e1558-e1566. doi: 10.1212/WNL.0000000000007250. Epub 2019 Mar 8. PubMed  PMID: 30850444.
  27. Fredericks CA, Brown JA, Deng J, Kramer A, Ossenkoppele R, Rankin K, Kramer JH, Miller BL, Rabinovici GD, Seeley WW. Intrinsic connectivity networks in posterior cortical atrophy: A role for the pulvinar? Neuroimage Clin. 2019;21:101628. doi: 10.1016/j.nicl.2018.101628. Epub 2018 Dec 3. PubMed PMID: 30528957; PubMed Central PMCID: PMC6411779.
  28. Frisoni GB, Barkhof F, Altomare D, Berkhof J, Boccardi M, Canzoneri E, Collij L, Drzezga A, Farrar G, Garibotto V, Gismondi R, Gispert JD, Jessen F, Kivipelto  M, Lopes Alves I, Molinuevo JL, Nordberg A, Payoux P, Ritchie C, Savicheva I, Scheltens P, Schmidt ME, Schott JM, Stephens A, van Berckel B, Vellas B, Walker Z, Raffa N. AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimers Dement. 2019 Mar;15(3):388-399. doi: 10.1016/j.jalz.2018.09.003. Epub 2018 Oct 16. PubMed PMID: 30339801.
  29. Fuermaier ABM, Piersma D, de Waard D, Davidse RJ, de Groot J, Doumen MJA, Bredewoud RA, Claesen R, Lemstra AW, Scheltens P, Vermeeren A, Ponds R, Verhey F, De Deyn PP, Brouwer WH, Tucha O. Driving Difficulties Among Patients with Alzheimer’s Disease and Other Neurodegenerative Disorders. J Alzheimers Dis. 2019;69(4):1019-1030. doi: 10.3233/JAD-181095. PubMed PMID: 31045516.
  30. Gallacher J, de Reydet de Vulpillieres F, Amzal B, Angehrn Z, Bexelius C, Bintener C, Bouvy JC, Campo L, Diaz C, Georges J, Gray A, Hottgenroth A, Jonsson  P, Mittelstadt B, Potashman MH, Reed C, Sudlow C, Thompson R, Tockhorn-Heidenreich A, Turner A, van der Lei J, Visser PJ; ROADMAP Consortium. Challenges for Optimizing Real-World Evidence in Alzheimer’s Disease: The ROADMAP Project. J Alzheimers Dis. 2019;67(2):495-501. doi: 10.3233/JAD-180370. PubMed PMID: 30584137; PubMed Central PMCID: PMC6398537.
  31. Gami-Patel P, van Dijken I, van Swieten JC, Pijnenburg YAL; Netherlands Brain Bank, Rozemuller AJM, Hoozemans JJM, Dijkstra AA. Von Economo neurons are part of a larger neuronal population that are selectively vulnerable in C9orf72 frontotemporal dementia. Neuropathol Appl Neurobiol. 2019 May 7. doi: 10.1111/nan.12558. Review. PubMed PMID: 31066065.
  32. Gardiner SL, Harder AVE, Campman YJM, Trompet S, Gussekloo J, van Belzen MJ, Boogaard MW, Roos RAC, Jansen IE, Pijnenburg YAL, Scheltens P, van der Flier WM, Aziz NA. Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer’s disease. Neurobiol Aging. 2019 Jan;73:230.e9-230.e17. doi: 10.1016/j.neurobiolaging.2018.09.007. Epub 2018 Sep 15. PubMed PMID: 30314815.
  33. Gerritsen AAJ, Bakker C, Verhey FRJ, Pijnenburg YAL, Millenaar JK, de Vugt ME, Koopmans RTCM. Survival and life-expectancy in a young-onset dementia cohort with six years of follow-up: the NeedYD-study. Int Psychogeriatr. 2019 Mar 27:1-9. doi: 10.1017/S1041610219000152. PubMed PMID: 30915930.
  34. Gossink FT, Vijverberg E, Krudop W, Scheltens P, Stek ML, Pijnenburg YAL, Dols A. Predicting progression in the late onset frontal lobe syndrome. Int Psychogeriatr. 2019 May;31(5):743-748. doi: 10.1017/S1041610218001242. Epub 2018 Oct 26. PubMed PMID: 30362933.
  35. Groeneveld ON, Moneti C, Heinen R, de Bresser J, Kuijf HJ, Exalto LG, Boomsma JMF, Kappelle LJ, Barkhof F, Prins ND, Scheltens P, van der Flier WM, Biessels GJ; TRACE-VCI study group. The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. J Alzheimers Dis. 2019;68(1):311-322. doi: 10.3233/JAD-180914. PubMed PMID: 30775988.
  36. Gruters AAA, Ramakers IHGB, Kessels RPC, Bouwman FH, Olde Rikkert MGM, Blom MM, de Vugt ME, Verhey FRJ. Development of memory clinics in the Netherlands over the last 20 years. Int J Geriatr Psychiatry. 2019 Aug;34(8):1267-1274. doi: 10.1002/gps.5132. Epub 2019 May 20. PubMed PMID: 31034652.
  37. Haaksma ML, Rizzuto D, Ramakers IHGB, Garcia-Ptacek S, Marengoni A, van der Flier WM, Verhey FRJ, Olde Rikkert MGM, Melis RJF. The Impact of Frailty and Comorbidity on Institutionalization and Mortality in Persons With Dementia: A Prospective Cohort Study. J Am Med Dir Assoc. 2019 Feb;20(2):165-170.e2. doi: 10.1016/j.jamda.2018.06.020. Epub 2018 Aug 23. PubMed PMID: 30145169.
  38. Haan JD, van de Kreeke JA, Konijnenberg E, Kate MT, Braber AD, Barkhof F, van Berckel BN, Teunissen CE, Scheltens P, Visser PJ, Verbraak FD, Bouwman FH. Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer’s disease. Alzheimers Dement (Amst). 2019 Jun 18;11:463-471. doi: 10.1016/j.dadm.2019.05.002. eCollection 2019 Dec. PubMed PMID: 31249859; PubMed Central PMCID: PMC6584766.
  39. Haan JD, van de Kreeke JA, van Berckel BN, Barkhof F, Teunissen CE, Scheltens P, Verbraak FD, Bouwman FH. Is retinal vasculature a biomarker in amyloid proven  Alzheimer’s disease? Alzheimers Dement (Amst). 2019 May 10;11:383-391. doi: 10.1016/j.dadm.2019.03.006. eCollection 2019 Dec. PubMed PMID: 31193094; PubMed Central PMCID: PMC6517376.
  40. Hahn A, Strandberg TO, Stomrud E, Nilsson M, van Westen D, Palmqvist S, Ossenkoppele R, Hansson O. Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. Cereb Cortex. 2019 May 1;29(5):2173-2182. doi: 10.1093/cercor/bhz020. PubMed PMID: 30877785; PubMed Central PMCID: PMC6458901.
  41. Harrison, J.E., (2019) The assessment of cognitive dysfunction in Major Depressive Disorder. In Baune, B. & Harmer, C. (eds) Cognitive Dimensions of Major Depressive Disorder (Oxford, Oxford University Press).
  42. Harrison, J.E. Screening and measurement of cognitive impairment in psychiatry. CNS Spectrums (Special edition): ‘Cognition in Psychiatry – A Transdiagnostic Phenomenological Domain’. 2019:24(1):144-153. https://doi.org/10.1017/S1092852918001657.
  43. Harrison, J.E. & Hendrix, S. (2019) The assessment of cognition in translational medicine: A contrast between the approaches used in Alzheimer’s disease and Major Depressive Disorder. In Nomikos, G., (ed.) Translational Medicine in CNS Drug Development: Handbook of Behavioral Neuroscience, volume 25 (Elsevier, Amsterdam):297-308.
  44. Hooghiemstra AM, Wesselman LMP, Franken L, van der Flier WM, Lemstra AW. Een interactieve website voor Alzheimercentrum Amsterdam: Wat vindt de gebruiker? Alzheimercentrum Amsterdam 2019; http://bit.ly/hooghiemstra2019.
  45. Hu X, Teunissen CE, Spottke A, Heneka MT, Düzel E, Peters O, Li S, Priller J, Buerger K, Teipel S, Laske C, Verfaillie SCJ, Barkhof F, Coll-Padrós N, Rami L, Molinuevo JL, van der Flier WM, Jessen F. Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer’s disease-Data from three memory clinic studies. Alzheimers Dement. 2019 Feb;15 (2):185-193. doi: 10.1016/j.jalz.2018.09.002. Epub 2018 Oct 12. PubMed PMID: 30321506.
  46. Jagust W, Jack CR Jr, Bennett DA, Blennow K, Haeberlein SB, Holtzman DM, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe  CC, Scheltens P, Siemers E, Sperling R. “Alzheimer’s disease” is neither “Alzheimer’s clinical syndrome” nor “dementia”. Alzheimers Dement. 2019 Jan;15(1):153-157. doi: 10.1016/j.jalz.2018.11.002. PubMed PMID: 30642435.
  47. Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, Sealock J, Karlsson IK, Hägg S, Athanasiu L, Voyle N, Proitsi P, Witoelar A, Stringer S,  Aarsland D, Almdahl IS, Andersen F, Bergh S, Bettella F, Bjornsson S, Brækhus A,  Bråthen G, de Leeuw C, Desikan RS, Djurovic S, Dumitrescu L, Fladby T, Hohman TJ, Jonsson PV, Kiddle SJ, Rongve A, Saltvedt I, Sando SB, Selbæk G, Shoai M, Skene NG, Snaedal J, Stordal E, Ulstein ID, Wang Y, White LR, Hardy J, Hjerling-Leffler J, Sullivan PF, van der Flier WM, Dobson R, Davis LK, Stefansson H, Stefansson K, Pedersen NL, Ripke S, Andreassen OA, Posthuma D. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat Genet. 2019 Mar;51(3):404-413. doi: 10.1038/s41588-018-0311-9. Epub 2019 Jan  7. PubMed PMID: 30617256.
  48. Jovicich J, Babiloni C, Ferrari C, Marizzoni M, Moretti DV, Del Percio C, Lizio R, Lopez S, Galluzzi S, Albani D, Cavaliere L, Minati L, Didic M, Fiedler U, Forloni G, Hensch T, Molinuevo JL, Bartrés Faz D, Nobili F, Orlandi D, Parnetti L, Farotti L, Costa C, Payoux P, Rossini PM, Marra C, Schönknecht P, Soricelli A, Noce G, Salvatore M, Tsolaki M, Visser PJ, Richardson JC, Wiltfang J, Bordet R, Blin O, Frisoniand GB; and the PharmaCog Consortium. Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. J Alzheimers Dis. 2019;69(1):15-35. doi: 10.3233/JAD-180158. PubMed PMID: 30400088.
  49. Jutten RJ, Harrison JE, Lee Meeuw Kjoe PR, Ingala S, Vreeswijk R, van Deelen  RAJ, de Jong FJ, Opmeer EM, Aleman A, Ritchie CW, Scheltens P, Sikkes SAM. Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort. Alzheimers Res Ther. 2019 May 15;11(1):45. doi: 10.1186/s13195-019-0500-5. PubMed PMID: 31092277; PubMed Central PMCID: PMC6521452.
  50. Jutten RJ, Dicks E, Vermaat L, Barkhof F, Scheltens P, Tijms BM, Sikkes SAM.  Impairment in complex activities of daily living is related to neurodegeneration  in Alzheimer’s disease-specific regions. Neurobiol Aging. 2019 Mar;75:109-116. doi: 10.1016/j.neurobiolaging.2018.11.018. Epub 2018 Nov 26. PubMed PMID: 30557769.
  51. Kenkhuis B, Jonkman LE, Bulk M, Buijs M, Boon BDC, Bouwman FH, Geurts JJG, van de Berg WDJ, van der Weerd L. 7T MRI allows detection of disturbed cortical lamination of the medial temporal lobe in patients with Alzheimer’s disease. Neuroimage Clin. 2019;21:101665. doi: 10.1016/j.nicl.2019.101665. Epub 2019 Jan PubMed PMID: 30642758; PubMed Central PMCID: PMC6413344.
  52. Kim M, Snowden S, Suvitaival T, Ali A, Merkler DJ, Ahmad T, Westwood S, Baird A, Proitsi P, Nevado-Holgado A, Hye A, Bos I, Vos S, Vandenberghe R, Teunissen C, Ten Kate M, Scheltens P, Gabel S, Meersmans K, Blin O, Richardson J, De Roeck E,  Sleegers K, Bordet R, Rami L, Kettunen P, Tsolaki M, Verhey F, Sala I, Lléo A, Peyratout G, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Engelborghs S, Frisoni GB, Molinuevo JL, Wallin A, Popp J, Martinez-Lage P, Bertram L, Barkhof F, Ashton N, Blennow K, Zetterberg H, Streffer J, Visser PJ, Lovestone S, Legido-Quigley C. Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort. Alzheimers Dement. 2019 Jun;15(6):817-827. doi: 10.1016/j.jalz.2019.03.004. Epub 2019 May 8. PubMed PMID: 31078433.
  53. Kleipool EEF, Trappenburg MC, Rhodius-Meester HFM, Lemstra AW, van der Flier  WM, Peters MJL, Muller M. Orthostatic Hypotension: An Important Risk Factor for Clinical Progression to Mild Cognitive Impairment or Dementia. The Amsterdam Dementia Cohort. J Alzheimers Dis. 2019 Jul 27. doi: 10.3233/JAD-190402. PubMed PMID: 31381517.
  54. Koikkalainen JR, Rhodius-Meester HFM, Frederiksen KS, Bruun M, Hasselbalch SG, Baroni M, Mecocci P, Vanninen R, Remes A, Soininen H, van Gils M, van der Flier WM, Scheltens P, Barkhof F, Erkinjuntti T, Lötjönen JMP; Alzheimer’s Disease Neuroimaging Initiative. Automatically computed rating scales from MRI for patients with cognitive disorders. Eur Radiol. 2019 Sep;29(9):4937-4947. doi: 10.1007/s00330-019-06067-1. Epub 2019 Feb 22. PubMed PMID: 30796570.
  55. Konijnenberg E, den Braber A, Ten Kate M, Tomassen J, Mulder SD, Yaqub M, Teunissen CE, Lammertsma AA, van Berckel BNM, Scheltens P, Boomsma DI, Visser PJ. Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. Neurobiol Aging. 2019 May;77:58-65. doi: 10.1016/j.neurobiolaging.2019.01.006. Epub 2019 Jan 21. PubMed PMID: 30784813.
  56. Leeuwis AE, Weaver NA, Biesbroek JM, Exalto LG, Kuijf HJ, Hooghiemstra AM, Prins ND, Scheltens P, Barkhof F, van der Flier WM, Biessels GJ; TRACE-VCI study  group. Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion–symptom mapping study. J Psychiatry Neurosci. 2019 Jul 1;44(4):E1-E10. PubMed PMID: 31021068; PubMed Central PMCID: PMC6606429.
  57. Legdeur N, van der Lee SJ, de Wilde M, van der Lei J, Muller M, Maier AB, Visser PJ. The association of vascular disorders with incident dementia in different age groups. Alzheimers Res Ther. 2019 May 17;11(1):47. doi: 10.1186/s13195-019-0496-x. PubMed PMID: 31097030; PubMed Central PMCID: PMC6524321.
  58. Legdeur N, Visser PJ, Woodworth DC, Muller M, Fletcher E, Maillard P, Scheltens P, DeCarli C, Kawas CH, Corrada MM. White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study. J Am Geriatr Soc. 2019 Jun 6. doi: 10.1111/jgs.15990. PubMed PMID: 31169919.
  59. Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P, Scheltens P, Poirier J, Saftig P, Bateman RJ, Breitner J, Hock C, Multhaup G. Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression. Nat Commun. 2019 May 20;10(1):2240. doi: 10.1038/s41467-019-10152-w. PubMed PMID: 31110178; PubMed Central PMCID: PMC6527709.
  60. Linszen MMJ, van Zanten GA, Teunisse RJ, Brouwer RM, Scheltens P, Sommer IE.  Auditory hallucinations in adults with hearing impairment: a large prevalence study. Psychol Med. 2019 Jan;49(1):132-139. doi: 10.1017/S0033291718000594. Epub  2018 Mar 20. PubMed PMID: 29554989.
  61. Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, Tainta M, Izaguirre A, Reijs BLR, Farotti L, Tsolaki M, Vandenbergue R, Freund-Levi Y, Verhey FRJ, Clarimón J, Fortea J, Frolich L, Santana I, Molinuevo JL, Lehmann S, Visser PJ, Teunissen CE, Zetterberg H, Blennow K. Longitudinal cerebrospinal fluid biomarker trajectories  along the Alzheimer’s disease continuum in the BIOMARKAPD study. Alzheimers Dement. 2019 Jun;15(6):742-753. doi: 10.1016/j.jalz.2019.01.015. Epub 2019 Apr 6. PubMed PMID: 30967340.
  62. Marizzoni M, Ferrari C, Jovicich J, Albani D, Babiloni C, Cavaliere L, Didic  M, Forloni G, Galluzzi S, Hoffmann KT, Molinuevo JL, Nobili F, Parnetti L, Payoux P, Ribaldi F, Rossini PM, Schönknecht P, Salvatore M, Soricelli A, Hensch T, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB; PharmaCog Consortium. Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease: Structural Brain Biomarkers. J Alzheimers Dis. 2019;69(1):3-14. doi: 10.3233/JAD-180152. PubMed PMID: 29914031.
  63. Marizzoni M, Ferrari C, Macis A, Jovicich J, Albani D, Babiloni C, Cavaliere L, Didic M, Forloni G, Galluzzi S, Hoffmann KT, Molinuevo JL, Nobili F, Parnetti  L, Payoux P, Pizzini F, Rossini PM, Salvatore M, Schönknecht P, Soricelli A, Del  Percio C, Hensch T, Hegerl U, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB; PharmaCog Consortium. Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease. J Alzheimers Dis. 2019;69(1):49-58. doi: 10.3233/JAD-181016. PubMed PMID: 30958351.
  64. Mattsson N, Insel PS, Donohue M, Jögi J, Ossenkoppele R, Olsson T, Schöll M, Smith R, Hansson O. Predicting diagnosis and cognition with (18)F-AV-1451 tau PET and structural MRI in Alzheimer’s disease. Alzheimers Dement. 2019 Apr;15(4):570-580. doi: 10.1016/j.jalz.2018.12.001. Epub 2019 Jan 25. PubMed PMID: 30639421.
  65. Meeter LHH, Steketee RME, Salkovic D, Vos ME, Grossman M, McMillan CT, Irwin DJ, Boxer AL, Rojas JC, Olney NT, Karydas A, Miller BL, Pijnenburg YAL, Barkhof F, Sánchez-Valle R, Lladó A, Borrego-Ecija S, Diehl-Schmid J, Grimmer T, Goldhardt O, Santillo AF, Hansson O, Vestberg S, Borroni B, Padovani A, Galimberti D, Scarpini E, Rohrer JD, Woollacott IOC, Synofzik M, Wilke C, de Mendonca A, Vandenberghe R, Benussi L, Ghidoni R, Binetti G, Niessen WJ, Papma JM, Seelaar H, Jiskoot LC, de Jong FJ, Donker Kaat L, Del Campo M, Teunissen CE, Bron EE, Van den Berg E, Van Swieten JC. Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. J Neurol Neurosurg Psychiatry. 2019 May 2. pii: jnnp-2018-319784. doi: 10.1136/jnnp-2018-319784. PubMed PMID: 31123142.
  66. Morgan AR, Touchard S, Leckey C, O’Hagan C, Nevado-Holgado AJ; NIMA Consortium, Barkhof F, Bertram L, Blin O, Bos I, Dobricic V, Engelborghs S, Frisoni G, Frölich L, Gabel S, Johannsen P, Kettunen P, Kłoszewska I, Legido-Quigley C, Lleó A, Martinez-Lage P, Mecocci P, Meersmans K, Molinuevo JL,  Peyratout G, Popp J, Richardson J, Sala I, Scheltens P, Streffer J, Soininen H, Tainta-Cuezva  M, Teunissen C, Tsolaki M, Vandenberghe R, Visser PJ, Vos S, Wahlund LO, Wallin A, Westwood S, Zetterberg H, Lovestone S, Morgan BP; Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer’s Disease. Inflammatory biomarkers in Alzheimer’s disease plasma. Alzheimers Dement. 2019 Jun;15(6):776-787. doi:  10.1016/j.jalz.2019.03.007. Epub  2019 Apr 30. PubMed PMID: 31047856; PubMed Central PMCID: PMC6565806.
  67. Oort Q, Taphoorn MJB, Sikkes SAM, Uitdehaag BMJ, Reijneveld JC, Dirven L. Evaluation of the  content coverage of questionnaires containing basic and instrumental activities of daily living (ADL) used in adult patients with brain tumors. J Neurooncol. 2019 May;143(1):1-13. doi: 10.1007/s11060-019-03136-9. Epub 2019 Mar 18.
  68. Ossenkoppele R, Iaccarino L, Schonhaut DR, Brown JA, La Joie R, O’Neil JP, Janabi M, Baker SL, Kramer JH, Gorno-Tempini ML, Miller BL, Rosen HJ, Seeley WW,  Jagust WJ, Rabinovici GD. Tau covariance patterns in Alzheimer’s disease patients match intrinsic connectivity networks in the healthy brain. Neuroimage Clin. 2019 May 2;23:101848. doi: 10.1016/j.nicl.2019.101848. PubMed PMID: 31077982; PubMed Central PMCID: PMC6510968.
  69. Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS, Palmqvist S, Hansson O. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019 Feb 5;92(6):e601-e612. doi: 10.1212/WNL.0000000000006875. Epub 2019 Jan 9. PubMed PMID: 30626656; PubMed Central PMCID: PMC6382060.
  70. Oudeman EA, Greving JP, Hooghiemstra AM, Brunner-La Rocca HP, Biessels GJ, Kappelle LJ; Heart-Brain Connection Consortium. Nonfocal transient neurological attacks are related to cognitive impairment in patients with heart failure. J Neurol. 2019 Aug;266(8):2035-2042. doi: 10.1007/s00415-019-09376-z. Epub 2019 May 21.
  71. Pelkmans W, Dicks E, Barkhof F, Vrenken H, Scheltens P, van der Flier WM, Tijms BM. Gray matter T1-w/T2-w ratios are higher in Alzheimer’s disease. Hum Brain Mapp. 2019 Sep;40(13):3900-3909. doi: 10.1002/hbm.24638. Epub 2019 Jun 3. PubMed PMID: 31157938.
  72. Rhodius-Meester HFM, Tijms BM, Lemstra AW, Prins ND, Pijnenburg YAL, Bouwman  F, Scheltens P, van der Flier WM. Survival in memory clinic cohort is short, even in young-onset dementia. J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):726-728. doi: 10.1136/jnnp-2018-318820. Epub 2018 Jul 25. PubMed PMID: 30045942; PubMed Central PMCID: PMC6581097.
  73. Rimkus CM, Schoonheim MM, Steenwijk MD, Vrenken H, Eijlers AJ, Killestein J, Wattjes MP, Leite CC, Barkhof F, Tijms BM. Gray matter networks and cognitive impairment in multiple sclerosis. Mult Scler. 2019 Mar;25(3):382-391. doi: 10.1177/1352458517751650. Epub 2018 Jan 11. PubMed PMID: 29320933; PubMed Central PMCID: PMC6393954.
  74. Rodríguez-Gómez O, Rodrigo A, Iradier F, Santos-Santos MA, Hundemer H, Ciudin  A, Sannemann L, Zwan M, Glaysher B, Wimo A, Bonn J, Johansson G, Rodriguez I, Alegret M, Gove D, Pinó S, Trigueros P, Kivipelto M, Mathews B, Ciudad A, Ferreira D, Bintener C, Gurruchaga M, Westman E, Belger M, Valero S, Maguire P, Krivec D, Kramberger M, Simó R, Garro IP, Visser PJ, Dumas A, Georges J, Jessen F, Winblad B, Shering C, Stewart N, Campo L, Boada M; MOPEAD Consortium. The MOPEAD project: Advancing patient engagement for the detection of “hidden” undiagnosed cases of Alzheimer’s disease in the community. Alzheimers Dement. 2019 Jun;15(6):828-839. doi: 10.1016/j.jalz.2019.02.003. Epub 2019 May 7. Review. PubMed PMID: 31076376.
  75. Sabbagh, M.N., Hendrix, S. & Harrison, J.E. FDA position statement “Early Alzheimer’s disease: developing drugs for treatment, Guidance for Industry”. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2019:5:13-19.
  76. Slot RER, Sikkes SAM, Berkhof J, Brodaty H, Buckley R, Cavedo E, Dardiotis E, Guillo-Benarous F, Hampel H, Kochan NA, Lista S, Luck T, Maruff P, Molinuevo JL,  Kornhuber J, Reisberg B, Riedel-Heller SG, Risacher SL, Roehr S, Sachdev PS, Scarmeas N, Scheltens P, Shulman MB, Saykin AJ, Verfaillie SCJ, Visser PJ, Vos SJB, Wagner M, Wolfsgruber S, Jessen F; Alzheimer’s Disease Neuroimaging Initiative; DESCRIPA working group; INSIGHT-preAD study group; SCD-I working group, van der Flier WM. Subjective cognitive decline and rates of incident Alzheimer’s disease and non-Alzheimer’s disease dementia. Alzheimers Dement. 2019 Mar;15(3):465-476. doi: 10.1016/j.jalz.2018.10.003. Epub 2018 Dec 13. PubMed PMID: 30555032; PubMed Central PMCID: PMC6465066.
  77. Slot RER, Kester MI, Van Harten AC, Jongbloed W, Bouwman FH, Teunissen CE, Scheltens P, van der Flier WM, Veerhuis R. ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF  Aβ42, levels in non-demented elderly. Neurobiol Aging. 2019 Jul;79:101-109. doi:  10.1016/j.neurobiolaging.2019.02.017. Epub 2019 Mar 1. PubMed PMID: 31029938.
  78. Stern Y, Chételat G, Habeck C, Arenaza-Urquijo EM, Vemuri P, Estanga A, Bartrés-Faz D, Cantillon M, Clouston SAP, Elman JA, Gold BT, Jones R, Kempermann  G, Lim YY, van Loenhoud A, Martínez-Lage P, Morbelli S, Okonkwo O, Ossenkoppele R, Pettigrew C, Rosen AC, Scarmeas N, Soldan A, Udeh-Momoh C, Valenzuela M, Vuoksimaa E. Mechanisms underlying resilience in ageing. Nat Rev Neurosci. 2019 Apr;20(4):246. doi: 10.1038/s41583-019-0138-0. PubMed PMID: 30814677.
  79. Tesi N, van der Lee SJ, Hulsman M, Jansen IE, Stringa N, van Schoor N, Meijers-Heijboer H, Huisman M, Scheltens P, Reinders MJT, van der Flier WM, Holstege H. Centenarian controls increase variant effect sizes by an average twofold in an extreme case-extreme control analysis of Alzheimer’s disease. Eur J Hum Genet. 2019 Feb;27(2):244-253. doi: 10.1038/s41431-018-0273-5. Epub 2018 Sep  26. PubMed PMID: 30258121; PubMed Central PMCID: PMC6336855.
  80. Timmers T, Ossenkoppele R, Wolters EE, Verfaillie SCJ, Visser D, Golla SSV, Barkhof F, Scheltens P, Boellaard R, van der Flier WM, van Berckel BNM. Associations between  quantitative [(18)F]flortaucipir tau PET and atrophy across  the Alzheimer’s disease spectrum. Alzheimers Res Ther. 2019 Jul 4;11(1):60. doi:  10.1186/s13195-019-0510-3. PubMed PMID: 31272512; PubMed Central PMCID: PMC6610969.
  81. Timmers T, Ossenkoppele R, Verfaillie SCJ, van der Weijden CWJ, Slot RER, Wesselman LMP, Windhorst AD, Wolters EE, Yaqub M, Prins ND, Lammertsma AA, Scheltens P, van der Flier WM, van Berckel BNM. Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project. Neurobiol Aging. 2019 Jul;79:50-58. doi: 10.1016/j.neurobiolaging.2019.02.020. Epub 2019 Mar 8. PubMed  PMID: 31026622.
  82. van de Beek M, van Steenoven I, Ramakers IHGB, Aalten P, Koek HL, Olde Rikkert MGM, Manniën J, Papma JM, de Jong FJ, Lemstra AW, van der Flier WM. Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer’s Disease. J Alzheimers Dis. 2019;70(2):389-397. doi: 10.3233/JAD-190041. PubMed PMID: 31177218.
  83. van de Kreeke JA, Nguyen HT, den Haan J, Konijnenberg E, Tomassen J, den Braber A, Ten Kate M, Collij L, Yaqub M, van Berckel B, Lammertsma AA, Boomsma DI, Tan HS, Verbraak FD, Visser PJ. Retinal layer thickness in preclinical Alzheimer’s disease. Acta Ophthalmol. 2019 May 6. doi: 10.1111/aos.14121. PubMed PMID: 31058465.
  84. van de Kreeke JA, Nguyen HT, Konijnenberg E, Tomassen J, den Braber A, Ten Kate M, Yaqub M, van Berckel B, Lammertsma AA, Boomsma DI, Tan SH, Verbraak F, Visser PJ. Optical coherence tomography angiography in preclinical Alzheimer’s disease. Br J Ophthalmol. 2019 May 22. pii: bjophthalmol-2019-314127. doi: 10.1136/bjophthalmol-2019-314127. PubMed PMID: 31118186.
  85. van der Ende EL, Meeter LH, Stingl C, van Rooij JGJ, Stoop MP, Nijholt DAT, Sanchez-Valle R, Graff C, Öijerstedt L, Grossman M, McMillan C, Pijnenburg YAL, Laforce R Jr, Binetti G, Benussi L, Ghidoni R, Luider TM, Seelaar H, van Swieten  JC. Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics. Ann Clin Transl Neurol. 2019 Mar 7;6(4):698-707. doi: 10.1002/acn3.745. eCollection 2019 Apr. PubMed PMID: 31019994; PubMed Central PMCID: PMC6469343.
  86. van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer  M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk  and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga  L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathol. 2019 Aug;138(2):237-250. doi: 10.1007/s00401-019-02026-8. Epub 2019  May 27. PubMed PMID: 31131421.
  87. van Loenhoud AC, van der Flier WM, Wink AM, Dicks E, Groot C, Twisk J, Barkhof F, Scheltens P, Ossenkoppele R; Alzheimer’s Disease Neuroimaging Initiative. Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship. Neurology. 2019 Jul 23;93(4):e334-e346. doi: 10.1212/WNL.0000000000007821. Epub 2019 Jul 2. PubMed PMID: 31266904.
  88. van Maurik IS, Visser LN, Pel-Littel RE, van Buchem MM, Zwan MD, Kunneman M,  Pelkmans W, Bouwman FH, Minkman M, Schoonenboom N, Scheltens P, Smets EM, van der Flier WM. Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease. JMIR Form Res. 2019 Jul 8;3(3):e13417. doi: 10.2196/13417. PubMed PMID: 31287061; PubMed Central PMCID: PMC6643768.
  89. van Maurik IS, Slot RER, Verfaillie SCJ, Zwan MD, Bouwman FH, Prins ND, Teunissen CE, Scheltens P, Barkhof F, Wattjes MP, Molinuevo JL, Rami L, Wolfsgruber S, Peters O, Jessen F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative. Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project. Alzheimers Res Ther. 2019 Apr 16;11(1):33. doi: 10.1186/s13195-019-0487-y. PubMed PMID: 30987684; PubMed Central PMCID: PMC6466790.
  90. Van Someren EJW, Oosterman JM, Van Harten B, Vogels RL, Gouw AA, Weinstein HC, Poggesi A, Scheltens P, Scherder EJA. Medial temporal lobe atrophy relates more strongly to sleep-wake rhythm fragmentation than to age or any other known risk. Neurobiol Learn Mem. 2019 Apr;160:132-138. doi: 10.1016/j.nlm.2018.05.017.  Epub 2018 Jun 1. PubMed PMID: 29864525.
  91. Verfaillie SCJ, Witteman J, Slot RER, Pruis IJ, Vermaat LEW, Prins ND, Schiller NO, van de Wiel M, Scheltens P, van Berckel BNM, van der Flier WM, Sikkes SAM. High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline. Neuropsychologia. 2019 Aug;131:184-192. doi: 10.1016/j.neuropsychologia.2019.05.006. Epub 2019 May 7. PubMed PMID: 31075283.
  92. Verfaillie SCJ, Timmers T, Slot RER, van der Weijden CWJ, Wesselman LMP, Prins ND, Sikkes SAM, Yaqub M, Dols A, Lammertsma AA, Scheltens P, Ossenkoppele R, van Berckel BNM, van der Flier WM. Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive  Decline: The SCIENCe Project. Front Aging Neurosci. 2019 Jan 25;11:7. doi: 10.3389/fnagi.2019.00007. eCollection 2019. PubMed PMID: 30760996; PubMed Central PMCID: PMC6362417.
  93. Vermunt L, van Paasen AJL, Teunissen CE, Scheltens P, Visser PJ, Tijms BM; Alzheimer’s Disease Neuroimaging Initiative. Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. Neurology. 2019 Jun 4;92(23):e2699-e2705. doi: 10.1212/WNL.0000000000007609. Epub 2019 May 8. PubMed  PMID: 31068481; PubMed Central PMCID: PMC6556092.
  94. Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM,  Kern S, Ousset PJ, Maruff P, Skoog I, Verhey FRJ, Freund-Levi Y, Tsolaki M, Wallin ÅK, Olde Rikkert M, Soininen H, Spiru L, Zetterberg H, Blennow K, Scheltens P, Muniz-Terrera G, Visser PJ; Alzheimer Disease Neuroimaging Initiative; AIBL Research Group; ICTUS/DSA study groups. Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019 Jul;15(7):888-898. doi: 10.1016/j.jalz.2019.04.001. Epub 2019 Jun 1. PubMed PMID: 31164314; PubMed Central PMCID: PMC6646097.
  95. Verwey NA, Teunissen CE, Hoozemans JJM, Rozemuller AJM, Scheltens P, Pijnenburg YAL. Cerebrospinal Fluid Amyloid-β Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study. J Alzheimers Dis. 2019 Jul 22. doi: 10.3233/JAD-190344. PubMed PMID: 31356209.
  96. Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg OT, Schöll M, Dansereau C, Villeneuve S, van der Flier WM, Scheltens P, Bellec P, Evans AC, Hansson O, Ossenkoppele R; Alzheimer’s Disease Neuroimaging Initiative; Swedish BioFINDER Study. Data-driven approaches for tau-PET imaging biomarkers in Alzheimer’s disease. Hum Brain Mapp. 2019 Feb 1;40(2):638-651. doi: 10.1002/hbm.24401. Epub 2018 Oct 19. PubMed PMID: 30368979.
  97. Wang Y, Haaksma ML, Ramakers IHGB, Verhey FRJ, van de Flier WM, Scheltens P,  van Maurik I, Olde Rikkert MGM, Leoutsakos JS, Melis RJF. Cognitive and functional progression of dementia in two longitudinal studies. Int J Geriatr Psychiatry. 2019 Jul 18. doi: 10.1002/gps.5175. PubMed PMID: 31318090.
  98. Wesselman LM, Hooghiemstra AM, Schoonmade LJ, de Wit MC, van der Flier WM, Sikkes SA. Web-Based Multidomain Lifestyle Programs for Brain Health: Comprehensive Overview and Meta-Analysis. JMIR Ment Health. 2019 Apr 9;6(4):e12104. doi: 10.2196/12104. Review. PubMed PMID: 30964438; PubMed Central  PMCID: PMC6477576.
  99. Wesselman LMP, Doorduijn AS, de Leeuw FA, Verfaillie SCJ, van Leeuwenstijn-Koopman M, Slot RER, Kester MI, Prins ND, van de Rest O, de van der  Schueren MAE, Scheltens P, Sikkes SAM, van der Flier WM. Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCe Project. Nutrients. 2019 May 11;11(5). pii: E1057. doi: 10.3390/nu11051057. PubMed PMID: 31083522; PubMed Central PMCID: PMC6566666.
  100. Willemse EAJ, Vermeiren Y, Garcia-Ayllon MS, Bridel C, De Deyn PP, Engelborghs S, van der Flier WM, Jansen EEW, Lopez-Font IB, Mendes V, Manadas B, de Roeck N, Saez-Valero J, Struys EA, Vanmechelen E, Andreasson U, Teunissen CE.  Pre-analytical stability of novel cerebrospinal fluid biomarkers. Clin Chim Acta.2019 Jul 23. pii: S0009-8981(19)31974-6. doi: 10.1016/j.cca.2019.07.024. PubMed PMID: 31348908.
  101. Wolfsgruber S, Molinuevo JL, Wagner M, Teunissen CE, Rami L, Coll-Padrós N, Bouwman FH, Slot RER, Wesselman LMP, Peters O, Luther K, Buerger K, Priller J, Laske C, Teipel S, Spottke A, Heneka MT, Düzel E, Drzezga A, Wiltfang J, Sikkes SAM, van der Flier WM, Jessen F; Euro-SCD working group. Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. Alzheimers Res Ther. 2019 Jan 17;11(1):8. doi: 10.1186/s13195-018-0463-y. PubMed PMID: 30654834; PubMed Central PMCID: PMC6337830.
  102. Wong TH, van der Lee SJ, van Rooij JGJ, Meeter LHH, Frick P, Melhem S, Seelaar H, Ikram MA, Rozemuller AJ, Holstege H, Hulsman M, Uitterlinden A, Neumann M, Hoozemans JJM, van Duijn CM, Rademakers R, van Swieten JC. EIF2AK3 variants in Dutch patients with Alzheimer’s disease.1. Neurobiol Aging. 2019 Jan;73:229.e11-229.e18. doi: 10.1016/j.neurobiolaging.2018.08.016. Epub 2018 Aug 24.
  103. Zhutovsky P, Vijverberg EGB, Bruin WB, Thomas RM, Wattjes MP, Pijnenburg YAL, van Wingen GA, Dols A. Individual Prediction of Behavioral Variant Frontotemporal Dementia Development Using Multivariate Pattern Analysis of Magnetic Resonance Imaging Data. J Alzheimers Dis. 2019;68(3):1229-1241. doi: 10.3233/JAD-181004. PubMed PMID: 30909224.

Publicaties 2018

  1. Agosta, F., Altomare, D., Festari, C., Orini, S., Gandolfo, F., Boccardi, M., Arbizu, J., Bouwman, F., Drzezga, A., Nestor, P., Nobili, F., Walker, Z., Pagani, M., 2018. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington’s disease. Eur. J. Nucl. Med. Mol. Imaging 45, 1546–1556. https://doi.org/10.1007/s00259-018-4033-0
  2. Aisen, P.S., Siemers, E., Michelson, D., Salloway, S., Sampaio, C., Carrillo, M.C., Sperling, R., Doody, R., Scheltens, P., Bateman, R., Weiner, M., Vellas, B., 2018. What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force. J. Prev. Alzheimer’s Dis. 5, 171–174. https://doi.org/10.14283/jpad.2018.23
  3. Albani, D., Marizzoni, M., Ferrari, C., Fusco, F., Boeri, L., Raimondi, I., Jovicich, J., Babiloni, C., Soricelli, A., Lizio, R., Galluzzi, S., Cavaliere, L., Didic, M., Schonknecht, P., Molinuevo, J.L., Nobili, F., Parnetti, L., Payoux, P., Bocchio, L., Salvatore, M., Rossini, P.M., Tsolaki, M., Visser, P.J., Richardson, J.C., Wiltfang, J., Bordet, R., Blin, O., Forloni, G., Frisoni, G.B., Consortium, P., 2018. Plasma Abeta42 as Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. J. Alzheimers. Dis. https://doi.org/10.3233/JAD-180321
  4. Amier, R.P., Smulders, M.W., van der Flier, W.M., Bekkers, S.C.A.M., Zweerink, A., Allaart, C.P., Demirkiran, A., Roos, S.T., Teunissen, P.F.A., Appelman, Y., van Royen, N., Kim, R.J., van Rossum, A.C., Nijveldt, R., 2018. Long-Term Prognostic Implications of Previous Silent Myocardial Infarction in Patients Presenting With Acute Myocardial Infarction. JACC. Cardiovasc. Imaging 11, 1773–1781. https://doi.org/10.1016/j.jcmg.2018.02.009
  5. Arbizu, J., Festari, C., Altomare, D., Walker, Z., Bouwman, F., Rivolta, J., Orini, S., Barthel, H., Agosta, F., Drzezga, A., Nestor, P., Boccardi, M., Frisoni, G.B., Nobili, F., 2018. Clinical utility of FDG-PET for the clinical diagnosis in MCI. Eur. J. Nucl. Med. Mol. Imaging 45, 1497–1508. https://doi.org/10.1007/s00259-018-4039-7
  6. Barnes, J., Bartlett, J.W., Wolk, D.A., van der Flier, W.M., Frost, C., 2018. Disease Course Varies According to Age and Symptom Length in Alzheimer’s Disease. J. Alzheimers. Dis. 64, 631–642. https://doi.org/10.3233/JAD-170841
  7. Beeldman, E., Raaphorst, J., Klein Twennaar, M., Govaarts, R., Pijnenburg, Y.A.L., de Haan, R.J., de Visser, M., Schmand, B.A., 2018. The cognitive profile of behavioural variant FTD and its similarities with ALS: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 89, 995–1002. https://doi.org/10.1136/jnnp-2017-317459
  8. Bergeron, D., Gorno-Tempini, M.L., Rabinovici, G.D., Santos-Santos, M.A., Seeley, W., Miller, B.L., Pijnenburg, Y., Keulen, M.A., Groot, C., van Berckel, B.N.M., van der Flier, W.M., Scheltens, P., Rohrer, J.D., Warren, J.D., Schott, J.M., Fox, N.C., Sanchez-Valle, R., Grau-Rivera, O., Gelpi, E., Seelaar, H., Papma, J.M., van Swieten, J.C., Hodges, J.R., Leyton, C.E., Piguet, O., Rogalski, E.J., Mesulam, M.M., Koric, L., Nora, K., Pariente, J., Dickerson, B., Mackenzie, I.R., Hsiung, G.-Y.R., Belliard, S., Irwin, D.J., Wolk, D.A., Grossman, M., Jones, M., Harris, J., Mann, D., Snowden, J.S., Chrem-Mendez, P., Calandri, I.L., Amengual, A.A., Miguet-Alfonsi, C., Magnin, E., Magnani, G., Santangelo, R., Deramecourt, V., Pasquier, F., Mattsson, N., Nilsson, C., Hansson, O., Keith, J., Masellis, M., Black, S.E., Matias-Guiu, J.A., Cabrera-Martin, M.-N., Paquet, C., Dumurgier, J., Teichmann, M., Sarazin, M., Bottlaender, M., Dubois, B., Rowe, C.C., Villemagne, V.L., Vandenberghe, R., Granadillo, E., Teng, E., Mendez, M., Meyer, P.T., Frings, L., Lleo, A., Blesa, R., Fortea, J., Seo, S.W., Diehl-Schmid, J., Grimmer, T., Frederiksen, K.S., Sanchez-Juan, P., Chetelat, G., Jansen, W., Bouchard, R.W., Laforce, R.J., Visser, P.J., Ossenkoppele, R., 2018. Prevalence of amyloid-beta pathology in distinct variants of primary progressive  aphasia. Ann. Neurol. 84, 729–740. https://doi.org/10.1002/ana.25333
  9. Bergeron, D., Ossenkoppele, R., Jr Laforce, R., 2018. Evidence-based Interpretation of Amyloid-beta PET Results: A Clinician’s Tool. Alzheimer Dis. Assoc. Disord. 32, 28–34. https://doi.org/10.1097/WAD.0000000000000239
  10. Boon, B.D.C., Hoozemans, J.J.M., Lopuhaa, B., Eigenhuis, K.N., Scheltens, P., Kamphorst, W., Rozemuller, A.J.M., Bouwman, F.H., 2018. Neuroinflammation is increased in the parietal cortex of atypical Alzheimer’s disease. J. Neuroinflammation 15, 170. https://doi.org/10.1186/s12974-018-1180-y
  11. Bos, I., Verhey, F.R., Ramakers, I.H.G.B., Jacobs, H.I.L., Soininen, H., Freund-Levi, Y., Hampel, H., Tsolaki, M., Wallin, A.K., van Buchem, M.A., Oleksik, A., Verbeek, M.M., Rikkert, M.O., van der Flier, W.M., Scheltens, P., Aalten, P., Visser, P.J., Vos, S.J.B., 2018. Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimers. Res. Ther. https://doi.org/10.1186/s13195-018-0391-x
  12. Bos, I., Vos, S.J.B., Jansen, W.J., Vandenberghe, R., Gabel, S., Estanga, A., Ecay-Torres, M., Tomassen, J., den Braber, A., Lleo, A., Sala, I., Wallin, A., Kettunen, P., Molinuevo, J.L., Rami, L., Chetelat, G., de la Sayette, V., Tsolaki, M., Freund-Levi, Y., Johannsen, P., Novak, G.P., Ramakers, I., Verhey, F.R., Visser, P.J., 2018. Amyloid-beta, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. Front. Aging Neurosci. 10, 193. https://doi.org/10.3389/fnagi.2018.00193
  13. Bos, I., Vos, S., Vandenberghe, R., Scheltens, P., Engelborghs, S., Frisoni, G., Molinuevo, J.L., Wallin, A., Lleo, A., Popp, J., Martinez-Lage, P., Baird, A., Dobson, R., Legido-Quigley, C., Sleegers, K., Van Broeckhoven, C., Bertram, L., Ten Kate, M., Barkhof, F., Zetterberg, H., Lovestone, S., Streffer, J., Visser, P.J., 2018. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimers. Res. Ther. 10, 64. https://doi.org/10.1186/s13195-018-0396-5
  14. Bouts, M.J.R.J., Moller, C., Hafkemeijer, A., van Swieten, J.C., Dopper, E., van der Flier, W.M., Vrenken, H., Wink, A.M., Pijnenburg, Y.A.L., Scheltens, P., Barkhof, F., Schouten, T.M., de Vos, F., Feis, R.A., van der Grond, J., de Rooij, M., Rombouts, S.A.R.B., 2018. Single Subject Classification of Alzheimer’s Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. J. Alzheimers. Dis. 62, 1827–1839. https://doi.org/10.3233/JAD-170893
  15. Bouwman, F., Orini, S., Gandolfo, F., Altomare, D., Festari, C., Agosta, F., Arbizu, J., Drzezga, A., Nestor, P., Nobili, F., Walker, Z., Morbelli, S., Boccardi, M., 2018. Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. Eur. J. Nucl. Med. Mol. Imaging 45, 1526–1533. https://doi.org/10.1007/s00259-018-4034-z
  16. Bruun, M., Rhodius-Meester, H.F.M., Koikkalainen, J., Baroni, M., Gjerum, L., Lemstra, A.W., Barkhof, F., Remes, A.M., Urhemaa, T., Tolonen, A., Rueckert, D., van Gils, M., Frederiksen, K.S., Waldemar, G., Scheltens, P., Mecocci, P., Soininen, H., Lotjonen, J., Hasselbalch, S.G., van der Flier, W.M., 2018. Evaluating combinations of diagnostic tests to discriminate different dementia types. Alzheimer’s Dement. 10, 509–518. https://doi.org/10.1016/j.dadm.2018.07.003
  17. Chakraborty, A., Chatterjee, M., Twaalfhoven, H., Del Campo Milan, M., Teunissen, C.E., Scheltens, P., Fontijn, R.D., van Der Flier, W.M., de Vries, H.E., 2018. Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia. Alzheimers. Res. Ther. 10, 58. https://doi.org/10.1186/s13195-018-0385-8
  18. Chakraborty, A., Kamermans, A., van Het Hof, B., Castricum, K., Aanhane, E., van Horssen, J., Thijssen, V.L., Scheltens, P., Teunissen, C.E., Fontijn, R.D., van der Flier, W.M., de Vries, H.E., 2018. Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy. Brain 141, 3377–3388. https://doi.org/10.1093/brain/awy274
  19. Chatterjee, M., Del Campo, M., Morrema, T.H.J., de Waal, M., van der Flier, W.M., Hoozemans, J.J.M., Teunissen, C.E., 2018. Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer’s disease. Alzheimers. Res. Ther. 10, 52. https://doi.org/10.1186/s13195-018-0383-x
  20. Ciliz, M., Sartor, J., Lindig, T., Pilotto, A., Schaffer, E., Weiss, M., Scheltens, P., Becker, S., Hobert, M.A., Berg, D., Liepelt-Scarfone, I., Maetzler, W., 2018. Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson’s Disease. J. Parkinsons. Dis. 8, 455–462. https://doi.org/10.3233/JPD-181351
  21. Claus, J.J., Coenen, M., Staekenborg, S.S., Schuur, J., Tielkes, C.E.M., Koster, P., Scheltens, P., 2018. Cerebral White Matter Lesions have Low Impact on Cognitive Function in a Large Elderly Memory Clinic Population. J. Alzheimers. Dis. 63, 1129–1139. https://doi.org/10.3233/JAD-171111
  22. Cohn-Hokke, P.E., van Swieten, J.C., Pijnenburg, Y.A.L., Tibben, A., Meijers-Heijboer, H., Kievit, A., 2018. The Effect of Predictive Testing in Adult-Onset Neurodegenerative Diseases on Social and Personal Life. J. Genet. Couns. 27, 947–954. https://doi.org/10.1007/s10897-017-0195-3
  23. Collij, L., Konijnenberg, E., Reimand, J., Ten Kate, M., Den Braber, A., Lopes Alves, I., Zwan, M., Yaqub, M., Van Assema, D., Wink, A.M., Lammertsma, A., Scheltens, P., Visser, P.J., Barkhof, F., Van Berckel, B., 2018. Assessing Amyloid Pathology in Cognitively Normal Subjects using [(18)F]Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. J. Nucl. Med. https://doi.org/10.2967/jnumed.118.211532
  24. Dauwan, M., Linszen, M.M.J., Lemstra, A.W., Scheltens, P., Stam, C.J., Sommer, I.E., 2018. EEG-based neurophysiological indicators of hallucinations in Alzheimer’s disease: Comparison with dementia with Lewy bodies. Neurobiol. Aging 67, 75–83. https://doi.org/10.1016/j.neurobiolaging.2018.03.013
  25. de Wilde, A., van Buchem, M.M., Otten, R.H.J., Bouwman, F., Stephens, A., Barkhof, F., Scheltens, P., van der Flier, W.M., 2018. Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. Alzheimers. Res. Ther. 10, 72. https://doi.org/10.1186/s13195-018-0398-3
  26. de Wilde, A., van der Flier, W.M., Pelkmans, W., Bouwman, F., Verwer, J., Groot, C., van Buchem, M.M., Zwan, M., Ossenkoppele, R., Yaqub, M., Kunneman, M., Smets, E.M.A., Barkhof, F., Lammertsma, A.A., Stephens, A., van Lier, E., Biessels, G.J., van Berckel, B.N., Scheltens, P., 2018. Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project. JAMA Neurol. 75, 1062–1070. https://doi.org/10.1001/jamaneurol.2018.1346
  27. Del Campo, M., Galimberti, D., Elias, N., Boonkamp, L., Pijnenburg, Y.A., van Swieten, J.C., Watts, K., Paciotti, S., Beccari, T., Hu, W., Teunissen, C.E., 2018. Novel CSF biomarkers to discriminate FTLD and its pathological subtypes. Ann. Clin. Transl. Neurol. 5, 1163–1175. https://doi.org/10.1002/acn3.629
  28. den Haan, J., Janssen, S.F., van de Kreeke, J.A., Scheltens, P., Verbraak, F.D., Bouwman, F.H., 2018. Retinal thickness correlates with parietal cortical atrophy in early-onset Alzheimer’s disease and controls. Alzheimer’s Dement. (Amsterdam, Netherlands) 10, 49–55. https://doi.org/10.1016/j.dadm.2017.10.005
  29. den Haan, J., Morrema, T.H.J., Rozemuller, A.J., Bouwman, F.H., Hoozemans, J.J.M., 2018. Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics. Acta Neuropathol. Commun. 6, 75. https://doi.org/10.1186/s40478-018-0577-2
  30. Dicks, E., Tijms, B.M., Ten Kate, M., Gouw, A.A., Benedictus, M.R., Teunissen, C.E., Barkhof, F., Scheltens, P., van der Flier, W.M., 2018. Gray matter network measures are associated with cognitive decline in mild cognitive impairment. Neurobiol. Aging 61, 198–206. https://doi.org/10.1016/j.neurobiolaging.2017.09.029
  31. Doorduijn, A.S., van de Rest, O., van der Flier, W.M., Visser, M., de van der Schueren, M.A.E., 2018. Energy and Protein Intake of Alzheimer’s Disease Patients Compared to Cognitively Normal Controls: Systematic Review. J. Am. Med. Dir. Assoc. https://doi.org/10.1016/j.jamda.2018.06.019
  32. Drzezga, A., Altomare, D., Festari, C., Arbizu, J., Orini, S., Herholz, K., Nestor, P., Agosta, F., Bouwman, F., Nobili, F., Walker, Z., Frisoni, G.B., Boccardi, M., 2018. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer’s disease. Eur. J. Nucl. Med. Mol. Imaging 45, 1487–1496. https://doi.org/10.1007/s00259-018-4032-1
  33. Dufresne, J., Bowden, P., Thavarajah, T., Florentinus-Mefailoski, A., Chen, Z.Z., Tucholska, M., Norzin, T., Ho, M.T., Phan, M., Mohamed, N., Ravandi, A., Stanton, E., Slutsky, A.S., Dos Santos, C.C., Romaschin, A., Marshall, J.C., Addison, C., Malone, S., Heyland, D., Scheltens, P., Killestein, J., Teunissen, C., Diamandis, E.P., Siu, K.W.M., Marshall, J.G., 2018. The plasma peptidome. Clin. Proteomics 15, 39. https://doi.org/10.1186/s12014-018-9211-3
  34. Duits, F.H., Brinkmalm, G., Teunissen, C.E., Brinkmalm, A., Scheltens, P., Van der Flier, W.M., Zetterberg, H., Blennow, K., 2018. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease. Alzheimers. Res. Ther. 10, 5. https://doi.org/10.1186/s13195-017-0335-x
  35. Eikelboom, W.S., van Rooij, J.G.J., van den Berg, E., Coesmans, M., Jiskoot, L.C., Singleton, E., Ossenkoppele, R., van Swieten, J.C., Seelaar, H., Papma, J.M., 2018. Neuropsychiatric Symptoms Complicating the Diagnosis of Alzheimer’s Disease: A Case Report. J. Alzheimers. Dis. https://doi.org/10.3233/JAD-180700
  36. Facal, D., Carabias, M.A.R., Pereiro, A.X., Lojo-Seoane, C., Campos-Magdaleno, M., Jutten, R.J., Sikkes, S.A.M., Juncos-Rabadan, O., 2018. Assessing Everyday Activities Across the Dementia Spectrum with the Amsterdam IADL Questionnaire. Curr. Alzheimer Res. 15, 1261–1266. https://doi.org/10.2174/1567205015666180925113411
  37. Fredericks, C.A., Brown, J.A., Deng, J., Kramer, A., Ossenkoppele, R., Rankin, K., Kramer, J.H., Miller, B.L., Rabinovici, G.D., Seeley, W.W., 2018. Intrinsic connectivity networks in posterior cortical atrophy: A role for the pulvinar? NeuroImage. Clin. https://doi.org/10.1016/j.nicl.2018.101628
  38. Frisoni, G.B., Barkhof, F., Altomare, D., Berkhof, J., Boccardi, M., Canzoneri, E., Collij, L., Drzezga, A., Farrar, G., Garibotto, V., Gismondi, R., Gispert, J.-D., Jessen, F., Kivipelto, M., Alves, I.L., Molinuevo, J.-L., Nordberg, A., Payoux, P., Ritchie, C., Savicheva, I., Scheltens, P., Schmidt, M.E., Schott, J., Stephens, A., van Berckel, B., Vellas, B., Walker, Z., Raffa, N., 2018. AMYPAD Diagnostic and Patient Management Study: Rationale and design.Alzheimers. Dement. https://doi.org/10.1016/j.jalz.2018.09.003
  39. Ganz, A.B., Beker, N., Hulsman, M., Sikkes, S., Bank, N.B., Scheltens, P., Smit, A.B., Rozemuller, A.J.M., Hoozemans, J.J.M., Holstege, H., 2018. Neuropathology and cognitive performance in self-reported cognitively healthy centenarians. Acta Neuropathol. Commun. 6, 64. https://doi.org/10.1186/s40478-018-0558-5
  40. Gardiner, S.L., Harder, A.V.E., Campman, Y.J.M., Trompet, S., Gussekloo, J., van Belzen, M.J., Boogaard, M.W., Roos, R.A.C., Jansen, I.E., Pijnenburg, Y.A.L., Scheltens, P., van der Flier, W.M., Aziz, N.A., 2019. Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer’s disease. Neurobiol. Aging 73, 230.e9-230.e17. https://doi.org/10.1016/j.neurobiolaging.2018.09.007
  41. Geijselaers, S.L.C., Aalten, P., Ramakers, I.H.G.B., De Deyn, P.P., Heijboer, A.C., Koek, H.L., OldeRikkert, M.G.M., Papma, J.M., Reesink, F.E., Smits, L.L., Stehouwer, C.D.A., Teunissen, C.E., Verhey, F.R.J., van der Flier, W.M., Biessels, G.J., 2018. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer’s Disease. J. Alzheimers. Dis. 61, 309–320. https://doi.org/10.3233/JAD-170522
  42. Gerritsen, A.A.J., Bakker, C., Verhey, F.R.J., Bor, H., Pijnenburg, Y.A.L., de Vugt, M.E., Koopmans, R.T.C.M., 2018. The Progression of Dementia and Cognitive Decline in a Dutch 2-Year Cohort Study  of People with Young-Onset Dementia. J. Alzheimers. Dis. 63, 343–351. https://doi.org/10.3233/JAD-170859
  43. Golla, S.S., Verfaillie, S.C., Boellaard, R., Adriaanse, S.M., Zwan, M.D., Schuit, R.C., Timmers, T., Groot, C., Schober, P., Scheltens, P., van der Flier, W.M., Windhorst, A.D., van Berckel, B.N., Lammertsma, A.A., 2018. Quantification of [(18)F]florbetapir: A test-retest tracer kinetic modelling study. J. Cereb. Blood Flow Metab. 271678X18783628. https://doi.org/10.1177/0271678X18783628
  44. Gossink, F.T., Vijverberg, E., Krudop, W., Scheltens, P., Stek, M.L., Pijnenburg, Y.A.L., Dols, A., 2018. Predicting progression in the late onset frontal lobe syndrome. Int. psychogeriatrics 1–6. https://doi.org/10.1017/S1041610218001242
  45. Gossink, F., Pijnenburg, Y., Scheltens, P., Pera, A., Kleverwal, R., Korten, N., Stek, M., Droes, R.-M., Dols, A., 2018. An intervention programme for caregivers of dementia patients with frontal behavioural changes: an explorative study with controlled effect on sense of competence. Psychogeriatrics 18, 451–459. https://doi.org/10.1111/psyg.12351
  46. Gossink, F., Schouws, S., Krudop, W., Scheltens, P., Stek, M., Pijnenburg, Y., Dols, A., 2018. Social Cognition Differentiates Behavioral Variant Frontotemporal Dementia From Other Neurodegenerative Diseases and Psychiatric Disorders. Am. J. Geriatr. Psychiatry 26, 569–579. https://doi.org/10.1016/j.jagp.2017.12.008
  47. Groot, C., Sudre, C.H., Barkhof, F., Teunissen, C.E., van Berckel, B.N.M., Seo, S.W., Ourselin, S., Scheltens, P., Cardoso, M.J., van der Flier, W.M., Ossenkoppele, R., 2018. Clinical phenotype, atrophy, and small vessel disease in APOEepsilon2 carriers with Alzheimer disease. Neurology 91, e1851–e1859. https://doi.org/10.1212/WNL.0000000000006503
  48. Groot, C., Tolboom, N., Ikonomovic, M.D., Lammertsma, A.A., Boon, B.D.C., Barkhof, F., Scheltens, P., Klunk, W.E., Rozemuller, A.J.M., Ossenkoppele, R., van Berckel, B.N.M., 2018. Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. J. Alzheimers. Dis. 65, 71–77. https://doi.org/10.3233/JAD-180316
  49. Groot, C., van Loenhoud, A.C., Barkhof, F., van Berckel, B.N.M., Koene, T., Teunissen, C.C., Scheltens, P., van der Flier, W.M., Ossenkoppele, R., 2018. Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology 90, e149–e156. https://doi.org/10.1212/WNL.0000000000004802
  50. Guerreiro, R., Ross, O.A., Kun-Rodrigues, C., Hernandez, D.G., Orme, T., Eicher, J.D., Shepherd, C.E., Parkkinen, L., Darwent, L., Heckman, M.G., Scholz, S.W., Troncoso, J.C., Pletnikova, O., Ansorge, O., Clarimon, J., Lleo, A., Morenas-Rodriguez, E., Clark, L., Honig, L.S., Marder, K., Lemstra, A., Rogaeva, E., St George-Hyslop, P., Londos, E., Zetterberg, H., Barber, I., Braae, A., Brown, K., Morgan, K., Troakes, C., Al-Sarraj, S., Lashley, T., Holton, J., Compta, Y., Van Deerlin, V., Serrano, G.E., Beach, T.G., Lesage, S., Galasko, D., Masliah, E., Santana, I., Pastor, P., Diez-Fairen, M., Aguilar, M., Tienari, P.J., Myllykangas, L., Oinas, M., Revesz, T., Lees, A., Boeve, B.F., Petersen, R.C., Ferman, T.J., Escott-Price, V., Graff-Radford, N., Cairns, N.J., Morris, J.C., Pickering-Brown, S., Mann, D., Halliday, G.M., Hardy, J., Trojanowski, J.Q., Dickson, D.W., Singleton, A., Stone, D.J., Bras, J., 2018. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage  genome-wide association study. Lancet. Neurol. 17, 64–74. https://doi.org/10.1016/S1474-4422(17)30400-3
  51. Haaksma, M.L., Rizzuto, D., Ramakers, I.H.G.B., Garcia-Ptacek, S., Marengoni, A., van der Flier, W.M., Verhey, F.R.J., Olde Rikkert, M.G.M., Melis, R.J.F., 2018. The Impact of Frailty and Comorbidity on Institutionalization and Mortality in Persons With Dementia: A Prospective Cohort Study. J. Am. Med. Dir. Assoc. https://doi.org/10.1016/j.jamda.2018.06.020
  52. Harrison, J.E. Cognition comes of age: Comments on the new FDA draft guidance for early Alzheimer’s disease. Alzheimer’s Research & Therapy. 2018:10;61.
  53. Harrison, J.E., Barry, H., Baune, B.T., Best, M.W., Bowie, C.R., Cha, D.S., Culpepper, L., Fossati, P., Greer, T.L., Harmer, C., Klag, E., Lam, R.W., Lee, Y., Mansur, R.B., Wittchen, H.U., McIntyre, R. Stability, reliability and validity of the THINC-it screening tool for cognitive impairment in depression: A psychometric exploration in healthy volunteers. International Journal of Methods in Psychiatric Research. 2018:7;e1736. doi: 10.1002/mpr.1736.
  54. Harrison, J.E., Rentz, D., Brashear, H.R., Arrighi, H.M., Ropacki, M., Liu, E. Psychometric evaluation of the Neuropsychological Test Battery in individuals with normal cognition, Mild Cognitive Impairment, or mild to moderate Alzheimer’s disease: Results from a longitudinal study. Journal for the Prevention of Alzheimer’s disease. 2018:5;236-244. doi: 10.14283/jpad.2018.31.
  55. Holstege, H., Beker, N., Dijkstra, T., Pieterse, K., Wemmenhove, E., Schouten, K., Thiessens, L., Horsten, D., Rechtuijt, S., Sikkes, S., van Poppel, F.W.A., Meijers-Heijboer, H., Hulsman, M., Scheltens, P., 2018. The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description. Eur. J. Epidemiol. 33, 1229–1249. https://doi.org/10.1007/s10654-018-0451-3
  56. Hu, X., Teunissen, C.E., Spottke, A., Heneka, M.T., Duzel, E., Peters, O., Li, S., Priller, J., Buerger, K., Teipel, S., Laske, C., Verfaillie, S.C.J., Barkhof, F., Coll-Padros, N., Rami, L., Molinuevo, J.L., van der Flier, W.M., Jessen, F., 2018. Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer’s disease-Data from three memory clinic studies. Alzheimers. Dement. https://doi.org/10.1016/j.jalz.2018.09.002
  57. Iaccarino, L., Tammewar, G., Ayakta, N., Baker, S.L., Bejanin, A., Boxer, A.L., Gorno-Tempini, M.L., Janabi, M., Kramer, J.H., Lazaris, A., Lockhart, S.N., Miller, B.L., Miller, Z.A., O’Neil, J.P., Ossenkoppele, R., Rosen, H.J., Schonhaut, D.R., Jagust, W.J., Rabinovici, G.D., 2018. Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer’s Disease. NeuroImage. Clin. 17, 452–464. https://doi.org/10.1016/j.nicl.2017.09.016
  58. Jack, C.R.J., Bennett, D.A., Blennow, K., Carrillo, M.C., Dunn, B., Haeberlein, S.B., Holtzman, D.M., Jagust, W., Jessen, F., Karlawish, J., Liu, E., Molinuevo, J.L., Montine, T., Phelps, C., Rankin, K.P., Rowe, C.C., Scheltens, P., Siemers, E., Snyder, H.M., Sperling, R., 2018. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers. Dement. 14, 535–562. https://doi.org/10.1016/j.jalz.2018.02.018
  59. Jansen, W.J., Ossenkoppele, R., Tijms, B.M., Fagan, A.M., Hansson, O., Klunk, W.E., van der Flier, W.M., Villemagne, V.L., Frisoni, G.B., Fleisher, A.S., Lleo, A., Mintun, M.A., Wallin, A., Engelborghs, S., Na, D.L., Chetelat, G., Molinuevo, J.L., Landau, S.M., Mattsson, N., Kornhuber, J., Sabri, O., Rowe, C.C., Parnetti, L., Popp, J., Fladby, T., Jagust, W.J., Aalten, P., Lee, D.Y., Vandenberghe, R., Resende de Oliveira, C., Kapaki, E., Froelich, L., Ivanoiu, A., Gabryelewicz, T., Verbeek, M.M., Sanchez-Juan, P., Hildebrandt, H., Camus, V., Zboch, M., Brooks, D.J., Drzezga, A., Rinne, J.O., Newberg, A., de Mendonca, A., Sarazin, M., Rabinovici, G.D., Madsen, K., Kramberger, M.G., Nordberg, A., Mok, V., Mroczko, B., Wolk, D.A., Meyer, P.T., Tsolaki, M., Scheltens, P., Verhey, F.R.J., Visser, P.J., Aarsland, D., Alcolea, D., Alexander, M., Almdahl, I.S., Arnold, S.E., Baldeiras, I., Barthel, H., van Berckel, B.N.M., Blennow, K., van Buchem, M.A., Cavedo, E., Chen, K., Chipi, E., Cohen, A.D., Forster, S., Fortea, J., Frederiksen, K.S., Freund-Levi, Y., Gkatzima, O., Gordon, M.F., Grimmer, T., Hampel, H., Hausner, L., Hellwig, S., Herukka, S.-K., Johannsen, P., Klimkowicz-Mrowiec, A., Kohler, S., Koglin, N., van Laere, K., de Leon, M., Lisetti, V., Maier, W., Marcusson, J., Meulenbroek, O., Mollergard, H.M., Morris, J.C., Nordlund, A., Novak, G.P., Paraskevas, G.P., Perera, G., Peters, O., Ramakers, I.H.G.B., Rami, L., Rodriguez-Rodriguez, E., Roe, C.M., Rot, U., Ruther, E., Santana, I., Schroder, J., Seo, S.W., Soininen, H., Spiru, L., Stomrud, E., Struyfs, H., Teunissen, C.E., Vos, S.J.B., van Waalwijk van Doorn, L.J.C., Waldemar, G., Wallin, A.K., Wiltfang, J., Zetterberg, H., 2018. Association of Cerebral Amyloid-beta Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA psychiatry 75, 84–95. https://doi.org/10.1001/jamapsychiatry.2017.3391
  60. Jansen, W.J., Wilson, R.S., Visser, P.J., Nag, S., Schneider, J.A., James, B.D., Leurgans, S.E., Capuano, A.W., Bennett, D.A., Boyle, P.A., 2018. Age and the association of dementia-related pathology with trajectories of cognitive decline. Neurobiol. Aging 61, 138–145. https://doi.org/10.1016/j.neurobiolaging.2017.08.029
  61. Jiskoot, L.C., Bocchetta, M., Nicholas, J.M., Cash, D.M., Thomas, D., Modat, M., Ourselin, S., Rombouts, S.A.R.B., Dopper, E.G.P., Meeter, L.H., Panman, J.L., van Minkelen, R., van der Ende, E.L., Donker Kaat, L., Pijnenburg, Y.A.L., Borroni, B., Galimberti, D., Masellis, M., Tartaglia, M.C., Rowe, J., Graff, C., Tagliavini, F., Frisoni, G.B., Laforce, R.J., Finger, E., de Mendonca, A., Sorbi, S., Papma, J.M., van Swieten, J.C., Rohrer, J.D., 2018. Presymptomatic white matter integrity loss in familial frontotemporal dementia in the GENFI cohort: A cross-sectional diffusion tensor imaging study. Ann. Clin. Transl. Neurol. 5, 1025–1036. https://doi.org/10.1002/acn3.601
  62. Joling, M., Vriend, C., van der Zande, J.J., Lemstra, A.W., van den Heuvel, O.A., Booij, J., Berendse, H.W., 2018. Lower (123)I-FP-CIT binding to the striatal dopamine transporter, but not to the  extrastriatal serotonin transporter, in Parkinson’s disease compared with dementia with Lewy bodies. NeuroImage. Clin. 19, 130–136. https://doi.org/10.1016/j.nicl.2018.04.009
  63. Jovicich, J., Babiloni, C., Ferrari, C., Marizzoni, M., Moretti, D. V, Del Percio, C., Lizio, R., Lopez, S., Galluzzi, S., Albani, D., Cavaliere, L., Minati, L., Didic, M., Fiedler, U., Forloni, G., Hensch, T., Molinuevo, J.L., Bartres Faz, D., Nobili, F., Orlandi, D., Parnetti, L., Farotti, L., Costa, C., Payoux, P., Rossini, P.M., Marra, C., Schonknecht, P., Soricelli, A., Noce, G., Salvatore, M., Tsolaki, M., Visser, P.J., Richardson, J.C., Wiltfang, J., Bordet, R., Blin, O., Frisoniand, G.B., 2018. Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. J. Alzheimers. Dis. https://doi.org/10.3233/JAD-180158
  64. Jutten, R.J., Harrison, J., Lee Meeuw Kjoe, P.R., Opmeer, E.M., Schoonenboom, N.S.M., de Jong, F.J., Ritchie, C.W., Scheltens, P., Sikkes, S.A.M., 2018. A novel cognitive-functional composite measure to detect changes in early Alzheimer’s disease: Test-retest reliability and feasibility. Alzheimer’s Dement. (Amsterdam, Netherlands) 10, 153–160. https://doi.org/10.1016/j.dadm.2017.12.002
  65. Konijnenberg, E., Carter, S.F., Ten Kate, M., den Braber, A., Tomassen, J., Amadi, C., Wesselman, L., Nguyen, H.-T., van de Kreeke, J.A., Yaqub, M., Demuru, M., Mulder, S.D., Hillebrand, A., Bouwman, F.H., Teunissen, C.E., Serne, E.H., Moll, A.C., Verbraak, F.D., Hinz, R., Pendleton, N., Lammertsma, A.A., van Berckel, B.N.M., Barkhof, F., Boomsma, D.I., Scheltens, P., Herholz, K., Visser, P.J., 2018. The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimers. Res. Ther. 10, 75. https://doi.org/10.1186/s13195-018-0406-7
  66. Kun-Rodrigues, C., Orme, T., Carmona, S., Hernandez, D.G., Ross, O.A., Eicher, J.D., Shepherd, C., Parkkinen, L., Darwent, L., Heckman, M.G., Scholz, S.W., Troncoso, J.C., Pletnikova, O., Dawson, T., Rosenthal, L., Ansorge, O., Clarimon, J., Lleo, A., Morenas-Rodriguez, E., Clark, L., Honig, L.S., Marder, K., Lemstra, A., Rogaeva, E., St George-Hyslop, P., Londos, E., Zetterberg, H., Barber, I., Braae, A., Brown, K., Morgan, K., Troakes, C., Al-Sarraj, S., Lashley, T., Holton, J., Compta, Y., Van Deerlin, V., Serrano, G.E., Beach, T.G., Lesage, S., Galasko, D., Masliah, E., Santana, I., Pastor, P., Diez-Fairen, M., Aguilar, M., Tienari, P.J., Myllykangas, L., Oinas, M., Revesz, T., Lees, A., Boeve, B.F., Petersen, R.C., Ferman, T.J., Escott-Price, V., Graff-Radford, N., Cairns, N.J., Morris, J.C., Pickering-Brown, S., Mann, D., Halliday, G.M., Hardy, J., Trojanowski, J.Q., Dickson, D.W., Singleton, A., Stone, D.J., Guerreiro, R., Bras, J., 2018. A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiol. Aging. https://doi.org/10.1016/j.neurobiolaging.2018.10.019
  67. Laforce, R.J., Soucy, J.-P., Sellami, L., Dallaire-Theroux, C., Brunet, F., Bergeron, D., Miller, B.L., Ossenkoppele, R., 2018. Molecular imaging in dementia: Past, present, and future. Alzheimers. Dement. 14, 1522–1552. https://doi.org/10.1016/j.jalz.2018.06.2855
  68. Leeuwis, A.E., Prins, N.D., Hooghiemstra, A.M., Benedictus, M.R., Scheltens, P., Barkhof, F., van der Flier, W.M., 2018. Microbleeds are associated with depressive symptoms in Alzheimer’s disease. Alzheimer’s Dement. (Amsterdam, Netherlands) 10, 112–120. https://doi.org/10.1016/j.dadm.2017.11.006
  69. Leeuwis, A.E., Smith, L.A., Melbourne, A., Hughes, A.D., Richards, M., Prins, N.D., Sokolska, M., Atkinson, D., Tillin, T., Jager, H.R., Chaturvedi, N., van der Flier, W.M., Barkhof, F., 2018. Cerebral Blood Flow and Cognitive Functioning in a Community-Based, Multi-Ethnic  Cohort: The SABRE Study.Front. Aging Neurosci. 10, 279. https://doi.org/10.3389/fnagi.2018.00279
  70. Legdeur, N., Heymans, M.W., Comijs, H.C., Huisman, M., Maier, A.B., Visser, P.J., 2018. Age dependency of risk factors for cognitive decline. BMC Geriatr. 18, 187. https://doi.org/10.1186/s12877-018-0876-2
  71. Legdeur, N., Badissi, M., Carter, S.F., de Crom, S., van de Kreeke, A., Vreeswijk, R., Trappenburg, M.C., Oudega, M.L., Koek, H.L., van Campen, J.P., Keijsers, C.J.P.W., Amadi, C., Hinz, R., Gordon, M.F., Novak, G., Podhorna, J., Serne, E., Verbraak, F., Yaqub, M., Hillebrand, A., Griffa, A., Pendleton, N., Kramer, S.E., Teunissen, C.E., Lammertsma, A., Barkhof, F., van Berckel, B.N.M., Scheltens, P., Muller, M., Maier, A.B., Herholz, K., Visser, P.J., 2018. Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. BMC Geriatr. 18, 289. https://doi.org/10.1186/s12877-018-0984-z
  72. Leijenaar, J.F., Groeneveld, G.J., van der Flier, W.M., Scheltens, P., Klaassen, E.S., Weinstein, H.C., Biessels, G.J., Barkhof, F., Prins, N.D., 2018. Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. JMIR Res. Protoc. 7, e80. https://doi.org/10.2196/resprot.9192
  73. Lewczuk, P., Riederer, P., O’Bryant, S.E., Verbeek, M.M., Dubois, B., Visser, P.J., Jellinger, K.A., Engelborghs, S., Ramirez, A., Parnetti, L., Jack, C.R.J., Teunissen, C.E., Hampel, H., Lleo, A., Jessen, F., Glodzik, L., de Leon, M.J., Fagan, A.M., Molinuevo, J.L., Jansen, W.J., Winblad, B., Shaw, L.M., Andreasson, U., Otto, M., Mollenhauer, B., Wiltfang, J., Turner, M.R., Zerr, I., Handels, R., Thompson, A.G., Johansson, G., Ermann, N., Trojanowski, J.Q., Karaca, I., Wagner, H., Oeckl, P., van Waalwijk van Doorn, L., Bjerke, M., Kapogiannis, D., Kuiperij, H.B., Farotti, L., Li, Y., Gordon, B.A., Epelbaum, S., Vos, S.J.B., Klijn, C.J.M., Van Nostrand, W.E., Minguillon, C., Schmitz, M., Gallo, C., Lopez Mato, A., Thibaut, F., Lista, S., Alcolea, D., Zetterberg, H., Blennow, K., Kornhuber, J., 2018. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J. Biol. Psychiatry 19, 244–328. https://doi.org/10.1080/15622975.2017.1375556
  74. Linszen, M.M.J., van Zanten, G.A., Teunisse, R.J., Brouwer, R.M., Scheltens, P., Sommer, I.E., 2018. Auditory hallucinations in adults with hearing impairment: a large prevalence study. Psychol. Med. 1–8. https://doi.org/10.1017/S0033291718000594
  75. Linszen, M.M.J., Lemstra, A.W., Dauwan, M., Brouwer, R.M., Scheltens, P., Sommer, I.E.C., 2018. Understanding hallucinations in probable Alzheimer’s disease: Very low prevalence rates in a tertiary memory clinic. Alzheimer’s Dement. (Amsterdam, Netherlands) 10, 358–362. https://doi.org/10.1016/j.dadm.2018.03.005
  76. Liu, E., Wang, D., Sperling, R., Salloway, S., Fox, N.C., Blennow, K., Scheltens, P., Schmidt, M.E., Streffer, J., Novak, G., Einstein, S., Booth, K., Ketter, N., Brashear, H.R., 2018. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. Neurology 90, e877–e886. https://doi.org/10.1212/WNL.0000000000005060
  77. Marizzoni, M., Ferrari, C., Jovicich, J., Albani, D., Babiloni, C., Cavaliere, L., Didic, M., Forloni, G., Galluzzi, S., Hoffmann, K.-T., Molinuevo, J.L., Nobili, F., Parnetti, L., Payoux, P., Ribaldi, F., Rossini, P.M., Schonknecht, P., Soricelli, A., Hensch, T., Tsolaki, M., Visser, P.J., Wiltfang, J., Richardson, J.C., Bordet, R., Blin, O., Frisoni, G.B., 2018. Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease: Structural Brain Biomarkers. J. Alzheimers. Dis. https://doi.org/10.3233/JAD-180152
  78. Mattsson, N., Groot, C., Jansen, W.J., Landau, S.M., Villemagne, V.L., Engelborghs, S., Mintun, M.M., Lleo, A., Molinuevo, J.L., Jagust, W.J., Frisoni, G.B., Ivanoiu, A., Chetelat, G., Resende de Oliveira, C., Rodrigue, K.M., Kornhuber, J., Wallin, A., Klimkowicz-Mrowiec, A., Kandimalla, R., Popp, J., Aalten, P.P., Aarsland, D., Alcolea, D., Almdahl, I.S., Baldeiras, I., van Buchem, M.A., Cavedo, E., Chen, K., Cohen, A.D., Forster, S., Fortea, J., Frederiksen, K.S., Freund-Levi, Y., Gill, K.D., Gkatzima, O., Grimmer, T., Hampel, H., Herukka, S.-K., Johannsen, P., van Laere, K., de Leon, M.J., Maier, W., Marcusson, J., Meulenbroek, O., Mollergard, H.M., Morris, J.C., Mroczko, B., Nordlund, A., Prabhakar, S., Peters, O., Rami, L., Rodriguez-Rodriguez, E., Roe, C.M., Ruther, E., Santana, I., Schroder, J., Seo, S.W., Soininen, H., Spiru, L., Stomrud, E., Struyfs, H., Teunissen, C.E., Verhey, F.R.J., Vos, S.J.B., van Waalwijk van Doorn, L.J.C., Waldemar, G., Wallin, A.K., Wiltfang, J., Vandenberghe, R., Brooks, D.J., Fladby, T., Rowe, C.C., Drzezga, A., Verbeek, M.M., Sarazin, M., Wolk, D.A., Fleisher, A.S., Klunk, W.E., Na, D.L., Sanchez-Juan, P., Lee, D.Y., Nordberg, A., Tsolaki, M., Camus, V., Rinne, J.O., Fagan, A.M., Zetterberg, H., Blennow, K., Rabinovici, G.D., Hansson, O., van Berckel, B.N.M., van der Flier, W.M., Scheltens, P., Visser, P.J., Ossenkoppele, R., 2018. Prevalence of the apolipoprotein E epsilon4 allele in amyloid beta positive subjects across the spectrum of Alzheimer’s disease. Alzheimers. Dement. 14, 913–924. https://doi.org/10.1016/j.jalz.2018.02.009
  79. Mattsson, N., Ossenkoppele, R., Smith, R., Strandberg, O., Ohlsson, T., Jogi, J., Palmqvist, S., Stomrud, E., Hansson, O., 2018. Greater tau load and reduced cortical thickness in APOE epsilon4-negative Alzheimer’s disease: a cohort study. Alzheimers. Res. Ther. 10, 77. https://doi.org/10.1186/s13195-018-0403-x
  80. Meeter, L.H.H., Gendron, T.F., Sias, A.C., Jiskoot, L.C., Russo, S.P., Donker Kaat, L., Papma, J.M., Panman, J.L., van der Ende, E.L., Dopper, E.G., Franzen, S., Graff, C., Boxer, A.L., Rosen, H.J., Sanchez-Valle, R., Galimberti, D., Pijnenburg, Y.A.L., Benussi, L., Ghidoni, R., Borroni, B., Laforce, R.J., Del Campo, M., Teunissen, C.E., van Minkelen, R., Rojas, J.C., Coppola, G., Geschwind, D.H., Rademakers, R., Karydas, A.M., Oijerstedt, L., Scarpini, E., Binetti, G., Padovani, A., Cash, D.M., Dick, K.M., Bocchetta, M., Miller, B.L., Rohrer, J.D., Petrucelli, L., van Swieten, J.C., Lee, S.E., 2018. Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Ann. Clin. Transl. Neurol. 5, 583–597. https://doi.org/10.1002/acn3.559
  81. Meeter, L.H.H., Vijverberg, E.G., Del Campo, M., Rozemuller, A.J.M., Donker Kaat, L., de Jong, F.J., van der Flier, W.M., Teunissen, C.E., van Swieten, J.C., Pijnenburg, Y.A.L., 2018. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology 90, e1231–e1239. https://doi.org/10.1212/WNL.0000000000005261
  82. Molinuevo, J.L., Ayton, S., Batrla, R., Bednar, M.M., Bittner, T., Cummings, J., Fagan, A.M., Hampel, H., Mielke, M.M., Mikulskis, A., O’Bryant, S., Scheltens, P., Sevigny, J., Shaw, L.M., Soares, H.D., Tong, G., Trojanowski, J.Q., Zetterberg, H., Blennow, K., 2018. Current state of Alzheimer’s fluid biomarkers. Acta Neuropathol. 136, 821–853. https://doi.org/10.1007/s00401-018-1932-x
  83. Nestor, P.J., Altomare, D., Festari, C., Drzezga, A., Rivolta, J., Walker, Z., Bouwman, F., Orini, S., Law, I., Agosta, F., Arbizu, J., Boccardi, M., Nobili, F., Frisoni, G.B., 2018. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. Eur. J. Nucl. Med. Mol. Imaging 45, 1509–1525. https://doi.org/10.1007/s00259-018-4035-y
  84. Nobili, F., Arbizu, J., Bouwman, F., Drzezga, A., Agosta, F., Nestor, P., Walker, Z., Boccardi, M., 2018. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain (18) F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur. J. Neurol. 25, 1201–1217. https://doi.org/10.1111/ene.13728
  85. Nobili, F., Festari, C., Altomare, D., Agosta, F., Orini, S., Van Laere, K., Arbizu, J., Bouwman, F., Drzezga, A., Nestor, P., Walker, Z., Boccardi, M., 2018. Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. Eur. J. Nucl. Med. Mol. Imaging 45, 1557–1566. https://doi.org/10.1007/s00259-018-4030-3
  86. Oppedal, K., Ferreira, D., Cavallin, L., Lemstra, A.W., Ten Kate, M., Padovani, A., Rektorova, I., Bonanni, L., Wahlund, L.-O., Engedal, K., Nobili, F., Kramberger, M., Taylor, J.-P., Hort, J., Snaedal, J., Blanc, F., Walker, Z., Antonini, A., Westman, E., Aarsland, D., 2018. A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on  333 patients from the European DLB consortium. Alzheimers. Dement. https://doi.org/10.1016/j.jalz.2018.09.011
  87. Ossenkoppele, R., Hansson, O., 2018. Genetic characterization of amyloid-beta and tau network spread. Nat. Med. 24, 1790–1792. https://doi.org/10.1038/s41591-018-0277-2
  88. Ossenkoppele, R., Rabinovici, G.D., Smith, R., Cho, H., Scholl, M., Strandberg, O., Palmqvist, S., Mattsson, N., Janelidze, S., Santillo, A., Ohlsson, T., Jogi, J., Tsai, R., La Joie, R., Kramer, J., Boxer, A.L., Gorno-Tempini, M.L., Miller, B.L., Choi, J.Y., Ryu, Y.H., Lyoo, C.H., Hansson, O., 2018. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA 320, 1151–1162. https://doi.org/10.1001/jama.2018.12917
  89. Ostrowitzki, S., Lasser, R.A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., Delmar, P., Klein, G., Andjelkovic, M., Dubois, B., Boada, M., Blennow, K., Santarelli, L., Fontoura, P., 2018. Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers. Res. Ther. https://doi.org/10.1186/s13195-018-0409-4
  90. Pendergrass, J.C., Targum, S.D, Harrison, J.E. Cognitive Impairment Associated with Cancer: A brief Review. Innovations in Clinical Neuroscience. 2018:15;36-44.
  91. Perera, G., Pedersen, L., Ansel, D., Alexander, M., Arrighi, H.M., Avillach, P., Foskett, N., Gini, R., Gordon, M.F., Gungabissoon, U., Mayer, M.-A., Novak, G., Rijnbeek, P., Trifiro, G., van der Lei, J., Visser, P.J., Stewart, R., 2018. Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource. Alzheimers. Dement. 14, 130–139. https://doi.org/10.1016/j.jalz.2017.06.2270
  92. Piersma, D., Fuermaier, A.B.M., de Waard, D., De Deyn, P.P., Davidse, R.J., de Groot, J., Doumen, M.J.A., Bredewoud, R.A., Claesen, R., Lemstra, A.W., Vermeeren, A., Ponds, R., Verhey, F., Brouwer, W.H., Tucha, O., 2018. The MMSE should not be the sole indicator of fitness to drive in mild Alzheimer’s dementia. Acta Neurol. Belg. 118, 637–642. https://doi.org/10.1007/s13760-018-1036-3
  93. Piersma, D., Fuermaier, A.B.M., De Waard, D., Davidse, R.J., De Groot, J., Doumen, M.J.A., Bredewoud, R.A., Claesen, R., Lemstra, A.W., Scheltens, P., Vermeeren, A., Ponds, R., Verhey, F., De Deyn, P.P., Brouwer, W.H., Tucha, O., 2018. Assessing Fitness to Drive in Patients With Different Types of Dementia. Alzheimer Dis. Assoc. Disord. 32, 70–75. https://doi.org/10.1097/WAD.0000000000000221
  94. Pijnenburg, Y.A.L., Dols, A., 2018. Meaning of psychiatric symptoms in frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry. https://doi.org/10.1136/jnnp-2017-317556
  95. Reus, L.M., Vijverberg, E.G., Tijms, B.M., Kate, M. Ten, Gossink, F., Krudop, W.A., Campo, M. Del, Teunissen, C.E., Barkhof, F., van der Flier, W.M., Visser, P.J., Dols, A., Pijnenburg, Y. Al, 2018. Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. J. Psychiatr. Res. 104, 183–191. https://doi.org/10.1016/j.jpsychires.2018.07.014
  96. Rhodius-Meester, H.F.M., Liedes, H., Koene, T., Lemstra, A.W., Teunissen, C.E., Barkhof, F., Scheltens, P., van Gils, M., Lotjonen, J., van der Flier, W.M., 2018. Disease-related determinants are associated with mortality in dementia due to Alzheimer’s disease. Alzheimers. Res. Ther. 10, 23. https://doi.org/10.1186/s13195-018-0348-0
  97. Rhodius-Meester, H.F.M., Tijms, B.M., Lemstra, A.W., Prins, N.D., Pijnenburg, Y.A.L., Bouwman, F., Scheltens, P., van der Flier, W.M., 2018. Survival in memory clinic cohort is short, even in young-onset dementia. J. Neurol. Neurosurg. Psychiatry. https://doi.org/10.1136/jnnp-2018-318820
  98. Rimkus, C.M., Schoonheim, M.M., Steenwijk, M.D., Vrenken, H., Eijlers, A.J., Killestein, J., Wattjes, M.P., Leite, C.C., Barkhof, F., Tijms, B.M., 2018. Gray matter networks and cognitive impairment in multiple sclerosis. Mult. Scler. 1352458517751650. https://doi.org/10.1177/1352458517751650
  99. Saridin, F.N., Schouws, S.N.T.M., de Jong, J., Pijnenburg, Y.A.L., Dols, A., 2018. Secondary mania as a possible presentation of a C9orf72 hexanucleotide repeat expansion. Bipolar Disord. https://doi.org/10.1111/bdi.12724
  100. Schaeverbeke, J., Evenepoel, C., Declercq, L., Gabel, S., Meersmans, K., Bruffaerts, R., Adamczuk, K., Dries, E., Van Bouwel, K., Sieben, A., Pijnenburg, Y., Peeters, R., Bormans, G., Van Laere, K., Koole, M., Dupont, P., Vandenberghe, R., 2018. Distinct [(18)F]THK5351 binding patterns in primary progressive aphasia variants. Eur. J. Nucl. Med. Mol. Imaging 45, 2342–2357. https://doi.org/10.1007/s00259-018-4075-3
  101. Schaeverbeke, J., Gabel, S., Meersmans, K., Bruffaerts, R., Liuzzi, A.G., Evenepoel, C., Dries, E., Van Bouwel, K., Sieben, A., Pijnenburg, Y., Peeters, R., Bormans, G., Van Laere, K., Koole, M., Dupont, P., Vandenberghe, R., 2018. Single-word comprehension deficits in the nonfluent variant of primary progressive aphasia. Alzheimers. Res. Ther. 10, 68. https://doi.org/10.1186/s13195-018-0393-8
  102. Scheltens, N.M.E., Tijms, B.M., Heymans, M.W., Rabinovici, G.D., Cohn-Sheehy, B.I., Miller, B.L., Kramer, J.H., Wolfsgruber, S., Wagner, M., Kornhuber, J., Peters, O., Scheltens, P., van der Flier, W.M., 2018. Prominent Non-Memory Deficits in Alzheimer’s Disease Are Associated with Faster Disease Progression. J. Alzheimers. Dis. 65, 1029–1039. https://doi.org/10.3233/JAD-171088
  103. Scheltens, N.M.E., van der Weijden, K., Adriaanse, S.M., van Assema, D., Oomen, P.P., Krudop, W.A., Lammertsma, A.A., Barkhof, F., Koene, T., Teunissen, C.E., Scheltens, P., van der Flier, W.M., Pijnenburg, Y.A.L., Yaqub, M., Ossenkoppele, R., van Berckel, B.N.M., 2018. Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer’s disease. NeuroImage. Clin. 19, 625–632. https://doi.org/10.1016/j.nicl.2018.05.024
  104. Scheltens, P., Hallikainen, M., Grimmer, T., Duning, T., Gouw, A.A., Teunissen, C.E., Wink, A.M., Maruff, P., Harrison, J., van Baal, C.M., Bruins, S., Lues, I., Prins, N.D., 2018. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimers. Res. Ther. 10, 107. https://doi.org/10.1186/s13195-018-0431-6
  105. Scheltens, P., Prins, N., Lammertsma, A., Yaqub, M., Gouw, A., Wink, A.M., Chu, H.-M., van Berckel, B.N.M., Alam, J., 2018. An exploratory clinical study of p38alpha kinase inhibition in Alzheimer’s disease. Ann. Clin. Transl. Neurol. 5, 464–473. https://doi.org/10.1002/acn3.549
  106. Schindler, S.E., Sutphen, C.L., Teunissen, C., McCue, L.M., Morris, J.C., Holtzman, D.M., Mulder, S.D., Scheltens, P., Xiong, C., Fagan, A.M., 2018.Upward drift in cerebrospinal fluid amyloid beta 42 assay values for more than 10 years. Alzheimers. Dement. 14, 62–70. https://doi.org/10.1016/j.jalz.2017.06.2264
  107. Slot, R.E.R., Verfaillie, S.C.J., Overbeek, J.M., Timmers, T., Wesselman, L.M.P., Teunissen, C.E., Dols, A., Bouwman, F.H., Prins, N.D., Barkhof, F., Lammertsma, A.A., Van Berckel, B.N.M., Scheltens, P., Sikkes, S.A.M., Van der Flier, W.M., 2018. Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimers. Res. Ther. 10, 76. https://doi.org/10.1186/s13195-018-0390-y
  108. Taskesen, E., Mishra, A., van der Sluis, S., Ferrari, R., Veldink, J.H., van Es, M.A., Smit, A.B., Posthuma, D., Pijnenburg, Y., 2018. Author Correction: Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS. Sci. Rep. https://doi.org/10.1038/s41598-018-21308-x
  109. Ten Kate, M., Dicks, E., Visser, P.J., van der Flier, W.M., Teunissen, C.E., Barkhof, F., Scheltens, P., Tijms, B.M., 2018. Atrophy subtypes in prodromal Alzheimer’s disease are associated with cognitive decline. Brain 141, 3443–3456. https://doi.org/10.1093/brain/awy264
  110. Ten Kate, M., Ingala, S., Schwarz, A.J., Fox, N.C., Chetelat, G., van Berckel, B.N.M., Ewers, M., Foley, C., Gispert, J.D., Hill, D., Irizarry, M.C., Lammertsma, A.A., Molinuevo, J.L., Ritchie, C., Scheltens, P., Schmidt, M.E., Visser, P.J., Waldman, A., Wardlaw, J., Haller, S., Barkhof, F., 2018. Secondary prevention of Alzheimer’s dementia: neuroimaging contributions. Alzheimers. Res. Ther. 10, 112. https://doi.org/10.1186/s13195-018-0438-z
  111. Ten Kate, M., Redolfi, A., Peira, E., Bos, I., Vos, S.J., Vandenberghe, R., Gabel, S., Schaeverbeke, J., Scheltens, P., Blin, O., Richardson, J.C., Bordet, R., Wallin, A., Eckerstrom, C., Molinuevo, J.L., Engelborghs, S., Van Broeckhoven, C., Martinez-Lage, P., Popp, J., Tsolaki, M., Verhey, F.R.J., Baird, A.L., Legido-Quigley, C., Bertram, L., Dobricic, V., Zetterberg, H., Lovestone, S., Streffer, J., Bianchetti, S., Novak, G.P., Revillard, J., Gordon, M.F., Xie, Z., Wottschel, V., Frisoni, G., Visser, P.J., Barkhof, F., 2018. MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimers. Res. Ther. 10, 100. https://doi.org/10.1186/s13195-018-0428-1
  112. Ten Kate, M., Sudre, C.H., den Braber, A., Konijnenberg, E., Nivard, M.G., Cardoso, M.J., Scheltens, P., Ourselin, S., Boomsma, D.I., Barkhof, F., Visser, P.J., 2018. White matter hyperintensities and vascular risk factors in monozygotic twins. Neurobiol. Aging 66, 40–48. https://doi.org/10.1016/j.neurobiolaging.2018.02.002
  113. Ten Kate, M., Visser, P.J., Bakardjian, H., Barkhof, F., Sikkes, S.A.M., van der Flier, W.M., Scheltens, P., Hampel, H., Habert, M.-O., Dubois, B., Tijms, B.M., 2018. Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. Front. Aging Neurosci. 10, 67. https://doi.org/10.3389/fnagi.2018.00067
  114. Tesi, N., van der Lee, S.J., Hulsman, M., Jansen, I.E., Stringa, N., van Schoor, N., Meijers-Heijboer, H., Huisman, M., Scheltens, P., Reinders, M.J.T., van der Flier, W.M., Holstege, H., 2018. Centenarian controls increase variant effect sizes by an average twofold in an extreme case-extreme control analysis of Alzheimer’s disease. Eur. J. Hum. Genet. https://doi.org/10.1038/s41431-018-0273-5
  115. Teunissen, C.E., Chiu, M.-J., Yang, C.-C., Yang, S.-Y., Scheltens, P., Zetterberg, H., Blennow, K., 2018. Plasma Amyloid-beta (Abeta42) Correlates with Cerebrospinal Fluid Abeta42 in Alzheimer’s Disease. J. Alzheimers. Dis. 62, 1857–1863. https://doi.org/10.3233/JAD-170784
  116. Tijms, B.M., Ten Kate, M., Gouw, A.A., Borta, A., Verfaillie, S., Teunissen, C.E., Scheltens, P., Barkhof, F., van der Flier, W.M., 2018. Gray matter networks and clinical progression in subjects with predementia Alzheimer’s disease. Neurobiol. Aging 61, 75–81. https://doi.org/10.1016/j.neurobiolaging.2017.09.011
  117. Tijms, B.M., Vermunt, L., Zwan, M.D., van Harten, A.C., van der Flier, W.M., Teunissen, C.E., Scheltens, P., Visser, P.J., 2018. Pre-amyloid stage of Alzheimer’s disease in cognitively normal individuals. Ann. Clin. Transl. Neurol. 5, 1037–1047. https://doi.org/10.1002/acn3.615
  118. Tijms, B.M., Visser, P.J., 2018. Capturing the Alzheimer’s disease pathological cascade. Lancet. Neurol. 17, 199–200. https://doi.org/10.1016/S1474-4422(18)30043-7
  119. Tijms, B.M., Visser, P.J., 2018. Chasing the start of sporadic Alzheimer’s disease running in families. Brain 141, 1589–1591. https://doi.org/10.1093/brain/awy113
  120. Tijms, B.M., Willemse, E.A.J., Zwan, M.D., Mulder, S.D., Visser, P.J., van Berckel, B.N.M., van der Flier, W.M., Scheltens, P., Teunissen, C.E., 2018. Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-beta  1-42 Analysis Results. Clin. Chem. 64, 576–585. https://doi.org/10.1373/clinchem.2017.281055
  121. Timmers, T., van Berckel, B.N.M., Lammertsma, A.A., Ossenkoppele, R., 2018. Quantification of Tau Load in Alzheimer’s Disease Clinical Trials Using Positron  Emission Tomography. Methods Mol. Biol. 1750, 221–229. https://doi.org/10.1007/978-1-4939-7704-8_15
  122. Tolonen, A., Rhodius-Meester, H.F.M., Bruun, M., Koikkalainen, J., Barkhof, F., Lemstra, A.W., Koene, T., Scheltens, P., Teunissen, C.E., Tong, T., Guerrero, R., Schuh, A., Ledig, C., Baroni, M., Rueckert, D., Soininen, H., Remes, A.M., Waldemar, G., Hasselbalch, S.G., Mecocci, P., van der Flier, W.M., Lotjonen, J., 2018. Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. Front. Aging Neurosci. 10, 111. https://doi.org/10.3389/fnagi.2018.00111
  123. van de Kreeke, J.A., Nguyen, H.T., Konijnenberg, E., Tomassen, J., den Braber, A., Ten Kate, M., Sudre, C.H., Barkhof, F., Boomsma, D.I., Tan, H.S., Verbraak, F.D., Visser, P.J., 2018. Retinal and Cerebral Microvasculopathy: Relationships and Their Genetic Contributions. Invest. Ophthalmol. Vis. Sci. 59, 5025–5031. https://doi.org/10.1167/iovs.18-25341
  124. van den Kommer, T.N., Deeg, D.J.H., van der Flier, W.M., Comijs, H.C., 2018. Time Trend in Persistent Cognitive Decline: Results From the Longitudinal Aging Study Amsterdam. J. Gerontol. B. Psychol. Sci. Soc. Sci. 73, S57–S64. https://doi.org/10.1093/geronb/gbx151
  125. van der Flier, W.M., Scheltens, P., 2018. Amsterdam Dementia Cohort: Performing Research to Optimize Care. J. Alzheimers. Dis. 62, 1091–1111. https://doi.org/10.3233/JAD-170850
  126. van der Flier, W.M., Skoog, I., Schneider, J.A., Pantoni, L., Mok, V., Chen, C.L.H., Scheltens, P., 2018. Vascular cognitive impairment. Nat. Rev. Dis. Prim. 4, 18003. https://doi.org/10.1038/nrdp.2018.3
  127. van der Lee, S.J., Teunissen, C.E., Pool, R., Shipley, M.J., Teumer, A., Chouraki, V., Melo van Lent, D., Tynkkynen, J., Fischer, K., Hernesniemi, J., Haller, T., Singh-Manoux, A., Verhoeven, A., Willemsen, G., de Leeuw, F.A., Wagner, H., van Dongen, J., Hertel, J., Budde, K., Willems van Dijk, K., Weinhold, L., Ikram, M.A., Pietzner, M., Perola, M., Wagner, M., Friedrich, N., Slagboom, P.E., Scheltens, P., Yang, Q., Gertzen, R.E., Egert, S., Li, S., Hankemeier, T., van Beijsterveldt, C.E.M., Vasan, R.S., Maier, W., Peeters, C.F.W., Jorgen Grabe, H., Ramirez, A., Seshadri, S., Metspalu, A., Kivimaki, M., Salomaa, V., Demirkan, A., Boomsma, D.I., van der Flier, W.M., Amin, N., van Duijn, C.M., 2018. Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. Alzheimers. Dement. 14, 707–722. https://doi.org/10.1016/j.jalz.2017.11.012
  128. van der Zande, J.J., Gouw, A.A., van Steenoven, I., Scheltens, P., Stam, C.J., Lemstra, A.W., 2018. EEG Characteristics of Dementia With Lewy Bodies, Alzheimer’s Disease and Mixed Pathology. Front. Aging Neurosci. 10, 190. https://doi.org/10.3389/fnagi.2018.00190
  129. van der Zande, J.J., Steenwijk, M.D., Ten Kate, M., Wattjes, M.P., Scheltens, P., Lemstra, A.W., 2018. Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer’s disease pathology. Neurobiol. Aging 71, 171–178. https://doi.org/10.1016/j.neurobiolaging.2018.07.005
  130. van Loenhoud, A.C., Groot, C., Vogel, J.W., van der Flier, W.M., Ossenkoppele, R., 2018. Is intracranial volume a suitable proxy for brain reserve? Alzheimers. Res. Ther. 10, 91. https://doi.org/10.1186/s13195-018-0408-5
  131. Van Someren, E.J.W., Oosterman, J.M., Van Harten, B., Vogels, R.L., Gouw, A.A., Weinstein, H.C., Poggesi, A., Scheltens, P., Scherder, E.J.A., 2018. Medial temporal lobe atrophy relates more strongly to sleep-wake rhythm fragmentation than to age or any other known risk. Neurobiol. Learn. Mem. https://doi.org/10.1016/j.nlm.2018.05.017
  132. van Steenoven, I., Majbour, N.K., Vaikath, N.N., Berendse, H.W., van der Flier, W.M., van de Berg, W.D.J., Teunissen, C.E., Lemstra, A.W., El-Agnaf, O.M.A., 2018. alpha-Synuclein species as potential cerebrospinal fluid biomarkers for dementia  with lewy bodies. Mov. Disord. 33, 1724–1733. https://doi.org/10.1002/mds.111
  133. Verberk, I.M.W., Slot, R.E., Verfaillie, S.C.J., Heijst, H., Prins, N.D., van Berckel, B.N.M., Scheltens, P., Teunissen, C.E., van der Flier, W.M., 2018. Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. Ann. Neurol. 84, 648–658. https://doi.org/10.1002/ana.25334
  134. Verfaillie, S.C.J., Pichet Binette, A., Vachon-Presseau, E., Tabrizi, S., Savard, M., Bellec, P., Ossenkoppele, R., Scheltens, P., van der Flier, W.M., Breitner, J.C.S., Villeneuve, S., 2018. Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer’s Disease. Biol. psychiatry. Cogn. Neurosci. neuroimaging 3, 463–472. https://doi.org/10.1016/j.bpsc.2017.11.012
  135. Verfaillie, S.C.J., Slot, R.E.R., Dicks, E., Prins, N.D., Overbeek, J.M., Teunissen, C.E., Scheltens, P., Barkhof, F., van der Flier, W.M., Tijms, B.M., 2018. A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. Hum. Brain Mapp. 39, 3143–3151. https://doi.org/10.1002/hbm.24065
  136. Verfaillie, S.C.J., Slot, R.E., Tijms, B.M., Bouwman, F., Benedictus, M.R., Overbeek, J.M., Koene, T., Vrenken, H., Scheltens, P., Barkhof, F., van der Flier, W.M., 2018. Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. Neurobiol. Aging 61, 238–244. https://doi.org/10.1016/j.neurobiolaging.2017.09.009
  137. Vermunt, L., Veal, C.D., Ter Meulen, L., Chrysostomou, C., van der Flier, W., Frisoni, G.B., Guessous, I., Kivipelto, M., Marizzoni, M., Martinez-Lage, P., Molinuevo, J.L., Porteous, D., Ritchie, K., Scheltens, P., Ousset, P.-J., Ritchie, C.W., Luscan, G., Brookes, A.J., Visser, P.J., 2018. European Prevention of Alzheimer’s Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. Alzheimers. Dement. 14, 837–842. https://doi.org/10.1016/j.jalz.2018.02.010
  138. Vijverberg, E.G.B., Gossink, F., Krudop, W., Dols, A., Pijnenburg, Y.A.L., 2018. . Ned. Tijdschr. Geneeskd. 162.
  139. Vogel, J.W., Mattsson, N., Iturria-Medina, Y., Strandberg, O.T., Scholl, M., Dansereau, C., Villeneuve, S., van der Flier, W.M., Scheltens, P., Bellec, P., Evans, A.C., Hansson, O., Ossenkoppele, R., 2018. Data-driven approaches for tau-PET imaging biomarkers in Alzheimer’s disease. Hum. Brain Mapp. https://doi.org/10.1002/hbm.24401
  140. Vos, S.J.B., Visser, P.J., 2018. Preclinical Alzheimer’s Disease: Implications for Refinement of the Concept. J. Alzheimers. Dis. 64, S213–S227. https://doi.org/10.3233/JAD-179943
  141. Walker, Z., Gandolfo, F., Orini, S., Garibotto, V., Agosta, F., Arbizu, J., Bouwman, F., Drzezga, A., Nestor, P., Boccardi, M., Altomare, D., Festari, C., Nobili, F., 2018. Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia. Eur. J. Nucl. Med. Mol. Imaging 45, 1534–1545. https://doi.org/10.1007/s00259-018-4031-2
  142. Weintraub, S., Carrillo, M.C., Farias, S.T., Goldberg, T.E., Hendrix, J.A., Jaeger, J., Knopman, D.S., Langbaum, J.B., Park, D.C., Ropacki, M.T., Sikkes, S.A.M., Welsh-Bohmer, K.A., Bain, L.J., Brashear, R., Budur, K., Graf, A., Martenyi, F., Storck, M.S., Randolph, C., 2018. Measuring cognition and function in the preclinical stage of Alzheimer’s disease. Alzheimer’s Dement. (New York, N. Y.) 4, 64–75. https://doi.org/10.1016/j.trci.2018.01.003
  143. Wesselman, L.M.P., Schild, A.-K., Coll-Padros, N., van der Borg, W.E., Meurs, J.H.P., Hooghiemstra, A.M., Slot, R.E.R., Sannemann, L., Rami, L., Molinuevo, J.L., Bouwman, F.H., Jessen, F., van der Flier, W.M., Sikkes, S.A.M., 2018. Wishes and preferences for an online lifestyle program for brain health-A mixed methods study. Alzheimer’s Dement. (New York, N. Y.) 4, 141–149. https://doi.org/10.1016/j.trci.2018.03.003
  144. Willemse, E.A.J., De Vos, A., Herries, E.M., Andreasson, U., Engelborghs, S., van der Flier, W.M., Scheltens, P., Crimmins, D., Ladenson, J.H., Vanmechelen, E., Zetterberg, H., Fagan, A.M., Blennow, K., Bjerke, M., Teunissen, C.E., 2018. Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. Clin. Chem. 64, 927–937. https://doi.org/10.1373/clinchem.2017.283028
  145. Willemse, E.A.J., van Maurik, I.S., Tijms, B.M., Bouwman, F.H., Franke, A., Hubeek, I., Boelaarts, L., Claus, J.J., Korf, E.S.C., van Marum, R.J., Roks, G., Schoonenboom, N., Verwey, N., Zwan, M.D., Wahl, S., van der Flier, W.M., Teunissen, C.E., 2018. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer’s disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. Alzheimer’s Dement. (Amsterdam, Netherlands) 10, 563–572. https://doi.org/10.1016/j.dadm.2018.08.006
  146. Wink, A.M., Tijms, B.M., Ten Kate, M., Raspor, E., de Munck, J.C., Altena, E., Ecay-Torres, M., Clerigue, M., Estanga, A., Garcia-Sebastian, M., Izagirre, A., Martinez-Lage Alvarez, P., Villanua, J., Barkhof, F., Sanz-Arigita, E., 2018. Functional brain network centrality is related to APOE genotype in cognitively normal elderly. Brain Behav. 8, e01080. https://doi.org/10.1002/brb3.1080
  147. Wolters, E.E., Golla, S.S. V, Timmers, T., Ossenkoppele, R., van der Weijden, C.W.J., Scheltens, P., Schwarte, L., Schuit, R.C., Windhorst, A.D., Barkhof, F., Yaqub, M., Lammertsma, A.A., Boellaard, R., van Berckel, B.N.M., 2018. A novel partial volume correction method for accurate quantification of [(18)F] flortaucipir in the hippocampus. EJNMMI Res. 8, 79. https://doi.org/10.1186/s13550-018-0432-2
  148. Wong, T.H., van der Lee, S.J., van Rooij, J.G.J., Meeter, L.H.H., Frick, P., Melhem, S., Seelaar, H., Ikram, M.A., Rozemuller, A.J., Holstege, H., Hulsman, M., Uitterlinden, A., Neumann, M., Hoozemans, J.J.M., van Duijn, C.M., Rademakers, R., van Swieten, J.C., 2019. EIF2AK3 variants in Dutch patients with Alzheimer’s disease. Neurobiol. Aging 73, 229.e11-229.e18. https://doi.org/10.1016/j.neurobiolaging.2018.08.016
  149. Zhang, M., Ferrari, R., Tartaglia, M.C., Keith, J., Surace, E.I., Wolf, U., Sato, C., Grinberg, M., Liang, Y., Xi, Z., Dupont, K., McGoldrick, P., Weichert, A., McKeever, P.M., Schneider, R., McCorkindale, M.D., Manzoni, C., Rademakers, R., Graff-Radford, N.R., Dickson, D.W., Parisi, J.E., Boeve, B.F., Petersen, R.C., Miller, B.L., Seeley, W.W., van Swieten, J.C., van Rooij, J., Pijnenburg, Y., van der Zee, J., Van Broeckhoven, C., Le Ber, I., Van Deerlin, V., Suh, E., Rohrer, J.D., Mead, S., Graff, C., Oijerstedt, L., Pickering-Brown, S., Rollinson, S., Rossi, G., Tagliavini, F., Brooks, W.S., Dobson-Stone, C., Halliday, G.M., Hodges, J.R., Piguet, O., Binetti, G., Benussi, L., Ghidoni, R., Nacmias, B., Sorbi, S., Bruni, A.C., Galimberti, D., Scarpini, E., Rainero, I., Rubino, E., Clarimon, J., Lleo, A., Ruiz, A., Hernandez, I., Pastor, P., Diez-Fairen, M., Borroni, B., Pasquier, F., Deramecourt, V., Lebouvier, T., Perneczky, R., Diehl-Schmid, J., Grafman, J., Huey, E.D., Mayeux, R., Nalls, M.A., Hernandez, D., Singleton, A., Momeni, P., Zeng, Z., Hardy, J., Robertson, J., Zinman, L., Rogaeva, E., 2018. A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain 141, 2895–2907. https://doi.org/10.1093/brain/awy238

Publicaties 2017

  1. Aalfs CM, Vervenne-van Spaendonk R, Pijnenburg YAL, Cohn-Hokke PE, Meijers HJ, Scheltens P. DNA diagnostics in dementia. Ned Tijdschr Geneeskd. 2017;161(0):D1774. Dutch.
  2. Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, Gauthier S, Hey JA, Power A, Wang P, Shen L, Tolar M. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease Suggest Disease Modification Potential. J Prev Alzheimers Dis. 2017;4(3):149-156. doi: 10.14283/jpad.2017.26.
  3. Aisen PS, Cummings J, Jack CR Jr, Morris JC, Sperling R, Frölich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, Scheltens P, Dubois B. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res Ther. 2017 Aug 9;9(1):60. doi: 10.1186/s13195-017-0283-5. Review.
  4. Babapour Mofrad R, Bouwman FH, Slot RER, Timmers T, van der Flier WM, Scheltens P, Teunissen CE. Lumbar puncture in patients with neurologic conditions. Alzheimers Dement (Amst). 2017 May 18;8:108-110. doi: 10.1016/j.dadm.2017.04.008.
  5. Benedictus MR, Leeuwis AE, Binnewijzend MA, Kuijer JP, Scheltens P, Barkhof F, van der Flier WM, Prins ND. Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer’s disease. Eur Radiol. 2017 Mar;27(3):1169-1175. doi: 10.1007/s00330-016-4450-z.
  6. Bertens D, Tijms BM, Scheltens Ph, Teunissen CE, Visser PJ. Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population. Alzheimer’s Research & Therapy.2017;9(8).DOI: 10.1186/s13195-016-0233-7
  7. Bertens D, Tijms BM, Vermunt L, Prins ND, Scheltens P, Visser PJ. The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer’s disease: Implications for trial design. Alzheimers Dement (N Y). 2017 Sep 21;3(4):513-523. doi: 10.1016/j.trci.2017.08.005.
  8. Boomsma JMF, Exalto LG, Barkhof F, van den Berg E, de Bresser J, Heinen R, Koek HL, Prins ND, Scheltens P, Weinstein HC, van der Flier WM, Biessels GJ. Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the “Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment” (TRACE-VCI) Study.  JMIR Res Protoc. 2017 Apr 19;6(4):e60. doi: 10.2196/resprot.6864.
  9. Bos I, Vos SJ, Frölich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Engelborghs S, Niemantsverdriet E, De Roeck EE, Tsolaki M, Freund-Levi Y, Johannsen P, Vandenberghe R, Lleó A, Alcolea D, Frisoni GB, Galluzzi S, Nobili F, Morbelli S, Drzezga A, Didic M, van Berckel BN, Salmon E, Bastin C, Dauby S, Santana I, Baldeiras I, de Mendonça A, Silva D, Wallin A, Nordlund A, Coloma PM, Wientzek A, Alexander M, Novak GP, Gordon MF; Alzheimer’s Disease Neuroimaging Initiative, Wallin ÅK, Hampel H, Soininen H, Herukka SK, Scheltens P, Verhey FR, Visser PJ. The frequency and influence of dementia risk factors in prodromal Alzheimer’s disease.Neurobiol Aging. 2017 Aug;56:33-40. doi: 10.1016/j.neurobiolaging.2017.03.034.
  10. Bridel C, Hoffmann T, Meyer A, Durieux S, Koel-Simmelink MA, Orth M, Scheltens P, Lues I, Teunissen CE. Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients. Alzheimers Res Ther. 2017 Jun 6;9(1):38. doi: 10.1186/s13195-017-0266-6.
  11. Cha DS, Carmona NE, Mansur RB, Lee Y, Park HJ, Rodrigues NB, Subramaniapillaia M, Rosenblat JD, Pan Z, Lee JH, Lee JG, Almatham F, Alageel A, Shekotokhina M, Zhou AJ, Rong C, Harrison JE, McIntyre RS. Pain and major depressive disorder: Associations with cognitive impairment as measured by the THINC-integrated tool (THINC-it). Scandinavian Journal of Pain. 2017:1;62–67. doi: 10.1016/j.sjpain.2016.12.004.
  12. Cha DS, Carmona NW, Subramaniapillai M, Mansur RB, Lee Y, Lee JH, Lee J, Rosenbalt JD, Shekotikhina M, Park C, Rong C, Greer TL, Lam R, Baune BT, Harrison J, McIntye RS. Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. Journal of Affective Disorders. J Affect Disord. 2017:222;14-20. doi: 10.1016/j.jad.2017.06.036.
  13. Chakraborty A, de Wit NM, van der Flier WM, de Vries HE. The blood brain barrier in Alzheimer’s disease. Vascul Pharmacol. 2017 Feb;89:12-18. doi: 10.1016/j.vph.2016.11.008. Epub 2016 Nov 25. Review.
  14. Chatterjee M, Nöding B, Willemse EAJ, Koel-Simmelink MJA, van der Flier WM, Schild D, Teunissen CE. Detection of contactin-2 in cerebrospinal fluid (CSF) of patients with Alzheimer’s disease using Fluorescence Correlation Spectroscopy (FCS). Clin Biochem. 2017 Dec;50(18):1061-1066. doi: 10.1016/j.clinbiochem.2017.08.017.
  15. Claus JJ, Staekenborg SS, Holl DC, Roorda JJ, Schuur J, Koster P, Tielkes CEM, Scheltens P. Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer’s disease: Validation in a large memory clinic population. Eur Radiol. 2017 Aug;27(8):3147-3155. doi: 10.1007/s00330-016-4726-3.
  16. Cohn-Hokke PE, Holstege H, Weiss MM, van der Flier WM, Barkhof F, Sistermans EA, Pijnenburg YA, van Swieten JC, Meijers-Heijboer H, Scheltens P. A novel CCM2 variant in a family with non-progressive cognitive complaints and cerebral microbleeds. Am J Med Genet B Neuropsychiatr Genet. 2017 Apr;174(3):220-226. doi: 10.1002/ajmg.b.32468.
  17. Costa A, Bak T, Caffarra P, Caltagirone C, Ceccaldi M, Collette F, Crutch S, Della Sala S, Démonet JF, Dubois B, Duzel E, Nestor P, Papageorgiou SG, Salmon E, Sikkes S, Tiraboschi P, van der Flier WM, Visser PJ, Cappa SF. The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group. Alzheimers Res Ther. 2017 Apr 17;9(1):27. doi: 10.1186/s13195-017-0254-x. Review.
  18. Crutch SJ, Schott JM, Rabinovici GD, Murray M, Snowden JS, van der Flier WM, Dickerson BC, Vandenberghe R, Ahmed S, Bak TH, Boeve BF, Butler C, Cappa SF, Ceccaldi M, de Souza LC, Dubois B, Felician O, Galasko D, Graff-Radford J, Graff-Radford NR, Hof PR, Krolak-Salmon P, Lehmann M, Magnin E, Mendez MF, Nestor PJ, Onyike CU, Pelak VS, Pijnenburg Y, Primativo S, Rossor MN, Ryan NS, Scheltens P, Shakespeare TJ, Suárez González A, Tang-Wai DF, Yong KXX, Carrillo M, Fox NC; Alzheimer’s Association ISTAART Atypical Alzheimer’s Disease and Associated Syndromes Professional Interest Area. Consensus classification of posterior cortical atrophy. Alzheimers Dement. 2017 Aug;13(8):870-884. doi: 10.1016/j.jalz.2017.01.014.
  19. Cummings J, Scheltens P, McKeith I, Blesa R, Harrison JE, Bertolucci PH, Rockwood K, Wilkinson D, Wijker W, Bennett DA, Shah RC. Effect Size Analyses of Souvenaid in Patients with Alzheimer’s Disease.
  20. Size Analyses of Souvenaid in Patients with Alzheimer’s Disease. J Alzheimers Dis. 2017;55(3):1131-1139.
  21. de Leeuw FA, Peeters CFW, Kester MI, Harms AC, Struys EA, Hankemeier T, van Vlijmen HWT, van der Lee SJ, van Duijn CM, Scheltens P, Demirkan A, van de Wiel MA, van der Flier WM, Teunissen CE. Blood-based metabolic signatures in Alzheimer’s disease. Alzheimers Dement (Amst). 2017 Sep 6;8:196-207. doi: 10.1016/j.dadm.2017.07.006.
  22. de Wilde A, van Maurik IS, Kunneman M, Bouwman F, Zwan M, Willemse EA, Biessels GJ, Minkman M, Pel R, Schoonenboom NS, Smets EM, Wattjes MP, Barkhof F, Stephens A, van Lier EJ, Batrla-Utermann R, Scheltens P, Teunissen CE, van Berckel BN, van der Flier WM. Alzheimer’s biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimers Dement (Amst). 2017 Jan 23;6:143-151. doi: 10.1016/j.dadm.2017.01.003. eCollection 2017.
  23. Demuru M, Gouw AA, Hillebrand A, Stam CJ, van Dijk BW, Scheltens P, Tijms BM, Konijnenberg E, Ten Kate M, den Braber A, Smit DJA, Boomsma DI, Visser PJ. Functional and effective whole brain connectivity using magnetoencephalography to identify monozygotic twin pairs. Sci Rep. 2017 Aug 29;7(1):9685. doi: 10.1038/s41598-017-10235-y.
  24. den Haan J, Verbraak FD, Visser PJ, Bouwman FH. Retinal thickness in Alzheimer’s disease: A systematic review and meta-analysis. Alzheimers Dement (Amst). 2017 Jan 25;6:162-170. doi: 10.1016/j.dadm.2016.12.014. eCollection 2017.
  25. Dicks E, Tijms BM, Ten Kate M, Gouw AA, Benedictus MR, Teunissen CE, Barkhof F, Scheltens P, van der Flier WM. Gray matter network measures are associated with cognitive decline in mild cognitive impairment. Neurobiol Aging. 2018 Jan;61:198-206. doi: 10.1016/j.neurobiolaging.2017.09.029.
  26. Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Dujmovic I, van der Flier W, Frölich L, Galimberti D, Gnanapavan S, Hemmer B, Hoff E, Hort J, Iacobaeus E, Ingelsson M, Jan de Jong F, Jonsson M, Khalil M, Kuhle J, Lleó A, de Mendonça A, Molinuevo JL, Nagels G, Paquet C, Parnetti L, Roks G, Rosa-Neto P, Scheltens P, Skårsgard C, Stomrud E, Tumani H, Visser PJ, Wallin A, Winblad B, Zetterberg H, Duits F, Teunissen CE. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst). 2017 May 18;8:111-126. doi: 10.1016/j.dadm.2017.04.007.
  27. Engels MMA, van der Flier WM, Stam CJ, Hillebrand A, Scheltens P, van Straaten ECW. Alzheimer’s disease: The state of the art in resting-state magnetoencephalography. Clin Neurophysiol. 2017 Aug;128(8):1426-1437. doi: 10.1016/j.clinph.2017.05.012. Epub 2017 May 21. Review.
  28. Engels MMA, Yu M, Stam CJ, Gouw AA, van der Flier WM, Scheltens P, van Straaten ECW, Hillebrand A. Directional information flow in patients with Alzheimer’s disease. A source-space resting-state MEG study. Neuroimage Clin. 2017 Jun 17;15:673-681. doi: 10.1016/j.nicl.2017.06.025. eCollection 2017.
  29. Freeze WM, Jacobs HI, Gronenschild EH, Jansen JF, Burgmans S, Aalten P, Clerx L, Vos SJ, van Buchem MA, Barkhof F, van der Flier WM, Verbeek MM, Rikkert MO, Backes WH, Verhey FR; LeARN project. White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid-β. J Alzheimers Dis. 2017;55(1):333-342.
  30. Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, Démonet JF, Garibotto V, Giannakopoulos P, Gietl A, Hansson O, Herholz K, Jack CR Jr, Nobili F, Nordberg A, Snyder HM, Ten Kate M, Varrone A, Albanese E, Becker S, Bossuyt P, Carrillo MC, Cerami C, Dubois B, Gallo V, Giacobini E, Gold G, Hurst S, Lönneborg A, Lovblad KO, Mattsson N, Molinuevo JL, Monsch AU, Mosimann U, Padovani A, Picco A, Porteri C, Ratib O, Saint-Aubert L, Scerri C, Scheltens P, Schott JM, Sonni I, Teipel S, Vineis P, Visser PJ, Yasui Y, Winblad B. Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers. Lancet Neurol. 2017 Aug;16(8):661-676. doi: 10.1016/S1474-4422(17)30159-X. Epub 2017 Jul 11. Review.
  31. Fuermaier AB, Piersma D, de Waard D, Davidse RJ, de Groot J, Doumen MJ, Bredewoud RA, Claesen R, Lemstra AW, Scheltens P, Vermeeren A, Ponds R, Verhey F, Brouwer WH, Tucha O. Assessing fitness to drive-A validation study on patients with mild cognitive impairment. Traffic Inj Prev. 2017 Feb 17;18(2):145-149. doi: 10.1080/15389588.2016.1232809
  32. Geijselaers SLC, Aalten P, Ramakers IHGB, De Deyn PP, Heijboer AC, Koek HL, OldeRikkert MGM, Papma JM, Reesink FE, Smits LL, Stehouwer CDA, Teunissen CE, Verhey FRJ, van der Flier WM, Biessels GJ; Parelsnoer Institute Neurodegenerative Diseases study group. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer’s Disease. J Alzheimers Dis. 2017 Nov 16. doi: 10.3233/JAD-170522.
  33. Golla SSV, Timmers T, Ossenkoppele R, Groot C, Verfaillie S, Scheltens P, van der Flier WM, Schwarte L, Mintun MA, Devous M, Schuit RC, Windhorst AD, Lammertsma AA, Boellaard R, van Berckel BNM, Yaqub M. Quantification of Tau Load Using [18F]AV1451 PET. Mol Imaging Biol. 2017 Dec;19(6):963-971. doi: 10.1007/s11307-017-1080-z.
  34. Gossink FT, Vijverberg EG, Krudop W, Scheltens P, Stek ML, Pijnenburg YA, Dols A. Psychosis in behavioral variant frontotemporal dementia.Neuropsychiatr Dis Treat. 2017 Apr 13;13:1099-1106. doi: 10.2147/NDT.S127863.
  35. Gouw AA, Alsema AM, Tijms BM, Borta A, Scheltens P, Stam CJ, van der Flier WM. EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. Neurobiol Aging. 2017 Sep;57:133-142. doi: 10.1016/j.neurobiolaging.2017.05.017.
  36. Groot C, van Loenhoud AC, Barkhof F, van Berckel BNM, Koene T, Teunissen CC, Scheltens P, van der Flier WM, Ossenkoppele R. Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology. 2017 Dec 13. pii: 10.1212/WNL.0000000000004802. doi: 10.1212/WNL.0000000000004802
  37. Hafkemeijer A, Möller C, Dopper EG, Jiskoot LC, van den Berg-Huysmans AA, van Swieten JC, van der Flier WM, Vrenken H, Pijnenburg YA, Barkhof F, Scheltens P, van der Grond J, Rombouts SA. A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer’s Disease. J Alzheimers Dis. 2017;55(2):521-537.
  38. Handels RLH, Vos SJB, Kramberger MG, Jelic V, Blennow K, van Buchem M, van der Flier W, Freund-Levi Y, Hampel H, Olde Rikkert M, Oleksik A, Pirtosek Z, Scheltens P, Soininen H, Teunissen C, Tsolaki M, Wallin AK, Winblad B, Verhey FRJ, Visser PJ. Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers.Alzheimers Dement. 2017 Aug;13(8):903-912. doi: 10.1016/j.jalz.2016.12.015.
  39. Handels RLH, Wimo A, Dodel R, Kramberger MG, Visser PJ, Molinuevo JL, Verhey FRJ, Winblad B. Cost-Utility of Using Alzheimer’s Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia. J Alzheimers Dis. 2017;60(4):1477-1487. doi: 10.3233/JAD-170324.
  40. Harper L, Bouwman F, Burton EJ, Barkhof F, Scheltens P, O’Brien JT, Fox NC, Ridgway GR, Schott JM. Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. J Neurol Neurosurg Psychiatry. 2017 Nov;88(11):908-916. doi: 10.1136/jnnp-2016-314978.
  41. Harvey PD, Sabbagh M, Harrison JE, Ginsberg HN, Chapman MJ, Manvelian G, Moryusef A, Mandel J, Farnier M. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials. European Heart Journal. 2017:39;374–381. http://dx.doi.org/10.1093/eurheartj/ehx661.
  42. Herukka SK, Simonsen AH, Andreasen N, Baldeiras I, Bjerke M, Blennow K, Engelborghs S, Frisoni GB, Gabryelewicz T, Galluzzi S, Handels R, Kramberger MG, Kulczyńska A, Molinuevo JL, Mroczko B, Nordberg A, Oliveira CR, Otto M, Rinne JO, Rot U, Saka E, Soininen H, Struyfs H, Suardi S, Visser PJ, Winblad B, Zetterberg H, Waldemar G. Recommendations for cerebrospinal fluid Alzheimer’s disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimers Dement. 2017 Mar;13(3):285-295. doi: 10.1016/j.jalz.2016.09.009. Epub 2016 Oct 27. Review.
  43. Holstege H, van der Lee SJ, Hulsman M, Wong TH, van Rooij JG, Weiss M, Louwersheimer E, Wolters FJ, Amin N, Uitterlinden AG, Hofman A, Ikram MA, van Swieten JC, Meijers-Heijboer H, van der Flier WM, Reinders MJ, van Duijn CM, Scheltens P. Characterization of pathogenic SORL1 genetic variants for association with Alzheimer’s disease: a clinical interpretation strategy. Eur J Hum Genet. 2017 Aug;25(8):973-981. doi: 10.1038/ejhg.2017.87.
  44. Hooghiemstra AM, Bertens AS, Leeuwis AE, Bron EE, Bots ML, Brunner-La Rocca HP, de Craen AJM, van der Geest RJ, Greving JP, Kappelle LJ, Niessen WJ, van Oostenbrugge RJ, van Osch MJP, de Roos A, van Rossum AC, Biessels GJ, van Buchem MA, Daemen MJAP, van der Flier WM; Heart-Brain Connection Consortium. The Missing Link in the Pathophysiology of Vascular Cognitive Impairment: Design of the Heart-Brain Study.Cerebrovasc Dis Extra. 2017 Oct 10;7(3):140-152. doi: 10.1159/000480738.
  45. Hooghiemstra AM, Ramakers IHGB, Sistermans N, Pijnenburg YAL, Aalten P, Hamel REG3, Melis RJF, Verhey FRJ, Olde Rikkert MGM, Scheltens P, van der Flier WM; 4C Study Group. Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study.J Gerontol A Biol Sci Med Sci. 2017 Jun 1;72(6):846-854. doi: 10.1093/gerona/glx003.
  46. Jansen WJ, Handels RL, Visser PJ, Aalten P, Bouwman F, Claassen J, van Domburg P, Hoff E, Hoogmoed J, Leentjens AF, Rikkert MO, Oleksik AM, Smid M, Scheltens P, Wolfs C, Verhey F, Ramakers IH. The Diagnostic and Prognostic Value of Neuropsychological Assessment in Memory Clinic Patients. J Alzheimers Dis. 2017;55(2):679-689.
  47. Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, van der Flier WM, Villemagne VL, Frisoni GB, Fleisher AS, Lleó A, Mintun MA, Wallin A, Engelborghs S, Na DL, Chételat G, Molinuevo JL, Landau SM, Mattsson N, Kornhuber J, Sabri O, Rowe CC, Parnetti L, Popp J, Fladby T, Jagust WJ, Aalten P, Lee DY, Vandenberghe R, Resende de Oliveira C, Kapaki E, Froelich L, Ivanoiu A, Gabryelewicz T, Verbeek MM, Sanchez-Juan P, Hildebrandt H, Camus V, Zboch M, Brooks DJ, Drzezga A, Rinne JO, Newberg A, de Mendonça A, Sarazin M, Rabinovici GD, Madsen K, Kramberger MG, Nordberg A, Mok V, Mroczko B, Wolk DA, Meyer PT, Tsolaki M, Scheltens P, Verhey FRJ, Visser PJ; Amyloid Biomarker Study Group, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BNM, Blennow K, van Buchem MA, Cavedo E, Chen K, Chipi E, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gkatzima O, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Johannsen P, Klimkowicz-Mrowiec A, Köhler S, Koglin N, van Laere K, de Leon M, Lisetti V, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Nordlund A, Novak GP, Paraskevas GP, Perera G, Peters O, Ramakers IHGB, Rami L, Rodríguez-Rodríguez E, Roe CM, Rot U, Rüther E, Santana I, Schröder J, Seo SW, Sorininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Zetterberg H. Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry. 2017 Nov 29. doi: 10.1001/jamapsychiatry.2017.3391
  48. Jansen WJ, Wilson RS, Visser PJ, Nag S, Schneider JA, James BD, Leurgans SE, Capuano AW, Bennett DA, Boyle PA. Age and the association of dementia-related pathology with trajectories of cognitive decline. Neurobiol Aging. 2018 Jan;61:138-145. doi: 10.1016/j.neurobiolaging.2017.08.029
  49. Jutten RJ, Harrison J, de Jong FJ, Alemand A, Ritchiee CW, Scheltens Ph Sikkes SAM. A composite measure of cognitive and functional progression in Alzheimer’s disease: Design of the Capturing Changes in Cognition study. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2017;3(1):130-138.
  50. Jutten RJ, Peeters CFW, Leijdesdorff SMJ, Visser PJ, Maier AB, Terwee CB, Scheltens P, Sikkes SAM. Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire. Alzheimers Dement (Amst). 2017 Mar 31;8:26-35. doi: 10.1016/j.dadm.2017.03.002. eCollection 2017
  51. Konijnenberg E, Fereshtehnejad SM, Kate MT, Eriksdotter M, Scheltens P, Johannsen P, Waldemar G, Visser PJ. Early-Onset Dementia: Frequency, Diagnostic Procedures, and Quality Indicators in Three European Tertiary Referral Centers. Alzheimer Dis Assoc Disord. 2017 Apr-Jun;31(2):146-151. doi: 10.1097/WAD.0000000000000152.
  52. Krudop WA, Dols A, Kerssens CJ, Eikelenboom P, Prins ND, Möller C, Schouws S, Rhebergen D, van Exel E, van der Flier WM, Sikkes S, Scheltens P, Stek ML, Pijnenburg YAL. The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics Despite Multidisciplinary Application of the FTDC Criteria.J Alzheimers Dis. 2017;60(3):959-975. doi: 10.3233/JAD-170608.
  53. Kun-Rodrigues C, Ross OA, Orme T, Shepherd C, Parkkinen L, Darwent L, Hernandez D, Ansorge O, Clark LN, Honig LS, Marder K, Lemstra A, Scheltens P, van der Flier W, Louwersheimer E, Holstege H, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Barber I, Braae A, Brown K, Morgan K, Maetzler W, Berg D, Troakes C, Al-Sarraj S, Lashley T, Holton J, Compta Y, Van Deerlin V, Trojanowski JQ, Serrano GE, Beach TG, Clarimon J, Lleó A, Morenas-Rodríguez E, Lesage S, Galasko D, Masliah E, Santana I, Diez M, Pastor P, Tienari PJ, Myllykangas L, Oinas M, Revesz T, Lees A, Boeve BF, Petersen RC, Ferman TJ, Escott-Price V, Graff-Radford N, Cairns NJ, Morris JC, Stone DJ, Pickering-Brown S, Mann D, Dickson DW, Halliday GM, Singleton A, Guerreiro R, Bras J. Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiol Aging. 2017 Jan;49:214.e13-214.e15. doi: 10.1016/j.neurobiolaging.2016.08.023.
  54. Kunneman M, Pel-Littel R, Bouwman FH, Gillissen F, Schoonenboom NSM, Claus JJ, van der Flier WM, Smets EMA. Patients’ and caregivers’ views on conversations and shared decision making in diagnostic testing for Alzheimer’s disease: The ABIDE project. Alzheimers Dement (N Y). 2017 May 10;3(3):314-322. doi: 10.1016/j.trci.2017.04.002.
  55. Kunneman M, Smets EMA, Bouwman FH, Schoonenboom NSM, Zwan MD, Pel-Littel R, van der Flier WM. Clinicians’ views on conversations and shared decision making in diagnostic testing for Alzheimer’s disease: The ABIDE project. Alzheimers Dement (N Y). 2017 May 10;3(3):305-313. doi: 10.1016/j.trci.2017.03.009.
  56. Lacour A, Espinosa A, Louwersheimer E, Heilmann S, Hernández I, Wolfsgruber S, Fernández V, Wagner H, Rosende-Roca M, Mauleón A, Moreno-Grau S, Vargas L, Pijnenburg YA, Koene T, Rodríguez-Gómez O, Ortega G, Ruiz S, Holstege H, Sotolongo-Grau O, Kornhuber J, Peters O, Frölich L, Hüll M, Rüther E, Wiltfang J, Scherer M, Riedel-Heller S, Alegret M, Nöthen MM, Scheltens P, Wagner M, Tárraga L, Jessen F, Boada M, Maier W, van der Flier WM, Becker T, Ramirez A, Ruiz A. Genome-wide significant risk factors for Alzheimer’s disease: role in progression to dementia due to Alzheimer’s disease among subjects with mild cognitive impairment. Mol Psychiatry. 2017 Jan;22(1):153-160. doi: 10.1038/mp.2016.18.
  57. Leeuwis AE, Benedictus MR, Kuijer JPA, Binnewijzend MAA, Hooghiemstra AM, Verfaillie SCJ, Koene T, Scheltens P, Barkhof F, Prins ND, van der Flier WM. Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer’s disease. Alzheimers Dement. 2017 May;13(5):531-540. doi: 10.1016/j.jalz.2016.08.013.
  58. Leeuwis AE, Hooghiemstra AM, Amier R, Ferro DA, Franken L, Nijveldt R, Kuijer JPA, Bronzwaer ASGT, van Lieshout JJ, Rietberg MB, Veerbeek JM, Huijsmans RJ, Backx FJG, Teunissen CE, Bron EE, Barkhof F, Prins ND, Shahzad R, Niessen WJ, de Roos A, van Osch MJP, van Rossum AC, Biessels GJ, van der Flier WM: on behalf of the Heart Brain Connection study group. Design of the ExCersion-VCI study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment.Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2017 June;3 (2):157–16. DOI: http://dx.doi.org/10.1016/j.trci.2017.02.002
  59. Legdeur N, Binnekade TT, Otten RH, Badissi M, Scheltens P, Visser PJ, Maier AB. Cognitive functioning of individuals aged 90 years and older without dementia: A systematic review. Ageing Res Rev. 2017 Mar 8;36:42-49. doi: 10.1016/j.arr.2017.02.006.
  60. Leijenaar JF, van Maurik IS, Kuijer JPA, van der Flier WM, Scheltens P, Barkhof F, Prins ND. Lower cerebral blood flow in subjects with Alzheimer’s dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging.Alzheimers Dement (Amst). 2017 Nov 2;9:76-83. doi: 10.1016/j.dadm.2017.10.001.
  61. Lemstra AW, de Beer MH, Teunissen CE, Schreuder C, Scheltens P, van der Flier WM, Sikkes SA. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):113-118. doi: 10.1136/jnnp-2016-313775.
  62. Lewczuk P, Riederer P, O’Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR Jr, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, van Waalwijk van Doorn L, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, Van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Lopez Mato A, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J; Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry. 2017 Oct 27:1-85. doi: 10.1080/15622975.2017.1375556.
  63. López ME, Engels MMA, van Straaten ECW, Bajo R, Delgado ML, Scheltens Ph, Hillebrand A,. Stam CJ, Maestú F. MEG Beamformer-Based Reconstructions of Functional Networks in Mild Cognitive Impairment.Front. Aging Neurosci., 25 April 2017. https://doi.org/10.3389/fnagi.2017.00107
  64. Louwersheimer E, Cohn-Hokke PE, Pijnenburg YA, Weiss MM, Sistermans EA, Rozemuller AJ, Hulsman M, van Swieten JC, van Duijn CM, Barkhof F, Koene T, Scheltens P, Van der Flier WM, Holstege H. Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer’s Disease in a Family with Several Generations of APOE-ɛ4 Homozygosity. J Alzheimers Dis. 2017;56(1):63-74. doi: 10.3233/JAD-160091.
  65. McIntyre RS, Barry H, Baune BT, Best MW, Bowie CR, Cha DS, Culpepper L, Fossati P, Greer TL, Harmer C, Klag E, Lam RW, Lee Y, Mansur RB, Wittchen H-U, Harrison JE. The THINC-integrated tool (THINC-it) screening assessment for cognitive dysfunction: Validation in patients with Major Depressive Disorder. Journal of Clinical Psychiatry, 2017:78;873-881. doi: 10.4088/JCP.16m11329.
  66. Miller AM, Balasa M, Blennow K, Gardiner M, Rutkowska A, Scheltens P, Teunissen CE, Visser PJ, Winblad B, Waldemar G, Lawlor B. Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. J Alzheimers Dis. 2017;60(1):201-210. doi: 10.3233/JAD-170502.
  67. Mo Y, Stromswold J, Wilson K, Holder D, Sur C, Laterza O, Savage MJ, Struyk A, Scheltens P, Teunissen CE, Burke J, Macaulay SL, Bråthen G, Sando SB, White LR, Weiss C, Cowes A, Bush MM, DeSilva G, Darby DG, Rainey-Smith SR, Surls J, Sagini E, Tanen M, Altman A, Luthman J, Egan MF. A multinational study distinguishing Alzheimer’s and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging. Alzheimers Dement (Amst). 2017 Mar 6;6:201-209. doi: 10.1016/j.dadm.2017.02.004.
  68. Molinuevo JL, Rabin LA, Amariglio R, Buckley R, Dubois B, Ellis KA, Ewers M, Hampel H, Klöppel S, Rami L, Reisberg B, Saykin AJ, Sikkes S, Smart CM, Snitz BE, Sperling R, van der Flier WM, Wagner M, Jessen F; Subjective Cognitive Decline Initiative (SCD-I) Working Group. Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement. 2017 Mar;13(3):296-311. doi: 10.1016/j.jalz.2016.09.012.
  69. Morbelli S, Bauckneht M, Scheltens P. Imaging biomarkers in Alzheimer’s disease: added value in the clinical setting. Q J Nucl Med Mol Imaging. 2017 Dec;61(4):360-371. doi: 10.23736/S1824-4785.17.03011-4.
  70. Nathan PJ, Lim YY, Abbott R, Galluzzi S, Marizzoni M, Babiloni C, Albani D, Bartres-Faz D, Didic M, Farotti L, Parnetti L, Salvadori N, Müller BW, Forloni G, Girtler N, Hensch T, Jovicich J, Leeuwis A, Marra C, Molinuevo JL, Nobili F, Pariente J, Payoux P, Ranjeva JP, Rolandi E, Rossini PM, Schönknecht P, Soricelli A, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB; PharmaCog Consortium. Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI). Neurobiol Aging. 2017 May;53:1-10. doi: 10.1016/j.neurobiolaging.2017.01.013.
  71. Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P; SCarlet RoAD Investigators. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther. 2017 Dec 8;9(1):95. doi: 10.1186/s13195-017-0318-y.
  72. Perera G, Pedersen L, Ansel D, Alexander M, Arrighi HM, Avillach P, Foskett N, Gini R, Gordon MF, Gungabissoon U, Mayer MA, Novak G, Rijnbeek P, Trifirò G, van der Lei J, Visser PJ, Stewart R. Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource. Alzheimers Dement. 2017 Jul 21. pii: S1552-5260(17)32523-2. doi: 10.1016/j.jalz.2017.06.2270.
  73. Piersma D, Fuermaier ABM, De Waard D, Davidse RJ, De Groot J, Doumen MJA, Bredewoud RA, Claesen R, Lemstra AW, Scheltens P, Vermeeren A, Ponds R, Verhey F, De Deyn PP, Brouwer WH, Tucha O. Assessing Fitness to Drive in Patients With Different Types of Dementia. Alzheimer Dis Assoc Disord. 2017 Nov 17. doi: 10.1097/WAD.0000000000000221
  74. Reijs BLR, Ramakers IHGB, Elias-Sonnenschein L, Teunissen CE, Koel-Simmelink M, Tsolaki M, Wahlund LO, Waldemar G, Hausner L, Johannsen P, Vanderstichele H, Verhey F, Devanand DP, Visser PJ. Relation of Odor Identification with Alzheimer’s Disease Markers in Cerebrospinal Fluid and Cognition. J Alzheimers Dis. 2017;60(3):1025-1034. doi: 10.3233/JAD-170564.
  75. Reijs BLR, Ramakers IHGB, Köhler S, Teunissen CE, Koel-Simmelink M, Nathan PJ, Tsolaki M, Wahlund LO, Waldemar G, Hausner L, Vandenberghe R, Johannsen P, Blackwell A, Vanderstichele H, Verhey F, Visser PJ. Memory Correlates of Alzheimer’s Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. J Alzheimers Dis. 2017;60(3):1119-1128. doi: 10.3233/JAD-160766.
  76. Reijs BLR, Vos SJB, Soininen H, Lötjonen J, Koikkalainen J, Pikkarainen M, Hall A, Vanninen R, Liu Y, Herukka SK, Freund-Levi Y, Frisoni GB, Frölich L, Nobili F, Rikkert MO, Spiru L, Tsolaki M, Wallin ÅK, Scheltens P, Verhey F, Visser PJ. Association Between Later Life Lifestyle Factors and Alzheimer’s Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. J Alzheimers Dis. 2017;60(4):1387-1395. doi: 10.3233/JAD-170039.
  77. Rhodius-Meester HFM, Benedictus MR, Wattjes MP, Barkhof F, Scheltens Ph, Muller M, van der Flier WM. MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. Front. Aging Neurosci., 09 May 2017 | https://doi.org/10.3389/fnagi.2017.00117
  78. Sartor J, Bettecken K, Bernhard FP, Hofmann M, Gladow T, Lindig T, Ciliz M, Ten Kate M, Geritz J, Heinzel S, Benedictus M, Scheltens P, Hobert MA, Maetzler W. White Matter Changes-Related Gait and Executive Function Deficits: Associations with Age and Parkinson’s Disease. Front Aging Neurosci. 2017 Jun 30;9:213. doi: 10.3389/fnagi.2017.00213.
  79. Scheltens NME, Tijms BM, Koene T, Barkhof F, Teunissen CE, Wolfsgruber S, Wagner M, Kornhuber J, Peters O, Cohn-Sheehy BI, Rabinovici GD, Miller BL, Kramer JH, Scheltens P, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative; German Dementia Competence Network; University of California San Francisco Memory and Aging Center; Amsterdam Dementia Cohort. Cognitive subtypes of probable Alzheimer’s disease robustly identified in four cohorts. Alzheimers Dement. 2017 Nov;13(11):1226-1236. doi: 10.1016/j.jalz.2017.03.002.
  80. Scheltens P, Gillissen F, Bouwman FH, van der Flier WM. Doctor, is my mother suffering from dementia? Ned Tijdschr Geneeskd. 2017;161(0):D2086. Dutch.
  81. Scheltens P, Zwan M, Ossenkoppele R, Bouwman F, van Berckel BN. Amyloid PET imaging in patients with Alzheimer’s disease Ned Tijdschr Geneeskd. 2017;161(0):D808. Dutch.
  82. Schindler SE, Sutphen CL, Teunissen C, McCue LM, Morris JC, Holtzman DM, Mulder SD, Scheltens P, Xiong C, Fagan AM. Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years.Alzheimers Dement. 2017 Jul 12. pii: S1552-5260(17)32516-5. doi: 10.1016/j.jalz.2017.06.2264.
  83. Simonsen AH, Herukka SK, Andreasen N, Baldeiras I, Bjerke M, Blennow K, Engelborghs S, Frisoni GB, Gabryelewicz T, Galluzzi S, Handels R, Kramberger MG, Kulczyńska A, Molinuevo JL, Mroczko B, Nordberg A, Oliveira CR, Otto M, Rinne JO, Rot U, Saka E, Soininen H, Struyfs H, Suardi S, Visser PJ, Winblad B, Zetterberg H, Waldemar G. Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement. 2017 Mar;13(3):274-284. doi: 10.1016/j.jalz.2016.09.008. Epub 2016 Oct 27. Review.
  84. Skillbäck T, Mattsson N, Hansson K, Mirgorodskaya E, Dahlén R, van der Flier W, Scheltens P, Duits F, Hansson O, Teunissen C, Blennow K, Zetterberg H, Gobom J. A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease. Sci Rep. 2017 Oct 17;7(1):13333. doi: 10.1038/s41598-017-13831-0.
  85. Slot RE, Van Harten AC, Kester MI, Jongbloed W, Bouwman FH, Teunissen CE, Scheltens P, Veerhuis R, van der Flier WM. Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer’s Disease in Non-Demented Elderly. J Alzheimers Dis. 2017;56(2):687-697. doi: 10.3233/JAD-151068.
  86. Smart CM, Karr JE, Areshenkoff CN, Rabin LA, Hudon C, Gates N, Ali JI, Arenaza-Urquijo EM, Buckley RF, Chetelat G, Hampel H, Jessen F, Marchant NL, Sikkes SAM, Tales A, van der Flier WM, Wesselman L; and the Subjective Cognitive Decline Initiative (SCD-I) Working Group. Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations. Neuropsychol Rev. 2017 Sep;27(3):245-257. doi: 10.1007/s11065-017-9342-8. Epub 2017 Mar 7. Review.
  87. Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, Hartmann T; LipiDiDiet clinical study group. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol. 2017 Dec;16(12):965-975. doi: 10.1016/S1474-4422(17)30332-0.
  88. Ten Kate M, Barkhof F, Boccardi M, Visser PJ, Jack CR Jr, Lovblad KO, Frisoni GB, Scheltens P; Geneva Task Force for the Roadmap of Alzheimer’s Biomarkers. Clinical validity of medial temporal atrophy as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017 Apr;52:167-182.e1. doi: 10.1016/j.neurobiolaging.2016.05.024. Review.
  89. Ten Kate M, Barkhof F, Visser PJ, Teunissen CE, Scheltens P, van der Flier WM, Tijms BM. Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. Alzheimers Res Ther. 2017 Sep 12;9(1):73. doi: 10.1186/s13195-017-0299-x.
  90. Tijms BM, Bertens D, Slot RE, Gouw AA, Teunissen CE, Scheltens P, van der Flier WM, Visser PJ. Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects. Ann Neurol. 2017 May;81(5):749-753. doi: 10.1002/ana.24921.
  91. Tijms BM, Ten Kate M, Gouw AA, Borta A, Verfaillie S, Teunissen CE, Scheltens P, Barkhof F, van der Flier WM. Gray matter networks and clinical progression in subjects with predementia Alzheimer’s disease.Neurobiol Aging. 2018 Jan;61:75-81. doi: 10.1016/j.neurobiolaging.2017.09.011.
  92. Tijms BM, Willemse EAJ, Zwan MD, Mulder SD, Visser PJ, van Berckel BNM, van der Flier WM, Scheltens P, Teunissen CE. Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1-42 Analysis Results. Clin Chem. 2017 Dec 5. pii: clinchem.2017.281055. doi: 10.1373/clinchem.2017.281055.
  93. van Dalen JW, Moll van Charante EP, Caan MWA, Scheltens P, Majoie CBLM, Nederveen AJ, van Gool WA, Richard E. Effect of Long-Term Vascular Care on Progression of Cerebrovascular Lesions: Magnetic Resonance Imaging Substudy of the PreDIVA Trial (Prevention of Dementia by Intensive Vascular Care). Stroke. 2017 Jul;48(7):1842-1848. doi: 10.1161/STROKEAHA.117.017207.
  94. van der Flier WM, Kunneman M, Bouwman FH, Petersen RC, Smets EMA. Diagnostic dilemmas in Alzheimer’s disease: Room for shared decision making. Alzheimers Dement (N Y). 2017 May 9;3(3):301-304. doi: 10.1016/j.trci.2017.03.008
  95. van Harten AC, Jongbloed W, Teunissen CE, Scheltens P, Veerhuis R, van der Flier WM. CSF ApoE predicts clinical progression in nondemented APOEε4 carriers. Neurobiol Aging. 2017 Sep;57:186-194. doi: 10.1016/j.neurobiolaging.2017.04.002. Epub 2017 Apr 12.
  96. van Loenhoud AC, Wink AM, Groot C, Verfaillie SCJ, Twisk J, Barkhof F, van Berckel B, Scheltens P, van der Flier WM, Ossenkoppele R. A neuroimaging approach to capture cognitive reserve: Application to Alzheimer’s disease.Hum Brain Mapp. 2017 Sep;38(9):4703-4715. doi: 10.1002/hbm.23695
  97. van Maurik IS, Zwan MD, Tijms BM, Bouwman FH, Teunissen CE, Scheltens P, Wattjes MP, Barkhof F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer’s Biomarkers in Daily Practice (ABIDE) Project. JAMA Neurol. 2017 Oct 16. doi: 10.1001/jamaneurol.2017.2712.
  98. Van Mierlo LD, Wouters H, Sikkes SA, Van der Flier WM, Prins ND, Bremer JA, Koene T, Van Hout HP. Screening for Mild Cognitive Impairment and Dementia with Automated, Anonymous Online and Telephone Cognitive Self-Tests. J Alzheimers Dis. 2017;56(1):249-259. doi: 10.3233/JAD-160566.
  99. van Waalwijk van Doorn LJ, Gispert JD, Kuiperij HB, Claassen JA, Arighi A, Baldeiras I, Blennow K, Bozzali M, Castelo-Branco M, Cavedo E, Emek-Savaş DD, Eren E, Eusebi P, Farotti L, Fenoglio C, Ormaechea JF, Freund-Levi Y, Frisoni GB, Galimberti D, Genc S, Greco V, Hampel H, Herukka SK, Liu Y, Lladó A, Lleó A, Nobili FM, Oguz KK, Parnetti L, Pereira J, Picco A, Pikkarainen M, de Oliveira CR, Saka E, Salvadori N, Sanchez-Valle R, Santana I, Scarpini E, Scheltens P, Soininen H, Tarducci R, Teunissen C, Tsolaki M, Urbani A, Vilaplana E, Visser PJ, Wallin AK, Yener G, Molinuevo JL, Meulenbroek O, Verbeek MM. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer’s Disease Patients and Controls after Correction for Ventricular Volumes. J Alzheimers Dis. 2017;56(2):543-555. doi: 10.3233/JAD-160668.
  100. van Wijk N, Slot RER, Duits FH, Strik M, Biesheuvel E, Sijben JWC, Blankenstein MA, Bierau J, van der Flier WM, Scheltens P, Teunissen CE. Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer’s disease dementia. Alzheimers Dement (Amst). 2017 May 16;8:139-146. doi: 10.1016/j.dadm.2017.04.005.
  101. Vandenberghe R, Riviere ME, Caputo A, Sovago J, Maguire RP, Farlow M, Marotta G, Sanchez-Valle R, Scheltens P, Ryan JM, Graf A. Active Aβ immunotherapy CAD106 in Alzheimer’s disease: A phase 2b study.Alzheimers Dement (N Y). 2016 Dec 23;3(1):10-22. doi: 10.1016/j.trci.2016.12.003.
  102. Verfaillie SCJ, Slot RE, Tijms BM, Bouwman F, Benedictus MR, Overbeek JM, Koene T, Vrenken H, Scheltens P, Barkhof F, van der Flier WM. Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. Neurobiol Aging. 2018 Jan;61:238-244. doi: 10.1016/j.neurobiolaging.2017.09.009.
  103. Vijverberg EG, Dols A, Krudop WA, Del Campo Milan M, Kerssens CJ, Gossink F, Prins ND, Stek ML, Scheltens P, Teunissen CE, Pijnenburg YA. Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders. Alzheimers Dement (Amst). 2017 Mar 2;7:99-106. doi: 10.1016/j.dadm.2017.01.009.
  104. Vijverberg EGB, Gossink F, Krudop W, Sikkes S, Kerssens C, Prins N, Stek M, Scheltens P, Pijnenburg Y, Dols A. The Diagnostic Challenge of the Late-Onset Frontal Lobe Syndrome: Clinical Predictors for Primary Psychiatric Disorders Versus Behavioral Variant Frontotemporal Dementia. J Clin Psychiatry. 2017 Oct 31. pii: 16m11078. doi: 10.4088/JCP.16m11078.
  105. Vijverberg EG, Pijnenburg AC, Scheltens P, Pijnenburg YA. Chronic traumatic encephalopathy: an old acquaintance in athletes Ned Tijdschr Geneeskd. 2017;161(0):D465. Dutch.
  106. Vijverberg EGB, Schouws S, Meesters PD, Verwijk E, Comijs H, Koene T, Schreuder C, Beekman A, Scheltens P, Stek M, Pijnenburg Y, Dols A. Cognitive Deficits in Patients With Neuropsychiatric Symptoms: A Comparative Study Between Behavioral Variant Frontotemporal Dementia and Primary Psychiatric Disorders. J Clin Psychiatry. 2017 Sep/Oct;78(8):e940-e946. doi: 10.4088/JCP.16m11019.
  107. Vijverberg EGB, Tijms BM, Dopp J, Hong YJ, Teunissen CE, Barkhof F, Scheltens P, Pijnenburg YAL. Gray matter network differences between behavioral variant frontotemporal dementia and Alzheimer’s disease.Neurobiol Aging. 2017 Feb;50:77-86. doi: 10.1016/j.neurobiolaging.2016.11.005.
  108. Visser PJ, Tijms B. Brain Amyloid Pathology and Cognitive Function: Alzheimer Disease Without Dementia? JAMA. 2017 Jun 13;317(22):2285-2287. doi: 10.1001/jama.2017.6895.
  109. Vos SJB, van Boxtel MPJ, Schiepers OJG, Deckers K, de Vugt M, Carrière I, Dartigues JF, Peres K, Artero S, Ritchie K, Galluzzo L, Scafato E, Frisoni GB, Huisman M, Comijs HC, Sacuiu SF, Skoog I, Irving K, O’Donnell CA, Verhey FRJ, Visser PJ, Köhler S. Modifiable Risk Factors for Prevention of Dementia in Midlife, Late Life and the Oldest-Old: Validation of the LIBRA Index. J Alzheimers Dis. 2017;58(2):537-547. doi: 10.3233/JAD-161208.
  110. Voyle N, Patel H, Folarin A, Newhouse S, Johnston C, Visser PJ, Dobson RJ, Kiddle SJ; EDAR and DESCRIPA study groups and the Alzheimer’s Disease Neuroimaging Initiative. Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid. J Alzheimers Dis. 2017;55(4):1417-1427. doi: 10.3233/JAD-160707.
  111. Willemse EAJ, van Uffelen KWJ, van der Flier WM, Teunissen CE. Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ1-42, T-tau, and P-tau values. Alzheimers Dement (Amst). 2017 Apr 4;8:45-50. doi: 10.1016/j.dadm.2017.03.005.
  112. Yu M, Engels MM, Hillebrand A, van Straaten EC, Gouw AA, Teunissen C, van der Flier WM, Scheltens P, Stam CJ. Selective impairment of hippocampus and posterior hub areas in Alzheimer’s disease: an MEG-based multiplex network study. Brain. 2017 Mar 16. doi: 10.1093/brain/awx050.
  113. Zwan MD, Bouwman FH, Konijnenberg E, van der Flier WM, Lammertsma AA, Verhey FR, Aalten P, van Berckel BN, Scheltens P. Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2017 Jan 17;9(1):2. doi: 10.1186/s13195-016-0228-4.

Publicaties 2016

Publicaties 2015

Publicaties 2014

Internationale publicaties

Vakpublicaties:

  • van Hout, H. P. J., Macneil Vroomen, J. L., Van Mierlo, L. D., Meiland, F. J. M., Moll van Charante, E. P., Joling, K. J., van den Dungen, P., Droes, R. M., van der Horst, H. E., de Rooij, S. E. J. A.Comparing case management care models for people with dementia and their caregivers: the design of the COMPAS study. Tijdschrift voor gerontologie en geriatrie 2014;45(2):105-16.

Dissertaties:

  • Binnewijzend M.A.A. Functional and perfusion MRI in dementia
    Vrije Universiteit Amsterdam 21 maart 2014.
    Promotoren: F. Barkhof, Ph. Scheltens, copromotor: J.P.A Kuijer
  • de Waal H. Understanding heterogeneity in Alzheimer’s disease: A neurophysiological perspective.
    Vrije Universiteit Amsterdam 25 april 2014.
    Promotoren: Ph. Scheltens, C.J. Stam, copromotoren: W.M. van der Flier, E.C.W. van Straaten.
  • Jongbloed W. Neurodegeneration: Biochemical signals from the brain
    Vrije Universiteit Amsterdam 8 mei 2014
    Promotoren: M.A. Blankenstein, Ph. Scheltens, copromotor: R. Veerhuis
  • Poortvliet-Koedam E.L.G.E. Early-onset dementia: Unravelling the clinical phenotypes.
    Vrije Universiteit Amsterdam 28 mei 2014.
    Promotoren: Ph. Scheltens, copromotoren: Y.A.L Pijnenburg, M.P. Wattjes
  • van Harten A.C. The road less traveled. CSF biomarkers for Alzheimer’s disease: predicting earliest cognitive decline and exploring microrna as a novel biomarker source.
    Vrije Universiteit Amsterdam 7 november 2014.
    Promotoren: Ph. Scheltens, C.B.M Oudejans, copromotoren: W.M. van der Flier, C.E. Teunissen
  • Hooghiemstra A. Early-onset dementia: with exercise in mind
    Vrije Universiteit Amsterdam 3 december 2014
    Promotoren: E.J.A Scherder, Ph. Scheltens, copromotor: L.H.P Eggermont

Publicaties 2013

Internationale publicaties:

  • Bakker, C., de Vugt, M. E., van Vliet, D., Verhey, F. R. J., Pijnenburg, Y. A., Vernooij-Dassen, M. J. F. J., Koopmans, R. T. C. M. The Use of Formal and Informal Care in Early Onset Dementia: Results From the NeedYD Study. American journal of geriatric psychiatry 2013;21(1):37-45. doi:10.1016/j.jagp.2012.10.004
  • Bakker, C., de Vugt, M. E., van Vliet, D., Verhey, F. R. J., Pijnenburg, Y. A., Vernooij-Dassen, M. J. F. J., Koopmans, R. T. C. M. Predictors of the Time to Institutionalization in Young- Versus Late-Onset Dementia: Results From the Needs in Young Onset Dementia (NeedYD) Study. Journal of the american medical directors association 2013;14(4):248-53. doi:10.1016/j.jamda.2012.09.011
  • Barkhof, F., Daams, M., Scheltens, P., Brashear, H. R., Arrighi, H. M., Bechten, A., Morris, K., McGovern, M., Wattjes, M. P. An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion. AJNR American journal of neuroradiology 2013;34(8):1550-5. doi:10.3174/ajnr.A3475
  • Benedictus, M. R., Goos, J. D., Binnewijzend, M. A. A., Muller, M., Barkhof, F., Scheltens, P., Prins, N. D., van der Flier, W. M. Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer’s disease. Neurobiology of aging 2013;34(11):2488-94. doi:10.1016/j.neurobiolaging.2013.04.023
  • Binnewijzend, M. A., Kuijer, J. P., Benedictus, M. R., van der Flier, W. M., Wink, A. M., Wattjes, M. P., van Berckel, B. N., Scheltens, P., Barkhof, F. Cerebral Blood Flow Measured with 3D Pseudocontinuous Arterial Spin-labeling MR Imaging in Alzheimer Disease and Mild Cognitive Impairment: A Marker for Disease Severity. Radiology 2013;267(1):221-30. Doi:10.1148/radiol.12120928
  • Boom, M., Olofsen, E., Neukirchen, M., Fussen, R., Hay, J., Groeneveld, G. J., Aarts, L., Sarton, E., Dahan, A. Fentanyl Utility Function: A Risk-Benefit Composite of Pain Relief and Breathing Responses. Anesthesiology 2013;119(3):663-74. Doi:10.1097/ALN.0b013e31829ce4cb
  • Bruggink, K. A., Jongbloed, W., Biemans, E. A. L. M., Veerhuis, R., Claassen, J. A. H. R., Kuiperij, H. B., Verbeek, M. M. Amyloid-beta oligomer detection by ELISA in cerebrospinal fluid and brain tissue. Analytical biochemistry 2013;433(2):112-20. Doi:10.1016/j.ab.2012.09.014
  • Clerx, L., Jacobs, H., I, Burgmans, S., Gronenschild, E., Uylings, H., Echavarri, C., Visser, P., Verhey, F., Aalten, P. Sensitivity of Different MRI-Techniques to Assess Gray Matter Atrophy Patterns in Alzheimer’s Disease is Region-Specific. Current alzheimer research 2013;10(9):940-51. WpR, VUmc NCA-NB
  • Clerx, L., van Rossum, I. A., Burns, L., Knol, D. L., Scheltens, P., Verhey, F., Aalten, P., Lapuerta, P., van de Pol, L., van Schijndel, R., de Jong, R., Barkhof, F., Wolz, R., Rueckert, D., Bocchetta, M., Tsolaki, M., Nobili, F., Wahlund, L. O., Minthon, L., Frolich, L., Hampel, H., Soininen, H., Visser, P. J. Measurements of medial temporal lobe atrophy for prediction of Alzheimer’s disease in subjects with mild cognitive impairment. Neurobiology of aging 2013;34(8):2003-13. Doi:10.1016/j.neurobiolaging.2013.02.002
  • Crutch, S. J., Schott, J. M., Rabinovici, G. D., Boeve, B. F., Cappa, S. F., Dickerson, B. C., Dubois, B., Graff-Radford, N. R., Krolak-Salmon, P., Lehmann, M., Mendez, M. F., Pijnenburg, Y. A. L., Ryan, N. S., Scheltens, P., Shakespeare, T., Tang-Wai, D. F., van der Flier, W. M., Bain, L., Carrillo, M. C., Fox, N. C. Shining a light on posterior cortical atrophy. Alzheimer’s & dementia : the journal of the Alzheimer’s Association 2013;9(4):463-5. Doi:10.1016/j.jalz.2012.11.004
  • Cummings, J. L., Dubois, B., Molinuevo, J. L., Scheltens, P. International Work Group Criteria for the Diagnosis of Alzheimer Disease. Medical clinics of north america 2013;97(3):363-+. Doi:10.1016/j.mcna.2013.01.001
  • Damian, M., Hausner, L., Jekel, K., Richter, M., Froelich, L., Almkvist, O., Boada, M., Bullock, R., De Deyn, P. P., Frisoni, G. B., Hampel, H., Jones, R. W., Kehoe, P., Lenoir, H., Minthon, L., Olde Rikkert, M. G. M., Rodriguez, G., Scheltens, P., Soininen, H., Spiru, L., Touchon, J., Tsolaki, M., Vellas, B., Verhey, F. R. J., Winblad, B., Wahlund, L. O., Wilcock, G., Visser, P. J. Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer’s disease in the european prospective DESCRIPA study. Dementia and geriatric cognitive disorders 2013;36(1-2):1-19. Doi:10.1159/000348354
  • de Haan, W., Mott, K., van Straaten, E. C. W., Scheltens, P., Stam, C. J. Activity Dependent Degeneration Explains Hub Vulnerability in Alzheimer’s Disease. Plos computational biology 2012;8(8):e1002582. Doi:10.1371/journal.pcbi.1002582
  • de Waal, H., Stam, C. J., de Haan, W., van Straaten, E. C. W., Blankenstein, M. A., Scheltens, P., van der Flier, W. M. Alzheimer’s disease patients not carrying the apolipoprotein E epsilon4 allele show more severe slowing of oscillatory brain activity. Neurobiology of aging 2013;34(9):2158-63. Doi:10.1016/j.neurobiolaging.2013.03.007
  • Duits, F. H., Kester, M. I., Scheffer, P. G., Blankenstein, M. A., Scheltens, P., Teunissen, C. E., van der Flier, W. M. Increase in Cerebrospinal Fluid F2-Isoprostanes is Related to Cognitive Decline in APOE epsilon4 Carriers. Journal of Alzheimer’s disease : JAD 2013;36(3):563-70. Doi:10.3233/JAD-122227
  • Elias-Sonnenschein, L. S., Helisalmi, S., Natunen, T., Hall, A., Paajanen, T., Herukka, S. K., Laitinen, M., Remes, A. M., Koivisto, A. M., Mattila, K. M., Lehtimaki, T., Verhey, F. R. J., Visser, P. J., Soininen, H., Hiltunen, M. Genetic Loci Associated with Alzheimer’s Disease and Cerebrospinal Fluid Biomarkers in a Finnish Case-Control Cohort. PloS one 2013;8(4). Doi:10.1371/journal.pone.0059676
  • Frisoni, G. B., Bocchetta, M., Chetelat, G., Rabinovici, G. D., de Leon, M. J., Kaye, J., Reiman, E. M., Scheltens, P., Barkhof, F., Black, S. E., Brooks, D. J., Carrillo, M. C., Fox, N. C., Herholz, K., Nordberg, A., Jack, C. R. J., Jagust, W. J., Johnson, K. A., Rowe, C. C., Sperling, R. A., Thies, W., Wahlund, L. O., Weiner, M. W., Pasqualetti, P., DeCarli, C. Imaging markers for Alzheimer disease: which vs how. Neurology 2013;81(5):487-500. Doi:10.1212/WNL.0b013e31829d86e8
  • Galasko, D., Golde, T. E., Scheltens, P. Progress in Alzheimer’s disease research circa 2013: Is the glass half empty or half full? Alzheimers research & therapy 2013;5(3):26. Doi:10.1186/alzrt180
  • Hooshmand, B., Polvikoski, T., Kivipelto, M., Tanskanen, M., Myllykangas, L., Erkinjuntti, T., Makela, M., Oinas, M., Paetau, A., Scheltens, P., van Straaten, E. C., Sulkava, R., Solomon, A. Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. Brain 2013;136:2707-16. Doi:10.1093/brain/awt206
  • IJsselstijn, L., Papma, J. M., Dekker, L. J., Calame, W., Stingl, C., Koudstaal, P. J., Prins, N. D., Smitt, P. A., Luider, T. M. Serum proteomics in amnestic mild cognitive impairment. Proteomics 2013;13(16):2526-33. Doi:10.1002/pmic.201200190
  • Jacobs, H. I., Visser, P. J., Van Boxtel, M. P., Frisoni, G. B., Tsolaki, M., Papapostolou, P., Nobili, F., Wahlund, L. O., Minthon, L., Frolich, L., Hampel, H., Soininen, H., van de Pol, L., Scheltens, P., Tan, F. E., Jolles, J., Verhey, F. R. The association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent. Neurobiology of aging 2012;33(1):201. Doi:10.1016/j.neurobiolaging.2010.07.015
  • Jochemsen, H. M., Kloppenborg, R. P., de Groot, L. C. P. G., Kampman, E., Mali, W. P. T. M., van der Graaf, Y., Geerlings, M. I. Homocysteine, progression of ventricular enlargement, and cognitive decline: The Second Manifestations of ARTerial disease-Magnetic Resonance study. Alzheimers & dementia 2013;9(3):302-9. Doi:10.1016/j.jalz.2011.11.008
  • Jochemsen, H. M., Muller, M., Visseren, F. L., Scheltens, P., Vincken, K. L., Mali, W. P., van der Graaf, Y., Geerlings, M. I. Blood Pressure and Progression of Brain Atrophy The SMART-MR Study. JAMA neurology 2013;70(8):1046-53. Doi:10.1001/jamaneurol.2013.217
  • Jokinen, H., Schmidt, R., Ropele, S., Fazekas, F., Gouw, A. A., Barkhof, F., Scheltens, P., Madureira, S., Verdelho, A., Ferro, J. M., Wallin, A., Poggesi, A., Inzitari, D., Pantoni, L., Erkinjuntti, T. Diffusion changes predict cognitive and functional outcome: The LADIS study. Annals of neurology 2013;73(5):576-83. Doi:10.1002/ana.23802
  • Joling, K. J., Bosmans, J. E., van Marwijk, H. W. J., van der Horst, H. E., Scheltens, P., Vroomen, J. L. M., van Hout, H. P. J. The cost-effectiveness of a family meetings intervention to prevent depression and anxiety in family caregivers of patients with dementia: a randomized trial. Trials 2013;14:305. Doi:10.1186/1745-6215-14-305
  • Jongbloed, W., Kester, M. I., van der Flier, W. M., Veerhuis, R., Scheltens, P., Blankenstein, M. A., Teunissen, C. E. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer’s disease study. Alzheimers & dementia 2013;9(3):276-83. Doi:10.1016/j.jalz.2012.01.004
  • Koedam, E. L. G. E., van der Vlies, A. E., van der Flier, W. M., Verwey, N. A., Koene, T., Scheltens, P., Blankenstein, M. A., Pijnenburg, Y. A. L. Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia. Alzheimers & dementia 2013;9(3):269-75. Doi:10.1016/j.jalz.2011.12.007
  • Kohler, S., Hamel, R., Sistermans, N., Koene, T., Pijnenburg, Y. A. L., van der Flier, W. M., Scheltens, P., Visser, P. J., Aalten, P., Verhey, F. R. J., Ramakers, I. Progression to dementia in memory clinic patients without dementia: a latent profile analysis. Neurology 2013;81(15):1342-9. Doi:10.1212/WNL.0b013e3182a82536
  • Kooij, C.H. Van der, Dröes, R.M., Lange, J. de, Ettema, T.P., Cools, H., Tilburg, VanThe implementation of integrated emotion-oriented care; did it actually change the attitude, skills and time spending of trained caregivers? Dementia: The International Journal of Social Research and Practice, 09/2013,12(5):536-550
  • Kreisel, S. H., Blahak, C., Bazner, H., Inzitari, D., Pantoni, L., Poggesi, A., Chabriat, H., Erkinjuntti, T., Fazekas, F., Ferro, J. M., Langhorne, P., O’Brien, J., Scheltens, P., Visser, M. C., Wahlund, L. O., Waldemar, G., Wallin, A., Hennerici, M. G. Deterioration of Gait and Balance over Time: The Effects of Age-Related White Matter Change – The LADIS Study. Cerebrovascular diseases 2013;35(6):544-53. Doi:10.1159/000350725
  • Lehmann, M., Koedam, E. L., Barnes, J., Bartlett, J. W., Barkhof, F., Wattjes, M. P., Schott, J. M., Scheltens, P., Fox, N. C. Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. Neurobiology of aging 2013;34(1):73-82. Doi:10.1016/j.neurobiolaging.2012.03.010
  • Meesters, P. D., Comijs, H. C., Droes, R. M., de Haan, L., Smit, J. H., Eikelenboom, P., Beekman, A. T. F., Stek, M. L. The Care Needs of Elderly Patients With Schizophrenia Spectrum Disorders. American journal of geriatric psychiatry 2013;21(2):129-37. Doi:10.1016/j.jagp.2012.10.008
  • Moleiro, C., Madureira, S., Verdelho, A., Ferro, J. M., Poggesi, A., Chabriat, H., Erkinjuntti, T., Fazekas, F., Hennerici, M., O’Brien, J., Pantoni, L., Salvadori, E., Scheltens, P., Visser, M. C., Wahlund, L. O., Waldemar, G., Wallin, A., Inzitari, D. Confirmatory factor analysis of the Neuropsychological Assessment Battery of the LADIS study: A longitudinal analysis. Journal of clinical and experimental neuropsychology 2013;35(3):269-78. Doi:10.1080/13803395.2013.770822
  • Molinuevo, J. L., Cummings, J. L., Dubois, B., Scheltens, P. Preface. Medical clinics of north america 2013;97(3):XIII-XIXV. Doi:10.1016/j.mcna.2013.01.003
  • Möller, C., Vrenken, H., Jiskoot, L., Versteeg, A., Barkhof, F., Scheltens, P., van der Flier, W. M. Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease. Neurobiology of aging 2013;34(8):2014-22. Doi:10.1016/j.neurobiolaging.2013.02.013
  • Morbelli, S., Perneczky, R., Drzezga, A., Frisoni, G. B., Caroli, A., van Berckel, B. N. M., Ossenkoppele, R., Guedj, E., Didic, M., Brugnolo, A., Naseri, M., Sambuceti, G., Pagani, M., Nobili, F. Metabolic Networks Underlying Cognitive Reserve in Prodromal Alzheimer Disease: A European Alzheimer Disease Consortium Project. Journal of nuclear medicine 2013;54(6):894-902. Doi:10.2967/jnumed.112.113928
  • Muller, M., Jochemsen, H., Visseren, F., Grool, A., Launer, L., van der Graaf, Y., Geerlings, M., I. Low blood pressure and antihypertensive treatment are independently associated with physical and mental health status in patients with arterial disease: the SMART study. Journal of internal medicine 2013;274(3):241-51. Doi:10.1111/joim.12069
  • Okroglic, S., Widmann, C. N., Urbach, H., Scheltens, P., Heneka, M. T. Clinical Symptoms and Risk Factors in Cerebral Microangiopathy Patients. PloS one 2013;8(2). Doi:10.1371/journal.pone.0053455
  • Ossenkoppele, R., Prins, N. D., Pijnenburg, Y. A., Lemstra, A. W., van der Flier, W. M., Adriaanse, S. F., Windhorst, A. D., Handels, R. L., Wolfs, C. A., Aalten, P., Verhey, F. R., Verbeek, M. M., van Buchem, M. A., Hoekstra, O. S., Lammertsma, A. A., Scheltens, P., van Berckel, B. N. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers & dementia 2013;9(4):414-21. Doi:10.1016/j.jalz.2012.07.003
  • Ossenkoppele, R., Prins, N. D., van Berckel, B. N. M. Amyloid imaging in clinical trials. Alzheimers research & therapy 2013;5(4):36. Doi:10.1186/1758-9193-5-36
  • Ossenkoppele, R., van der Flier, W. M., Zwan, M. D., Adriaanse, S. F., Boellaard, R., Windhorst, A. D., Barkhof, F., Lammertsma, A. A., Scheltens, P., van Berckel, B. N. M. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology 2013;80(4):359-65. WpR, VUmc NCA-NB
  • Palm, W. M., Ferrarini, L., van der Flier, W. M., Westendorp, R. G., Bollen, E. L., Middelkoop, H. A., Milles, J. R., van der Grond, J., van Buchem, M. A. Cerebral atrophy in elderly with subjective memory complaints. Journal of magnetic resonance imaging 2013;38(2):358-64. Doi:10.1002/jmri.23977
  • Papma, J. M., Seelaar, H., de Koning, I., Hasan, D., Reijs, A., Valkema, R., Prins, N. D., van Swieten, J. C. Episodic Memory Impairment in Frontotemporal Dementia; A Tc-99m-HMPAO SPECT Study. Current alzheimer research 2013;10(3):332-9. WpR, VUmc NCA-NB
  • Poggesi, A., Gouw, A., van der Flier, W., Pracucci, G., Chabriat, H., Erkinjuntti, T., Fazekas, F., Ferro, J. M., Hennerici, M., Langhorne, P., O’Brien, J. T., Visser, M. C., Wahlund, L. O., Waldemar, G., Wallin, A., Scheltens, P., Inzitari, D., Pantoni, L. Cerebral white matter changes are associated with abnormalities on neurological examination in non-disabled elderly: the LADIS study. Journal of neurology 2013;260(4):1014-21. Doi:10.1007/s00415-012-6748-3
  • Poil, S. S., de Haan, W., van der Flier, W. M., Mansvelder, H. D., Scheltens, P., Linkenkaer-Hansen, K. Integrative EEG biomarkers predict progression to Alzheimer’s disease at the MCI stage. Frontiers in aging neuroscience 2013;5:UNSP. Doi:10.3389/fnagi.2013.00058
  • Prestia, A., Caroli, A., van der Flier, W. M., Ossenkoppele, R., van Berckel, B., Barkhof, F., Teunissen, C. E., Wall, A. E., Carter, S. F., Scholl, M., Choo, I. H., Nordberg, A., Scheltens, P., Frisoni, G. B. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 2013;80(11):1048-56. Doi:10.1212/WNL.0b013e3182872830
  • Prins, N. D., van der Flier, W. M., Brashear, H. R., Knol, D. L., van De Pol, L. A., Barkhof, F., Scheltens, P. Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population. Journal of Alzheimer’s disease : JAD 2013;36(1):79-85. Doi:10.3233/JAD-122233
  • Ramakers, I. H. G. B., Verhey, F. R. J., Scheltens, P., Hampel, H., Soininen, H., Aalten, P., Rikkert, M. O., Verbeek, M. M., Spiru, L., Blennow, K., Trojanowski, J. Q., Shaw, L. M., Visser, P. J. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychological medicine 2013;43(5):911-20. Doi:10.1017/S0033291712001870
  • Ravenscroft, T. A., Baker, M. C., Rutherford, N. J., Neumann, M., Mackenzie, I. R., Josephs, K. A., Boeve, B. F., Petersen, R., Halliday, G. M., Kril, J., van Swieten, J. C., Seeley, W. W., Dickson, D. W., Rademakers, R. Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS. Neurobiology of aging 2013;34(9):UNSP. Doi:10.1016/j.neurobiolaging.2013.04.004
  • Scheltens, P. DEMENTIA Mild cognitive impairment-amyloid and beyond. Nature reviews neurology 2013;9(9):493-5. Doi:10.1038/nrneurol.2013.147
  • Schuitemaker, A., Kropholler, M. A., Boellaard, R., van der Flier, W. M., Kloet, R. W., van der Doef, T. F., Knol, D. L., Windhorst, A. D., Luurtsema, G., Barkhof, F., Jonker, C., Lammertsma, A. A., Scheltens, P., van Berckel, B. N. M. Microglial activation in Alzheimer’s disease: an (R)-PK11195 positron emission tomography study. Neurobiology of aging 2013;34(1):128-36. Doi:10.1016/j.neurobiolaging.2012.04.021
  • Sikkes, S. A. M., Knol, D. L., Pijnenburg, Y. A. L., de Lange-de Klerk, E., Uitdehaag, B. M. J., Scheltens, P. Validation of the Amsterdam IADL Questionnaire (c), a New Tool to Measure Instrumental Activities of Daily Living in Dementia. Neuroepidemiology 2013;41(1):35-41. Doi:10.1159/000346277
  • Sikkes, S. A. M., Pijnenburg, Y. A. L., Knol, D. L., de Lange-de Klerk, E., Scheltens, P., Uitdehaag, B. M. J. Assessment of Instrumental Activities of Daily Living in Dementia: Diagnostic Value of the Amsterdam Instrumental Activities of Daily Living Questionnaire. Journal of geriatric psychiatry and neurology 2013;26(4):244-50. Doi:10.1177/0891988713509139
  • Spies, P. E., Claassen, J. A. H. R., Peer, P. G. M., Blankenstein, M. A., Teunissen, C. E., Scheltens, P., van der Flier, W. M., Rikkert, M. G. M. O., Verbeek, M. M. A prediction model to calculate probability of Alzheimer’s disease using cerebrospinal fluid biomarkers. Alzheimers & dementia 2013;9(3):262-8. Doi:10.1016/j.jalz.2012.01.010
  • Tijms, B. M., Möller, C., Vrenken, H., Wink, A. M., de Haan, W., van der Flier, W. M., Stam, C. J., Scheltens, P., Barkhof, F. Single-Subject Grey Matter Graphs in Alzheimer’s Disease. PloS one 2013;8(3). Doi:10.1371/journal.pone.0058921
  • Tijms, B. M., Wink, A. M., de Haan, W., van der Flier, W. M., Stam, C. J., Scheltens, P., Barkhof, F. Alzheimer’s disease: connecting findings from graph theoretical studies of brain networks. Neurobiology of aging 2013;34(8):2023-36. Doi:10.1016/j.neurobiolaging.2013.02.020
  • van Berckel, B. N., Ossenkoppele, R., Tolboom, N., Yaqub, M., Foster-Dingley, J. C., Windhorst, A. D., Scheltens, P., Lammertsma, A. A., Boellaard, R. Longitudinal Amyloid Imaging Using C-11-PiB: Methodologic Considerations. Journal of nuclear medicine 2013;54(9):1570-6. Doi:10.2967/jnumed.112.113654
  • van de Glind, E. M. M., van Enst, W. A., van Munster, B. C., Olde Rikkert, M. G. M., Scheltens, P., Scholten, R. J. P. M., Hooft, L. Pharmacological treatment of dementia: a scoping review of systematic reviews. Dementia and geriatric cognitive disorders 2013;36(3-4):211-28. Doi:10.1159/000353892
  • van der Vlies, A. E., Staekenborg, S. S., dmiraal-Behloul, F., Prins, N. D., Barkhof, F., Vrenken, H., Reiber, J. H. C., Scheltens, P., van der Flier, W. M. Associations between Magnetic Resonance Imaging Measures and Neuropsychological Impairment in Early and Late Onset Alzheimer’s Disease. Journal of alzheimers disease 2013;35(1):169-78. Doi:10.3233/JAD-121291
  • van Harten, A. C., Smits, L. L., Teunissen, C. E., Visser, P. J., Koene, T., Blankenstein, M. A., Scheltens, P., van der Flier, W. M. Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology 2013;81(16):1409-16. Doi:10.1212/WNL.0b013e3182a8418b
  • van Harten, A. C., Visser, P. J., Pijnenburg, Y. A., Teunissen, C. E., Blankenstein, M. A., Scheltens, P., van der Flier, W. M. Cerebrospinal fluid A beta 42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers & dementia 2013;9(5):481-7. Doi:10.1016/j.jalz.2012.08.004
  • van Swieten, J. C., Pijnenburg, Y. The role of the subgenual cingulate cortex in self-appraisal. Journal of neurology neurosurgery and psychiatry 2013;84(2):121. Doi:10.1136/jnnp-2012-303571
  • van Vliet, D., de Vugt, M. E., Aalten, P., Bakker, C., Pijnenburg, Y. A. L., Vernooij-Dassen, M. J. F. J., Koopmans, R. T. C. M., Verhey, F. R. J. Prevalence of Neuropsychiatric Symptoms in Young-Onset Compared to Late-Onset Alzheimer’s Disease – Part 1: Findings of the Two-Year Longitudinal NeedYD-Study. Dementia and geriatric cognitive disorders 2012;34(5-6):319-27. Doi:10.1159/000342824
  • van Vliet, D., de Vugt, M. E., Bakker, C., Pijnenburg, Y. A. L., Vernooij-Dassen, M. J. F. J., Koopmans, R. T. C. M., Verhey, F. R. J. Time to diagnosis in young-onset dementia as compared with late-onset dementia. Psychological medicine 2013;43(2):423-32. Doi:10.1017/S0033291712001122
  • van Vliet, D., de Vugt, M. E., Koehler, S., Aalten, P., Bakker, C., Pijnenburg, Y. A., Vernooij-Dassen, M. J., Koopmans, R. T., Verhey, F. R. Awareness and Its Association With Affective Symptoms in Young-onset and Late-onset Alzheimer Disease: A Prospective Study. Alzheimer disease & associated disorders 2013;27(3):265-71. Doi:10.1097/WAD.0b013e31826cffa5
  • Vellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., Cedarbaum, J., Grundman, M., Broich, K., Giacobini, E., Dubois, B., Sperling, R., Wilcock, G. K., Fox, N. C., Scheltens, P., Touchon, J., Hendrix, S., Andrieu, S., Aisen, P. Designing drug trials for Alzheimer’s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force. Alzheimer’s & dementia : the journal of the Alzheimer’s Association 2013;9(4):438-44. Doi:10.1016/j.jalz.2013.03.007
  • Verdelho, A., Madureira, S., Moleiro, C., Ferro, J. M., O’Brien, J. T., Poggesi, A., Pantoni, L., Fazekas, F., Scheltens, P., Waldemar, G., Wallin, A., Erkinjuntti, T., Inzitari, D. Depressive symptoms predict cognitive decline and dementia in older people independently of cerebral white matter changes: the LADIS study. Journal of neurology, neurosurgery, and psychiatry 2013;84(11):1250-4. Doi:10.1136/jnnp-2012-304191
  • Vermeiren, A. P. A., Bosma, H., Visser, P. J., Zeegers, M. P., Graff, C., Ewers, M., Frisoni, G. B., Frolich, L., Hampel, H., Jones, R. W., Kehoe, P. G., Lenoir, H., Minthon, L., Nobili, F. M., Rikkert, M. O., Rigaud, A. S., Scheltens, P., Soininen, H., Spiru, L., Tsolaki, M., Wahlund, L. O., Vellas, B., Wilcock, G., Elias-Sonnenschein, L. S., Verhey, F. R. J. The Association Between APOE epsilon 4 and Alzheimer-type Dementia Among Memory Clinic Patients is Confined to those with a Higher Education. The DESCRIPA Study. Journal of alzheimers disease 2013;35(2):241-6. Doi:10.3233/JAD-122182
  • Verwey, N. A., Hoozemans, J. J., Korth, C., van Royen, M. R., Prikulis, I., Wouters, D., Twaalfhoven, H. A., van Haastert, E. S., Schenk, D., Scheltens, P., Rozemuller, A. J., Blankenstein, M. A., Veerhuis, R. Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid beta-peptide. Amyloid-journal of protein folding disorders 2013;20(3):179-87. Doi:10.3109/13506129.2013.797389
  • Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., Fagan, A. M. Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet neurology 2013;12(10):957-65. Doi:10.1016/S1474-4422(13)70194-7
  • Vos, S. J. B., van Rossum, I. A., Verhey, F., Knol, D. L., Soininen, H., Wahlund, L. O., Hampel, H., Tsolaki, M., Minthon, L., Frisoni, G. B., Froelich, L., Nobili, F., van der Flier, W., Blennow, K., Wolz, R., Scheltens, P., Visser, P. J. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology 2013;80(12):1124-32. Doi:10.1212/WNL.0b013e318288690c
  • Zarei, M., Beckmann, C. F., Binnewijzend, M. A., Schoonheim, M. M., Oghabian, M. A., Sanz-Arigita, E. J., Scheltens, P., Matthews, P. M., Barkhof, F. Functional segmentation of the hippocampus in the healthy human brain and in Alzheimer’s disease. Neuroimage 2013;66:28-35. Doi:10.1016/j.neuroimage.2012.10.071

Vakpublicaties:

  • Gossink, F., Dols, A., Kerssens, C. J., Scheltens, P., Stek, M. L., Pijnenburg, Y. A. L. . Nederlands tijdschrift voor geneeskunde 2013;157(42):A6370. VP, VUmc NCA-NB
  • Huber, E., Meiland, F., Stek, M., Dröes, R.M., Bootsma-vd Wiel, A. De overdracht van GGZ naar verpleeghuis. Continuiteit van zorg voor patiënten met dementie. Tijdschrift voor Ouderengeneeskunde, 2013, 04, 177-181
  • Meesters, P.D., Comijs, C., Dröes, R.M., Haan, L.de, Smit, J. Eikelenboom, P., Beekman, A.T.F., Stek, M. Ouderen met schizoofrenie; zorgbehoeften en zorgvernieuwing. MGv, 68 (4) 2013,174-183.
  • Scheltens, P., Twisk, J. W. R. . Nederlands tijdschrift voor geneeskunde 2013;157(0):A6721. VP, VUmc NCA-NB
  • van der Flier, W. M., Ossenkoppele, R., van Berckel, B. N. M., Scheltens, P. Vroegdiagnostiek van de ziekte van Alzheimer: de rol van Positron Emissie Tomografie (PET). Tijdschrift voor gerontologie en geriatrie 2013;44(4):190-1. VP, VUmc NCA-NB.10.1007/s12439-013-0033-5
  • Verberne, W. R., Snijders, T. J., Liem, K. S., Baakman, A. C., Veldhuijzen, D. S. . Nederlands tijdschrift voor geneeskunde 2013;157(5):A5434. VP, VUmc NCA-NB
  • Verhey, F. R. J., Visser, P. J. . Nederlands tijdschrift voor geneeskunde 2013;157(11):A5596. VP, VUmc NCA-NB

Boekhoofdstukken :

  • A.W. Lemstra, H. Seelaar, J.C. van Swieten. Primary Dementia Syndromes and Parkinsonism. In Oxford textbook of movement Disorders edited by DJ Burns, Oxford 2013

Dissertaties:

  • Goos J.D.C. Microbleeds in dementia: Connecting the dots  Vrije Universiteit Amsterdam 6 februari 2013. Promotoren: Ph. Scheltens, F. Barkhof, copromotor: W.M. van der Flier
  • Ossenkoppele R. Alzheimer PEThology Vrije Universiteit Amsterdam 8 mei 2013. Promotoren: Ph. Scheltens, A Lammertsma, copromotoren: B.N.M. van Berckel, W.M. van der Flier
  • Jochemsen H. Brain under pressure. Influences of blood pressure and angiotensin-converting enzyme on the brain. Vrije Universiteit Amsterdam 4 oktober 2013. Promotoren: Ph. Scheltens, Y. van der Graaf, copromotoren: M. Muler, M.I. Geerlings /li>
  • Van der Vlies A. Cognitive profiles in Alzheimer’s disease. Recognizing its many faces. Vrije Universiteit Amsterdam 27 november 2013. Promotor: Ph. Scheltens, copromotor: W.M. van der Flier
  • Van Rossum I. Diagnosis and prognosis of Alzheimer’s disease in subjects with mild cognitive impairment.  Vrije Universiteit Amsterdam 28 november 2013. Promotor: Ph. Scheltens, copromotor: P.J. Visser

Publicaties 2012

Internationale wetenschappelijke publicaties:

  • Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimers Dement 2011;7:270-279.
  • Bateman RJ, Aisen PS, de Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther 2011;3(1):1-13.
  • Brodaty H, Breteler MMB, Dekosky ST, Dorenlot P, Fratiglioni L, Hock C, Kenigsberg P-A, Scheltens P, de Strooper B. The world of dementia beyond 2020. J Am Geriatr Soc 2011;59:923-927.
  • Cardoso MJ, Clarkson MJ, Ridgway GR, Modat M, Fox NC, Ourselin S,and The Alzheimer’s Disease Neuroimaging Initiative. LoAd: A locally adaptive cortical segmentation algorithm. Neuroimage 2011;56:1386-1397.
  • Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Thompson PM, Reiman EM, Jack CR Jr, Fox NC, Jagust WJ, Harvey DJ, Beckett LA, Gamst A, Aisen PS, Petersen RC, Weiner MW, for the Alzheimer’s Disease Neuroimaging Initiative. Impact of apolipoprotein ɛ4-cerebrospinal fluid beta-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimers Dement 2011;7:514-520.
  • Clarkson MJ, Cardoso MJ, Ridgway GR, Modat M, Leung KK, Rohrer JD, Fox NC, Ourselin S. A comparison of voxel and surface based cortical thickness estimation methods. Neuroimage 2011;57:856-865.
  • Cordonnier C, van der Flier WM. Brain microbleeds and Alzheimer’s disease: innocent observation or key player? Brain 2011;134:335-344.
  • Echávarri C, Aalten P, Uylings HBM, Jacobs HIL, Visser PJ, Gronenschild EHBM, Verhey FRJ, Burgmans S. Atrophy in the parahippocampal gyrus as an early biomarker of Alzheimer’s disease. Brain Struct Funct 2011;215:265-271.
  • Elias-Sonnenschein LS, Viechtbauer W, Ramakers IHGB, Verhey FRJ, Visser PJ. Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis.  J Neurol Neurosurg Psychiatry 2011;82:1149-1156.
  • van der Flier WM, Pijnenburg YAL Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer’s disease: the case of the missing APOE ε4 allele. Lancet Neurol 2011;10:280-288.
  • Feldman FH, Scheltens Ph, Dubois B, on behalf of the International Working Group for New Research Criteria for AD.  New lexicon and criteria for the diagnosis of Alzheimer’s disease – Authors’ reply. Lancet Neurol 2011;11:300-301.
  • Fonteijn HM, Clarkson MJ, Modat M, Barnes J, Lehmann M, Ourselin S, Fox NC, Alexander DC.  An event-based disease progression model and its application to familial Alzheimer’s disease. Inf Process Med Imaging 2011;22:748-759.
  • Fox NC, Ridgway GR, Schott JM.Algorithms, atrophy and Alzheimer’s disease. Cautionary tales for clinical trials. Neuroimage 2011;57:15-18.
  • Gao FQ, Swartz RH, Scheltens P, Leibovitch FS, Kiss A, Honjo K, Black SE. Complexity of MRI white matter hyperintensity assessments in relation to cognition in aging and dementia from the sunnybrook dementia study. J Alzheimers Dis 2011;26:379-388.
  • Goos JDC, van der Flier WM, Knol DL, Pouwels PJW, Scheltens P, Barkhof F, Wattjes MP. Clinical Relevance of Improved Microbleed Detection by Susceptibility-Weighted Magnetic Resonance Imaging. Stroke 2011;42:1894-1900.
  • Gouw AA, Seewann A, van der Flier WM, Barkhof F, Rozemuller AM, Scheltens P, Geurts JJG. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 2011;82:126-135.
  • Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, K B, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B, for the Oxford Task Force Group. Biomarkers for Alzheimer’s disease therapeutic trials. Prog Neurobiol 2011;95:579-593.
  • van Harten AC, Kester MI, Visser PJ, Blankenstein MA, Pijnenburg YAL, van der Flier WM, Scheltens P. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med 2011;49:353-366.
  • Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC,  et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 2011;43:429-436.
  • Jack CR Jr, Barkhof F, Bernstein MA, Cantillon M, Cole PE, Decarli C, Dubois B, Duchesne S, Fox NC, Frisoni GB, Hampel H, Hill DL, Johnson K, Mangin JF, Scheltens P, Schwarz AJ, Sperling R, Suhy J, Thompson PM, Weiner M, Foster NL. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease. Alzheimers Dement 2011;7:474-485.
  • Jansen C, Parchi P, Jelles B, Gouw AA, Beunders G, van Spaendonk RML, van de Kamp JM, Lemstra AW, Capellari S, Rozemuller AJM. The first case of fatal familial insomnia (FFI) in the Netherlands: a patient from Egyptian descent with concurrent 4 repeat tau deposits.  Neuropathol Appl Neurobiol 2011;37:549-553.
  • Jokinen H, Gouw AA, Madureira S, Ylikoski R, van Straaten ECW, van der Flier WM, Barkhof F, Scheltens P, Fazekas F, Schmidt R, Verdelho A, Ferro JM, Pantoni L, Inzitari D, Erkinjuntti T, On behalf of the LADIS Study Group. Incident lacunes influence cognitive decline: The LADIS study. Neurology 2011;76:1872-1878.
  • de Jong-Hagelstein M, van de Sandt-Koenderman WME, Prins ND, Dippel DWJ, Koudstaal PJ, Visch-Brink EG. Efficacy of early cognitive-linguistic treatment and communicative treatment in aphasia after stroke: a randomised controlled trial (RATS-2). J Neurol Neurosurg Psychiatry 2011;82:399-404.
  • Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Twisk JWR, Swinkels SHN, Scheltens P. Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer’s disease: secondary analyses from a randomized, controlled trial. J Nutr Health Aging 2011;15:672-676.
  • Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Twisk JWR, Swinkels SHN, Scheltens P. Efficacy of a medical food on cognition in Alzheimer’s disease: results from secondary analyses of a randomized, controlled trial. J Nutr Health Aging 2011;15:720-724.
  • Kester MI, Verwey NA, van Elk EJ, Blankenstein MA, Scheltens P, van der Flier WM. Progression from MCI to AD: Predictive value of CSF Abeta42 is modified by APOE genotype. Neurobiol Aging 2011;32:1372-1378.
  • Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ, for the Alzheimer’s Disease Neuroimaging Initiative. (waaronder o.a. Fox N.) Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 2011;76:69-79.
  • Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodríguez Martinez de Llano S, Edison P, Douglas J, Fox NC, Brooks DJ, Rossor MN. Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain 2011;134:293-300.
  • Koedam ELGE, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YAL, Fox N, Barkhof F, Wattjes MP. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 2011;21:2618-2625.
  • Lashley T, Rohrer JD, Bandopadhyay R, Fry C, Ahmed Z, Isaacs AM, Brelstaff JH, Borroni B, Warren JD, Troakes C, King A, Al-Saraj S, Newcombe J, Quinn N, Ostergaard K, Schøder HD, Bojsen-Møller M, Braendgaard H, Fox NC, Rossor MN, Lees AJ, Holton JL, Revesz T. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain 2011;134:2548-2564.
  • Lehmann M, Barnes J, Ridgway GR, Wattam-Bell J, Warrington EK, Fox NC, Crutch SJ.  Basic visual function and cortical thickness patterns in posterior cortical atrophy. Cereb Cortex 2011;21:2122-2132.
  • Lehmann M, Crutch SJ, Ridgway GR, Ridha BH, Barnes J, Warrington EK, Rossor MN, Fox NC. Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer’s disease. Neurobiol Aging 2011;32:1466-1476.
  • Leung KK, Barnes J, Modat M, Ridgway GR, Bartlett JW, Fox NC, Ourselin S, and the Alzheimer’s Disease Neuroimaging Initiative. Brain MAPS: An automated, accurate and robust brain extraction technique using a template library. Neuroimage 2011;55:1091-1108.
  • McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement 2011;7:263-269.
  • Mahoney CJ, Rohrer JD, Goll JC, Fox NC, Rossor MN, Warren JD. Structural neuroanatomy of tinnitus and hyperacusis in semantic dementia. J Neurol Neurosurg Psychiatry 2011;82:1274-1278.
  • Maruta C, Guerreiro M, de Mendonça A, Hort J, Scheltens P. The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia. Eur J Neurol 2011;18:279-286.
  • Norberg J, Graff C, Almkvist O, Ewers M, Frisoni GB, Frölich L, Hampel H, Jones RW, Kehoe PG, Lenoir H, Minthon L, Nobili F, Olde Rikkert M, Rigaud A-S, Scheltens P, Soininen H, Spiru L, Tsolaki M, Wahlund L-O, Vellas B, Wilcock G, Elias-Sonnenschein LS, Verhey FRJ, Visser PJ. Regional differences in effects of APOE ε4 on cognitive impairment in non-demented subjects. Dement Geriatr Cogn Disord 2011;32:135-142.
  • O’Brien J, Scheltens P. Clinical use of neuroimaging in dementia: an international perspective. Int Psychogeriatr 2011;23(suppl 2):S3-S5.
  • Ossenkoppele R, Tolboom N, Pijnenburg YA, Lammertsma AA, Scheltens P, van Berckel BNM.  Afbeelden van amyloïdplaques in de hersenen met PET. Ned Tijdschr Geneeskd 2011;155:A2981.
  • Ossenkoppele R, van Berckel BNM, Tolboom N, PijnenburgYA, Prins ND, Lemstra AW, Lammertsma AA, Scheltens Ph. Moleculaire beeldvorming bij de ziekte van Alzheimer. Tschr Neurol Neurochir 2011;112:201-208.
  • Ossenkoppele R, van Berckel BNM, Prins ND. Amyloid imaging in prodromal Alzheimer’s disease. Alzheimers Res Ther 2011;3(5):26.
  • Oudega ML, van Exel E, Wattjes MP, Comijs HC, Scheltens P, Barkhof F, Eikelenboom P, de Craen AJM, Beekman ATF, Stek ML. White matter hyperintensities, medial temporal lobe atrophy, cortical atrophy, and response to electroconvulsive therapy in severely depressed elderly patients.  J Clin Psychiatry 2011;72:104-112.
  • Pievani M, de Haan W, Wu T, Seeley WW, Frisoni GB. Functional network disruption in the degenerative dementias. Lancet Neurol 2011;10:829-843.
  • van de Pol L, Gertz H-J, Scheltens P, Wolf H. Hippocampal atrophy in subcortical vascular dementia. Neurodegener Dis 2011;8:465-469.
  • Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EGP, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain  2011;134:2456-2477.
  • Rohrer JD, Lashley T, Holton J, Revesz T, Urwin H, Isaacs AM, Fox NC, Rossor MN, Warren J. The clinical and neuroanatomical phenotype of FUS associated frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 2011;82:1405-1407.
  • Rohrer JD, Lashley T, Schott JM, Warren JE, Mead S, Isaacs AM, Beck J, Hardy J, de Silva R, Warrington E, Troakes C, Al-Sarraj S, King A, Borroni B, Clarkson MJ, Ourselin S, Holton JL, Fox NC, Revesz T, Rossor MN, Warren JD. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain 2011;134:2565-2581.
  • Ryberg C, Rostrup E, Paulson OB, Barkhof F, Scheltens P, van Straaten ECW, van der Flier WM, Fazekas F, Schmidt R, Ferro JM, Baezner H, Erkinjuntti T, Jokinen H, Wahlund L-O, Poggesi A, Pantoni L, Inzitari D, Waldemar G, and on behalf of the LADIS study group. Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: A 3-year follow-up of the LADIS study cohort. J Neurol Sci 2011;307:100-105.
  • Scheltens P, Rockwood K. How golden is the gold standard of neuropathology in dementia? Alzheimers Dement 2011;7:486-489.
  • Scher AI, Xu Y, Korf ESC, Hartley SW, Witter MP, Scheltens P, White LR, Thompson PM, Toga AW, Valentino DJ, Launer LJ. Hippocampal morphometry in population-based incident Alzheimer’s disease and vascular dementia: the HAAS. J Neurol Neurosurg Psychiatry 2011;82:373-377.
  • Scherder E, Eggermont L, Visscher C, Scheltens P, Swaab D. Understanding higher level gait disturbances in mild dementia in order to improve rehabilitation; ‘Last in – first out’. Neurosci Biobehav Rev 2011;35:699-714.
  • Schmidt R, Schmidt H, Haybaeck J, Loitfelder M, Weis S, Cavalieri M, Seiler S, Enzinger C, Ropele S, Erkinjuntti T, Pantoni L, Scheltens P, Fazekas F, Jellinger K. Heterogeneity in age-related white matter changes. Acta Neuropathol 2011;122:171-178.
  • Schott JM, Warren JD, Barkhof F, Rossor MN, Fox NC. Suspected early dementia. BMJ 2011;343:d5568:1-5.
  • Sikkes SAM, Knol DL, van den Berg MT, de Lange-de Klerk ESM, Scheltens P, Klein M, Pijnenburg YAL, Uitdehaag, BMJ. An informant questionnaire for detecting Alzheimer’s disease: are some items better than others? J Int Neuropsychol Soc 2011;17:674-681.
  • Sims R, Dwyer S, Harold D, Gerrish A, Hollingworth P, Chapman J, Jones N, Abraham R, Ivanov D, Pahwa JS, Moskvina V, Dowzell K, Thomas C, Stretton A, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuiness B, Todd S, Johnston JA, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Livingston G, Bass NJ, Gurling H, McQuillin A, Jones L, Holmans PA, O’Donovan M, Owen MJ, Williams J. No evidence that extended tracts of homozygosity are associated with Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 2011;156:764-771.
  • Smits LL, Liedorp M, Koene T, Roos-Reuling IEW, Lemstra AW, Scheltens P, Stam CJ, van der Flier WM. EEG abnormalities are associated with different cgnitive profiles in Alzheimer’s disease. Dement Geriatr Cogn Disord 2011;31:1-6.
  • Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement 2011;7:367-385.
  • Tabrizi SJ, Scahill RI, Durr A, Roos RAC, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC, and the TRACK-HD investigators. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10:31-421.
  • Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni GB, Weiner M, Schneider L, Gauthier S, Gispen-de Wied CC, Hendrix S, Feldman H, Cedarbaum J, Petersen R, Siemers E, Andrieu S, Prvulovic D, Touchon J, Hampel H. Prevention trials in Alzheimer’s disease: An EU-US task force report. Prog Neurobiol 2011;95:594-600.
  • Verdelho A, Madureira S, Moleiro C, Santos CO, Ferro JM, Erkinjuntti T, Poggesi A, Pantoni L, Fazekas F, Scheltens P, Waldemar G, Wallin A, Inzitari D, and on behalf of the LADIS study(waaronder Scheltens P, van Straaten I, Gouw A, van der Flier W, Visser M). Self-perceived memory complaints predict progression to Alzheimer disease. The LADIS study. J Alzheimers Dis  2011;27:491-498.
  • van Vliet D, de Vugt ME, Bakker C, Koopmans RTCM, Pijnenburg YAL, Vernooij-Dassen MJFJ, Verhey FR. Caregivers’ perspectives on the pre-diagnostic period in early onset dementia: a long and winding road. Int Psychogeriatr 2011;23:1393-1404.
  • de Waal H, Stam CJ, Blankenstein MA, Pijnenburg YAL, Scheltens P, van der Flier WM. EEG abnormalities in early and late onset Alzheimer’s disease: understanding heterogeneity. J Neurol Neurosurg Psychiatry 2011;82:67-71.
  • de Wilde MC, Kamphuis PJGH, Sijben JWC, Scheltens P. Utility of imaging for nutritional intervention studies in Alzheimer’s disease. Eur J Pharmacol 2011;668(suppl.1):S59-S69.
  • Witlox J, Kalisvaart KJ, de Jonghe JFM, Verwey NA, van Stijn MFM, Houdijk APJ, Traast HS, Maclullich AMJ, van Gool WA, Eikelenboom P. Cerebrospinal fluid β-amyloid and tau are not associated with risk of delirium: a prospective cohort study in older adults with hip fracture. J Am Geriatr Soc 2011;59:1260-1267.
  • Dröes, R.M., Van Mierlo, L.D., Meiland, F.J.M., Van der Roest, H.G. Memory problems in dementia: Adaptation and copingstrategies, and psychosocial treatments. Expert Reviews Neurotherapeutics, 2011,11(12)1769-1782.
  • De Boer ME, Dröes RM, Jonker C, Eefsting JA, Hertogh CMPM. Advance directives for euthanasia in dementia: how are they dealt with in Dutch nursing homes? Experiences of physicians and relatives.Journal of the American Geriatrics Society 2011;59(6):989-96.
  • Jansen APD, Van Hout HPJ, Nijpels G, Rijmen F, Dröes RM, Pot AM, Schellevis F, Van Marwijk HWJ, Stalman W. Effectiveness of case management among older adults with early symptoms of dementia and their primary informal caregivers: a randomised clinical trial. International Journal of Nursing Studies 2011 Aug;48(8):933-43.
  • Meiland FJM, Jonker C, Dröes RM. Predictors of effective support in meeting centers for people with dementia and their carers,Nonpharmacological therapies in dementia2010; 1(3):251-270.
  • Monfort JC, Villemur V, Lezy AM, Baron-Laforet S, Dröes RM. From paedophilia to gerontophilia. Lancet 2011; Vol. 377, Jan 22, 300. Van Mierlo LD, Meiland FJM, Dröes RM. Dementelcoach: effect of telephone coaching on carers of community dwelling people with dementia. Int Psychogeriatr. 2011 Oct 14:1-11.

Boek(hoofdstukken) en vakpublicaties:

  • Barkhof F, Fox NC, Bastos-Leite AJ, Scheltens Ph. Neuroimaging in dementia. New York, Springer, 2011. 278 pp.
  • van Exel E, Eikelenboom P, Comijs HC, Kurniawan C, Frölich M, Smit JH, Stek ML, Scheltens P, Eefsting JE, Westendorp  RGJ.  Het immuunsysteem en de ziekte van Alzheimer. Tijdschr Psychiatr 2011;53:637-643.
  • Hort J, O’Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P. Alzheimer’s disease. In: Gilhus NE, Barnes M, Brainin M (eds), European handbook of neurological management. Oxford, John Wiley-Blackwell Publishing, 2011:269-281.
  • Kerklaan BJ, Scheltens P, Schoonderwoerd GC, Killestein J, Rozemuller AJM, van der Knaap MS. ‘Adult polyglucosan body disease’: een weinig bekende maar herkenbare wittestofziekte. Tschr Neurol Neurochir 2011;112:25-31.
  • Vos SJB, Visser PJ, Verhey FRJ. De rol van liquormarkers bij de vroege diagnostiek van de ziekte van Alzheimer. Tijdschr Psychiatr 2011;53:647-653.
  • Dijk M van, Weert J van, Dröes RM. De Veder methode. Contact maken door middel van theater. Denkbeeld; Tijdschrift voor Psychogeriatrie, 23, 2011, 2-5.
  • Mierlo L, Dröes RM. Dementelcoach; telefonische ondersteuning voor mantelzorgers van mensen met dementie. Vita Valley, Nieuwsbrief, juli 2011.

Dissertaties:

  • Kester, MI. Biomarkers for Alzheimer’s pathology; monitoring, predicting and understanding the disease.
    Vrije Universiteit Amsterdam 14 januari 2011
    promotoren: Ph Scheltens, MA Blankenstein, copromotor: WM van der Flier
  • Mulder SD. Amyloid associated proteins in Alzheimer’s disease.
    Vrije Universiteit Amsterdam 7 oktober 2011
    promotoren: MA Blankenstein. Ph Scheltens, copromotor: R Veerhuis
  • Sikkes SAM. Measuring IADL in dementia.
    Vrije Universiteit Amsterdam 14 oktober 2011.
    promotoren: Ph Scheltens, BMJ Uitdehaag, copromotoren: YAL Pijnenburg, ESM de Lange-de Klerk
  • Sluimer JD. Visualizing the shrinking brain: longitudinal MR studies in the spectrum of cognitive decline.
    Vrije Universiteit Amsterdam 28 april 2011.
    promotoren: F Barkhof, Ph Scheltens, copromotoren: WM van der Flier, H. Vrenken
  • Van der Roest HG. Care needs in dementia and digital interactive information provisioning.
    Vrije Universiteit Amsterdam 12 oktober 2009
    Promotoren: RM Dröes, C Jonker, copromotoren: FJ Meiland, P. Scheltens

Publicaties 2011

Internationale wetenschappelijke publicaties:

  • Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimers Dement 2011;7:270-279.
  • Bateman RJ, Aisen PS, de Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther 2011;3(1):1-13.
  • Brodaty H, Breteler MMB, Dekosky ST, Dorenlot P, Fratiglioni L, Hock C, Kenigsberg P-A, Scheltens P, de Strooper B. The world of dementia beyond 2020. J Am Geriatr Soc 2011;59:923-927.
  • Cardoso MJ, Clarkson MJ, Ridgway GR, Modat M, Fox NC, Ourselin S,and The Alzheimer’s Disease Neuroimaging Initiative. LoAd: A locally adaptive cortical segmentation algorithm. Neuroimage 2011;56:1386-1397.
  • Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Thompson PM, Reiman EM, Jack CR Jr, Fox NC, Jagust WJ, Harvey DJ, Beckett LA, Gamst A, Aisen PS, Petersen RC, Weiner MW, for the Alzheimer’s Disease Neuroimaging Initiative. Impact of apolipoprotein ɛ4-cerebrospinal fluid beta-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimers Dement 2011;7:514-520.
  • Clarkson MJ, Cardoso MJ, Ridgway GR, Modat M, Leung KK, Rohrer JD, Fox NC, Ourselin S. A comparison of voxel and surface based cortical thickness estimation methods. Neuroimage 2011;57:856-865.
  • Cordonnier C, van der Flier WM. Brain microbleeds and Alzheimer’s disease: innocent observation or key player? Brain 2011;134:335-344.
  • Echávarri C, Aalten P, Uylings HBM, Jacobs HIL, Visser PJ, Gronenschild EHBM, Verhey FRJ, Burgmans S. Atrophy in the parahippocampal gyrus as an early biomarker of Alzheimer’s disease. Brain Struct Funct 2011;215:265-271.
  • Elias-Sonnenschein LS, Viechtbauer W, Ramakers IHGB, Verhey FRJ, Visser PJ. Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis.  J Neurol Neurosurg Psychiatry 2011;82:1149-1156.
  • van der Flier WM, Pijnenburg YAL Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer’s disease: the case of the missing APOE ε4 allele. Lancet Neurol 2011;10:280-288.
  • Feldman FH, Scheltens Ph, Dubois B, on behalf of the International Working Group for New Research Criteria for AD.  New lexicon and criteria for the diagnosis of Alzheimer’s disease – Authors’ reply. Lancet Neurol 2011;11:300-301.
  • Fonteijn HM, Clarkson MJ, Modat M, Barnes J, Lehmann M, Ourselin S, Fox NC, Alexander DC.  An event-based disease progression model and its application to familial Alzheimer’s disease. Inf Process Med Imaging 2011;22:748-759.
  • Fox NC, Ridgway GR, Schott JM.Algorithms, atrophy and Alzheimer’s disease. Cautionary tales for clinical trials. Neuroimage 2011;57:15-18.
  • Gao FQ, Swartz RH, Scheltens P, Leibovitch FS, Kiss A, Honjo K, Black SE. Complexity of MRI white matter hyperintensity assessments in relation to cognition in aging and dementia from the sunnybrook dementia study. J Alzheimers Dis 2011;26:379-388.
  • Goos JDC, van der Flier WM, Knol DL, Pouwels PJW, Scheltens P, Barkhof F, Wattjes MP. Clinical Relevance of Improved Microbleed Detection by Susceptibility-Weighted Magnetic Resonance Imaging. Stroke 2011;42:1894-1900.
  • Gouw AA, Seewann A, van der Flier WM, Barkhof F, Rozemuller AM, Scheltens P, Geurts JJG. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 2011;82:126-135.
  • Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, K B, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B, for the Oxford Task Force Group. Biomarkers for Alzheimer’s disease therapeutic trials. Prog Neurobiol 2011;95:579-593.
  • van Harten AC, Kester MI, Visser PJ, Blankenstein MA, Pijnenburg YAL, van der Flier WM, Scheltens P. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med 2011;49:353-366.
  • Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC,  et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 2011;43:429-436.
  • Jack CR Jr, Barkhof F, Bernstein MA, Cantillon M, Cole PE, Decarli C, Dubois B, Duchesne S, Fox NC, Frisoni GB, Hampel H, Hill DL, Johnson K, Mangin JF, Scheltens P, Schwarz AJ, Sperling R, Suhy J, Thompson PM, Weiner M, Foster NL. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease. Alzheimers Dement 2011;7:474-485.
  • Jansen C, Parchi P, Jelles B, Gouw AA, Beunders G, van Spaendonk RML, van de Kamp JM, Lemstra AW, Capellari S, Rozemuller AJM. The first case of fatal familial insomnia (FFI) in the Netherlands: a patient from Egyptian descent with concurrent 4 repeat tau deposits.  Neuropathol Appl Neurobiol 2011;37:549-553.
  • Jokinen H, Gouw AA, Madureira S, Ylikoski R, van Straaten ECW, van der Flier WM, Barkhof F, Scheltens P, Fazekas F, Schmidt R, Verdelho A, Ferro JM, Pantoni L, Inzitari D, Erkinjuntti T, On behalf of the LADIS Study Group. Incident lacunes influence cognitive decline: The LADIS study. Neurology 2011;76:1872-1878.
  • de Jong-Hagelstein M, van de Sandt-Koenderman WME, Prins ND, Dippel DWJ, Koudstaal PJ, Visch-Brink EG. Efficacy of early cognitive-linguistic treatment and communicative treatment in aphasia after stroke: a randomised controlled trial (RATS-2). J Neurol Neurosurg Psychiatry 2011;82:399-404.
  • Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Twisk JWR, Swinkels SHN, Scheltens P. Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer’s disease: secondary analyses from a randomized, controlled trial. J Nutr Health Aging 2011;15:672-676.
  • Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Twisk JWR, Swinkels SHN, Scheltens P. Efficacy of a medical food on cognition in Alzheimer’s disease: results from secondary analyses of a randomized, controlled trial. J Nutr Health Aging 2011;15:720-724.
  • Kester MI, Verwey NA, van Elk EJ, Blankenstein MA, Scheltens P, van der Flier WM. Progression from MCI to AD: Predictive value of CSF Abeta42 is modified by APOE genotype. Neurobiol Aging 2011;32:1372-1378.
  • Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ, for the Alzheimer’s Disease Neuroimaging Initiative. (waaronder o.a. Fox N.) Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 2011;76:69-79.
  • Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodríguez Martinez de Llano S, Edison P, Douglas J, Fox NC, Brooks DJ, Rossor MN. Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain 2011;134:293-300.
  • Koedam ELGE, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YAL, Fox N, Barkhof F, Wattjes MP. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 2011;21:2618-2625.
  • Lashley T, Rohrer JD, Bandopadhyay R, Fry C, Ahmed Z, Isaacs AM, Brelstaff JH, Borroni B, Warren JD, Troakes C, King A, Al-Saraj S, Newcombe J, Quinn N, Ostergaard K, Schøder HD, Bojsen-Møller M, Braendgaard H, Fox NC, Rossor MN, Lees AJ, Holton JL, Revesz T. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain 2011;134:2548-2564.
  • Lehmann M, Barnes J, Ridgway GR, Wattam-Bell J, Warrington EK, Fox NC, Crutch SJ.  Basic visual function and cortical thickness patterns in posterior cortical atrophy. Cereb Cortex 2011;21:2122-2132.
  • Lehmann M, Crutch SJ, Ridgway GR, Ridha BH, Barnes J, Warrington EK, Rossor MN, Fox NC. Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer’s disease. Neurobiol Aging 2011;32:1466-1476.
  • Leung KK, Barnes J, Modat M, Ridgway GR, Bartlett JW, Fox NC, Ourselin S, and the Alzheimer’s Disease Neuroimaging Initiative. Brain MAPS: An automated, accurate and robust brain extraction technique using a template library. Neuroimage 2011;55:1091-1108.
  • McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement 2011;7:263-269.
  • Mahoney CJ, Rohrer JD, Goll JC, Fox NC, Rossor MN, Warren JD. Structural neuroanatomy of tinnitus and hyperacusis in semantic dementia. J Neurol Neurosurg Psychiatry 2011;82:1274-1278.
  • Maruta C, Guerreiro M, de Mendonça A, Hort J, Scheltens P. The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia. Eur J Neurol 2011;18:279-286.
  • Norberg J, Graff C, Almkvist O, Ewers M, Frisoni GB, Frölich L, Hampel H, Jones RW, Kehoe PG, Lenoir H, Minthon L, Nobili F, Olde Rikkert M, Rigaud A-S, Scheltens P, Soininen H, Spiru L, Tsolaki M, Wahlund L-O, Vellas B, Wilcock G, Elias-Sonnenschein LS, Verhey FRJ, Visser PJ. Regional differences in effects of APOE ε4 on cognitive impairment in non-demented subjects. Dement Geriatr Cogn Disord 2011;32:135-142.
  • O’Brien J, Scheltens P. Clinical use of neuroimaging in dementia: an international perspective. Int Psychogeriatr 2011;23(suppl 2):S3-S5.
  • Ossenkoppele R, Tolboom N, Pijnenburg YA, Lammertsma AA, Scheltens P, van Berckel BNM.  Afbeelden van amyloïdplaques in de hersenen met PET. Ned Tijdschr Geneeskd 2011;155:A2981.
  • Ossenkoppele R, van Berckel BNM, Tolboom N, PijnenburgYA, Prins ND, Lemstra AW, Lammertsma AA, Scheltens Ph. Moleculaire beeldvorming bij de ziekte van Alzheimer. Tschr Neurol Neurochir 2011;112:201-208.
  • Ossenkoppele R, van Berckel BNM, Prins ND. Amyloid imaging in prodromal Alzheimer’s disease. Alzheimers Res Ther 2011;3(5):26.
  • Oudega ML, van Exel E, Wattjes MP, Comijs HC, Scheltens P, Barkhof F, Eikelenboom P, de Craen AJM, Beekman ATF, Stek ML. White matter hyperintensities, medial temporal lobe atrophy, cortical atrophy, and response to electroconvulsive therapy in severely depressed elderly patients.  J Clin Psychiatry 2011;72:104-112.
  • Pievani M, de Haan W, Wu T, Seeley WW, Frisoni GB. Functional network disruption in the degenerative dementias. Lancet Neurol 2011;10:829-843.
  • van de Pol L, Gertz H-J, Scheltens P, Wolf H. Hippocampal atrophy in subcortical vascular dementia. Neurodegener Dis 2011;8:465-469.
  • Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EGP, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain  2011;134:2456-2477.
  • Rohrer JD, Lashley T, Holton J, Revesz T, Urwin H, Isaacs AM, Fox NC, Rossor MN, Warren J. The clinical and neuroanatomical phenotype of FUS associated frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 2011;82:1405-1407.
  • Rohrer JD, Lashley T, Schott JM, Warren JE, Mead S, Isaacs AM, Beck J, Hardy J, de Silva R, Warrington E, Troakes C, Al-Sarraj S, King A, Borroni B, Clarkson MJ, Ourselin S, Holton JL, Fox NC, Revesz T, Rossor MN, Warren JD. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain 2011;134:2565-2581.
  • Ryberg C, Rostrup E, Paulson OB, Barkhof F, Scheltens P, van Straaten ECW, van der Flier WM, Fazekas F, Schmidt R, Ferro JM, Baezner H, Erkinjuntti T, Jokinen H, Wahlund L-O, Poggesi A, Pantoni L, Inzitari D, Waldemar G, and on behalf of the LADIS study group. Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: A 3-year follow-up of the LADIS study cohort. J Neurol Sci 2011;307:100-105.
  • Scheltens P, Rockwood K. How golden is the gold standard of neuropathology in dementia? Alzheimers Dement 2011;7:486-489.
  • Scher AI, Xu Y, Korf ESC, Hartley SW, Witter MP, Scheltens P, White LR, Thompson PM, Toga AW, Valentino DJ, Launer LJ. Hippocampal morphometry in population-based incident Alzheimer’s disease and vascular dementia: the HAAS. J Neurol Neurosurg Psychiatry 2011;82:373-377.
  • Scherder E, Eggermont L, Visscher C, Scheltens P, Swaab D. Understanding higher level gait disturbances in mild dementia in order to improve rehabilitation; ‘Last in – first out’. Neurosci Biobehav Rev 2011;35:699-714.
  • Schmidt R, Schmidt H, Haybaeck J, Loitfelder M, Weis S, Cavalieri M, Seiler S, Enzinger C, Ropele S, Erkinjuntti T, Pantoni L, Scheltens P, Fazekas F, Jellinger K. Heterogeneity in age-related white matter changes. Acta Neuropathol 2011;122:171-178.
  • Schott JM, Warren JD, Barkhof F, Rossor MN, Fox NC. Suspected early dementia. BMJ 2011;343:d5568:1-5.
  • Sikkes SAM, Knol DL, van den Berg MT, de Lange-de Klerk ESM, Scheltens P, Klein M, Pijnenburg YAL, Uitdehaag, BMJ. An informant questionnaire for detecting Alzheimer’s disease: are some items better than others? J Int Neuropsychol Soc 2011;17:674-681.
  • Sims R, Dwyer S, Harold D, Gerrish A, Hollingworth P, Chapman J, Jones N, Abraham R, Ivanov D, Pahwa JS, Moskvina V, Dowzell K, Thomas C, Stretton A, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuiness B, Todd S, Johnston JA, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Livingston G, Bass NJ, Gurling H, McQuillin A, Jones L, Holmans PA, O’Donovan M, Owen MJ, Williams J. No evidence that extended tracts of homozygosity are associated with Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 2011;156:764-771.
  • Smits LL, Liedorp M, Koene T, Roos-Reuling IEW, Lemstra AW, Scheltens P, Stam CJ, van der Flier WM. EEG abnormalities are associated with different cgnitive profiles in Alzheimer’s disease. Dement Geriatr Cogn Disord 2011;31:1-6.
  • Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement 2011;7:367-385.
  • Tabrizi SJ, Scahill RI, Durr A, Roos RAC, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC, and the TRACK-HD investigators. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10:31-421.
  • Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni GB, Weiner M, Schneider L, Gauthier S, Gispen-de Wied CC, Hendrix S, Feldman H, Cedarbaum J, Petersen R, Siemers E, Andrieu S, Prvulovic D, Touchon J, Hampel H. Prevention trials in Alzheimer’s disease: An EU-US task force report. Prog Neurobiol 2011;95:594-600.
  • Verdelho A, Madureira S, Moleiro C, Santos CO, Ferro JM, Erkinjuntti T, Poggesi A, Pantoni L, Fazekas F, Scheltens P, Waldemar G, Wallin A, Inzitari D, and on behalf of the LADIS study(waaronder Scheltens P, van Straaten I, Gouw A, van der Flier W, Visser M). Self-perceived memory complaints predict progression to Alzheimer disease. The LADIS study. J Alzheimers Dis  2011;27:491-498.
  • van Vliet D, de Vugt ME, Bakker C, Koopmans RTCM, Pijnenburg YAL, Vernooij-Dassen MJFJ, Verhey FR. Caregivers’ perspectives on the pre-diagnostic period in early onset dementia: a long and winding road. Int Psychogeriatr 2011;23:1393-1404.
  • de Waal H, Stam CJ, Blankenstein MA, Pijnenburg YAL, Scheltens P, van der Flier WM. EEG abnormalities in early and late onset Alzheimer’s disease: understanding heterogeneity. J Neurol Neurosurg Psychiatry 2011;82:67-71.
  • de Wilde MC, Kamphuis PJGH, Sijben JWC, Scheltens P. Utility of imaging for nutritional intervention studies in Alzheimer’s disease. Eur J Pharmacol 2011;668(suppl.1):S59-S69.
  • Witlox J, Kalisvaart KJ, de Jonghe JFM, Verwey NA, van Stijn MFM, Houdijk APJ, Traast HS, Maclullich AMJ, van Gool WA, Eikelenboom P. Cerebrospinal fluid β-amyloid and tau are not associated with risk of delirium: a prospective cohort study in older adults with hip fracture. J Am Geriatr Soc 2011;59:1260-1267.
  • Dröes, R.M., Van Mierlo, L.D., Meiland, F.J.M., Van der Roest, H.G. Memory problems in dementia: Adaptation and copingstrategies, and psychosocial treatments. Expert Reviews Neurotherapeutics, 2011,11(12)1769-1782.
  • De Boer ME, Dröes RM, Jonker C, Eefsting JA, Hertogh CMPM. Advance directives for euthanasia in dementia: how are they dealt with in Dutch nursing homes? Experiences of physicians and relatives.Journal of the American Geriatrics Society 2011;59(6):989-96.
  • Jansen APD, Van Hout HPJ, Nijpels G, Rijmen F, Dröes RM, Pot AM, Schellevis F, Van Marwijk HWJ, Stalman W. Effectiveness of case management among older adults with early symptoms of dementia and their primary informal caregivers: a randomised clinical trial. International Journal of Nursing Studies 2011 Aug;48(8):933-43.
  • Meiland FJM, Jonker C, Dröes RM. Predictors of effective support in meeting centers for people with dementia and their carers,Nonpharmacological therapies in dementia2010; 1(3):251-270.
  • Monfort JC, Villemur V, Lezy AM, Baron-Laforet S, Dröes RM. From paedophilia to gerontophilia. Lancet 2011; Vol. 377, Jan 22, 300. Van Mierlo LD, Meiland FJM, Dröes RM. Dementelcoach: effect of telephone coaching on carers of community dwelling people with dementia. Int Psychogeriatr. 2011 Oct 14:1-11.

Boek(hoofdstukken) en vakpublicaties:

  • Barkhof F, Fox NC, Bastos-Leite AJ, Scheltens Ph. Neuroimaging in dementia. New York, Springer, 2011. 278 pp.
  • van Exel E, Eikelenboom P, Comijs HC, Kurniawan C, Frölich M, Smit JH, Stek ML, Scheltens P, Eefsting JE, Westendorp  RGJ.  Het immuunsysteem en de ziekte van Alzheimer. Tijdschr Psychiatr 2011;53:637-643.
  • Hort J, O’Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P. Alzheimer’s disease. In: Gilhus NE, Barnes M, Brainin M (eds), European handbook of neurological management. Oxford, John Wiley-Blackwell Publishing, 2011:269-281.
  • Kerklaan BJ, Scheltens P, Schoonderwoerd GC, Killestein J, Rozemuller AJM, van der Knaap MS. ‘Adult polyglucosan body disease’: een weinig bekende maar herkenbare wittestofziekte. Tschr Neurol Neurochir 2011;112:25-31.
  • Vos SJB, Visser PJ, Verhey FRJ. De rol van liquormarkers bij de vroege diagnostiek van de ziekte van Alzheimer. Tijdschr Psychiatr 2011;53:647-653.
  • Dijk M van, Weert J van, Dröes RM. De Veder methode. Contact maken door middel van theater. Denkbeeld; Tijdschrift voor Psychogeriatrie, 23, 2011, 2-5.
  • Mierlo L, Dröes RM. Dementelcoach; telefonische ondersteuning voor mantelzorgers van mensen met dementie. Vita Valley, Nieuwsbrief, juli 2011.

Dissertaties:

  • Kester, MI. Biomarkers for Alzheimer’s pathology; monitoring, predicting and understanding the disease.
    Vrije Universiteit Amsterdam 14 januari 2011
    promotoren: Ph Scheltens, MA Blankenstein, copromotor: WM van der Flier
  • Mulder SD. Amyloid associated proteins in Alzheimer’s disease.
    Vrije Universiteit Amsterdam 7 oktober 2011
    promotoren: MA Blankenstein. Ph Scheltens, copromotor: R Veerhuis
  • Sikkes SAM. Measuring IADL in dementia.
    Vrije Universiteit Amsterdam 14 oktober 2011.
    promotoren: Ph Scheltens, BMJ Uitdehaag, copromotoren: YAL Pijnenburg, ESM de Lange-de Klerk
  • Sluimer JD. Visualizing the shrinking brain: longitudinal MR studies in the spectrum of cognitive decline.
    Vrije Universiteit Amsterdam 28 april 2011.
    promotoren: F Barkhof, Ph Scheltens, copromotoren: WM van der Flier, H. Vrenken
  • Van der Roest HG. Care needs in dementia and digital interactive information provisioning.
    Vrije Universiteit Amsterdam 12 oktober 2009
    Promotoren: RM Dröes, C Jonker, copromotoren: FJ Meiland, P. Scheltens

Publicaties 2010

Internationale wetenschappelijk publicaties (peer reviewed):

  • Archer HA, Kennedy J, Barnes J, Pepple T, Boyes R, Randlesome K, Clegg S, Leung KK, Ourselin S, Frost C, Rossor MN, Fox NC. Memory complaints and increased rates of brain atrophy: risk factors for mild cognitive impairment and Alzheimer’s disease. Int J Geriatr Psychiatry 2010;25:1119-1126.
  • Babiloni C, Visser PJ, Frisoni G, De Deyn PP, Bresciani L, Jelic V, Nagels G, Rodriguez G, Rossini PM, Vecchio F, Colombo D, Verhey F, Wahlund L-O, Nobili F. Cortical sources of resting EEG rhythms in mild cognitive impairment and subjective memory complaint. Neurobiol Aging 2010;31:1787-1798.
  • Barnes J, Mitchell LA, Kennedy J, Bastos-Leite AJ, Barker S, Lehmann M, Nordstrom RC, Frost C, Smith JR, Garde E, Rossor MN, Fox NC. Does registration of serial MRI improve diagnosis of dementia? Neuroradiology 2010;52:987-995.
  • Barnes J, Ridgway GR, Bartlett J, Henley SMD, Lehmann M, Hobbs N, Clarkson MJ, Macmanus DG, Ourselin S, Fox NC.  Head size, age and gender adjustment in MRI studies: A necessary nuisance?  Neuroimage 2010;53:1244-1255.
  • Bird CM, Chan D, Hartley T, Pijnenburg YA, Rossor MN, Burgess N. Topographical short-term memory differentiates Alzheimer’s disease from frontotemporal lobar degeneration. Hippocampus 2010;20:1154-1169.
  • Bour AMJJ, Rasquin SMC, Baars L, van Boxtel MPJ, Visser PJ, Limburg M, Verhey FRJ. The effect of the APOE-ε4 allele and ACE-I/D polymorphism on cognition during a two-year follow-up in first-ever stroke patients. Dement Geriatr Cogn Disord 2010;29:534-542.
  • Bouwman FH, Verwey NA, Klein M, Kok A, Blankenstein MA, Sluimer JD, Barkhof F,van der Flier WM, Scheltens P. New research criteria for the diagnosis of Alzheimer’s disease applied in a memory clinic population.  Dement Geriatr Cogn Disord 2010;30:1-7.
  • Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, Jack CR Jr, Weiner M, DeCarli C, for the Alzheimer’s Disease Neuroimaging Initiative.(waaronder Visser PJ)Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol 2010;67:1370-1378.
  • Chouliaras L, Rutten BPF, Kenis G, Peerbooms O, Visser PJ, Verhey F, van Os J, Steinbusch HWM, van den Hove DLA. Epigenetic regulation in the pathophysiology of Alzheimer’s disease. Prog Neurobiol 2010;90:498-510.
  • Clarkson MJ, Malone IB, Modat M, Leung KK, Ryan N, Alexander DC, Fox NC, Ourselin S. A framework for using diffusion weighted imaging to improve cortical parcellation. Med Image Comput Comput Assist Interv. 2010;13:534-541.
  • Delaloye C, Moy G, de Bilbao F, Baudois S, Weber K, Hofer F, Paquier CR, Donati A, Canuto A, Giardini U, von Gunten A, Stancu RI, Lazeyras F, Millet P, Scheltens P, Giannakopoulos P, Gold G. Neuroanatomical and neuropsychological features of elderly euthymic depressed patients with early- and late-onset. J Neurol Sci 2010;299:19-23.
  • Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 2010;9:1118-1127.
  • Evans MC, Barnes J, Nielsen C, Kim LG, Clegg SL, Blair M, Leung KK, Douiri A, Boyes RG, Ourselin S, Fox NC, and the Alzheimer’s Disease Neuroimaging Initiative.  Volume changes in Alzheimer’s disease and mild cognitive impairment: cognitive associations. Eur Radiol 2010;20:674-682.
  • Exalto LG, van der Flier WM, Scheltens P, Biessels GJ. Glycemia and levels of cerebrospinal fluid amyloid and tau in patients attending a memory clinic.  J Am Geriatr Soc 2010;58:1318-1321.
  • Fox N. Clinical advances in our understanding and classification of the dementias. J Neurol Neurosurg Psychiatry 2010;81(10):e3,006.
  • Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease.  Nat Rev Neurol 2010;6:67-77.
  • Goos JDC, Henneman WJP, Sluimer JD, Vrenken H, Sluimer IC, Barkhof F, Blankenstein MA, Scheltens PH, van der Flier WM. Incidence of cerebral microbleeds: A longitudinal study in a memory clinic population. Neurology 2010;74:1954-1960.
  • Gordon E, Rohrer JD, Kim LG, Omar R, Rossor MN, Fox NC, Warren JD. Measuring disease progression in frontotemporal lobar degeneration: a clinical and MRI study. Neurology 2010:74: 666-673.
  • Guerreiro RJ, Beck J, Gibbs JR, Santana I, Rossor MN, Schott JM, Nalls MA, Ribeiro H, Santiago B, Fox NC, Oliveira C, Collinge J, Mead S, Singleton A, Hardy J.  Genetic variability inCLU and its association with Alzheimer’s disease.  PLoS One 2010;5(3):e9510.
  • Henley SMD, Ridgway GR, Scahill RI, Klöppel S, Tabrizi SJ, Fox NC, Kassubek J, for the EHDN Imaging Working Group. Pitfalls in the Use of Voxel-Based Morphometry as a Biomarker: Examples from Huntington Disease. AJNR Am J Neuroradiol 2010;31:711-719.
  • Hobbs NZ, Barnes J, Frost C, Henley SMD, Wild EJ, Macdonald K, Barker RA, Scahill RI, Fox NC, Tabrizi SJ. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. AJNR Am J Neuroradiol 2010;31:1036-1041.
  • Hobbs NZ, Henley SMD, Ridgway G, Wild EJ, Barker R, Scahill RI, Barnes J, Fox NC, Tabrizi SJ. The progression of regional atrophy in premanifest and early Huntington’s disease: a longitudinal voxel-based morphometry study. J Neurol Neurosurg Psychiatry 2010;81:756-763.
  • Hort J, O’Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P, on Behalf of the EFNS Scientist Panel on Dementia. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol 2010;17:1236-1248.
  • Hort J, Bartos A, Pirttilä T, Scheltens P. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe.  Eur J Neurol 2010;17:90-96.
  • Hyare H, Wroe S, Siddique D, Webb T, Fox NC, Stevens J, Collinge J, Yousry T, Thornton JS. Brain-water diffusion coefficients reflect the severity of inherited prion disease. Neurology 2010;74:658-665.
  • Jack CR Jr, Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, Schuff N, Krueger G, Killiany RJ, DeCarli CS, Dale AM, Carmichael OW, Tosun D, Weiner MW and the Alzheimer’s Disease Neuroimaging Initiative.  Update on the magnetic resonance imaging core of the Alzheimer’s disease neuroimaging initiative.  Alzheimers Dement 2010;6:212-220.
  • Joling KJ, van Hout HPJ, Schellevis FG, van der Horst HE, Scheltens P, Knol DL, van Marwijk HWJ. Incidence of depression and anxiety in the spouses of patients with dementia: a naturalistic cohort study of recorded morbidity with a 6-year follow-up. Am J Geriatr Psychiatry 2010;18:146-153.
  • Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, Gerrish A, Pahwa JS, Jones N, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Mead S, Fox N, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS One 2010;5(11):e13950.
  • Jonsson M, Zetterberg H, van Straaten E, Lind K, Syversen S, Edman A, Blennow K, Rosengren L, Pantoni L, Inzitari D, Wallin A. Cerebrospinal fluid biomarkers of white matter lesions – cross-sectional results from the LADIS study. Eur J Neurol 2010;17:377-382.
  • Kamphuis PJGH, Scheltens P. Can nutrients prevent or delay onset of Alzheimer’s disease? J Alzheimers Dis 2010;20:765-775.
  • Keihaninejad S, Heckemann RA, Fagiolo G, Symms MR, Hajnal JV, Hammers A, Alzheimer’s Disease Neuroimaging Initiative.(waaronder Fox NC) A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T). Neuroimage 2010;50:1427-1437.
  • Kester MI, Boelaarts L, Bouwman FH, Vogels RL, Groot ER, van Elk EJ, Blankenstein MA, van der Flier WM, Scheltens P. Diagnostic impact of CSF biomarkers in a local hospital memory clinic. Dement Geriatr Cogn Disord 2010;29:491-497.
  • Kester MI, Verwey NA, van Elk EJ, Scheltens P, Blankenstein MA. Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment. Neurobiol Aging 2010;31:539-540.
  • Kester MI, van der Flier WM, Mandic G, Blankenstein MA, Scheltens P, Muller M. Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer’s disease.
  • J Alzheimers Dis 2010;20:1083-1090.
  • Keihaninejad S, Heckemann RA, Fagiolo G, Symms MR, Hajnal JV, Hammers A, Alzheimer’s Disease Neuroimaging Initiative (waaronder Fox N). A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T). Neuroimage 2010;50:1427-1437.
  • Koedam ELGE, Van der Flier WM, Barkhof F, Koene T, Scheltens P, Pijnenburg YAL. Clinical characteristics of patients with frontotemporal dementia with and without lobar atrophy on MRI. Alzheimer Dis Assoc Disord 2010;24:242-247.
  • Koedam ELGE, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YAL. Early- versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis 2010;19:1401-1408.
  • Lehmann M, Douiri A, Kim LG, Modat M, Chan D, Ourselin S, Barnes J, Fox NC. Atrophy patterns in Alzheimer’s disease and semantic dementia: A comparison of FreeSurfer and manual volumetric measurements. Neuroimage 2010;49:2264-2274.
  • Lehmann M, Rohrer JD, Clarkson MJ, Ridgway GR, Scahill RI, Modat M, Warren JD, Ourselin S, Barnes J, Rossor MN, Fox NC. Reduced cortical thickness in the posterior cingulate gyrus is characteristic of both typical and atypical Alzheimer’s disease. J Alzheimers Dis 2010;20:587-598.
  • Leung KK, Barnes J, Ridgway GR, Bartlett JW, Clarkson MJ, Macdonald K, Schuff N, Fox NC, Ourselin S, and  the Alzheimer’s Disease Neuroimaging Initiative. Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer’s disease.  Neuroimage 2010;51:1345-1359.
  • Leung KK, Shen KK, Barnes J, Ridgway GR, Clarkson MJ, Fripp J, Salvado O, Meriaudeau F, Fox NC, Bourgeat P, Ourselin S, Increasing power to predict mild cognitive impairment conversion to Alzheimer’s disease using hippocampal atrophy rate and statistical shape models. Med Image Comput Comput Assist Interv. 2010;13:125-132.
  • Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack CR Jr, Weiner MW, Fox NC, Ourselin S, and the Alzheimer’s Disease Neuroimaging Initiative. Robust atrophy rate measurement in Alzheimer’s disease using multi-site serial MRI: tissue-specifi c intensity normalisation and parameter selection.  Neuroimage 2010;50:516-523.
  • Liedorp M, Stam CJ, van der Flier WM, Pijnenburg YAL, Scheltens Ph. Prevalence and clinical significance of epileptiform EEG discharges in a large memory clinic cohort. Dement Geriatr Cogn Disord 2010;29:432-437.
  • Madureira S, Verdelho A, Moleiro C, Ferro JM, Erkinjuntti T, Jokinen H, Pantoni L, Fazekas F, van der Flier W, Visser M, Waldemar G, Wallin A, Hennerici M, Inzitari D. Neuropsychological predictors of dementia in a three-year follow-up period: data from the LADIS study. Dement Geriatr Cogn Disord 2010;29:325-334.
  • Mihaescu R, Detmar SB, Cornel MC, van der Flier WM, Heutink P, Hol EM, Olde Rikkert MGM, van Duijn CM, Janssens ACJW. Translational research in genomics of Alzheimer’s disease: a review of current practice and future perspectives. J Alzheimers Dis 2010;20:967-980.
  • Modat M, Ridgway GR, Taylor ZA, Lehmann M, Barnes J, Hawkes DJ, Fox NC, Ourselin S. Fast free-form deformation using graphics processing units.
  • Comput Methods Programs Biomed 2010;98:278-184.
  • Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, Scheltens P, Blankenstein MA. Amyloid-β(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 2010;56:248-253.
  • Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, Hack CE, Veerhuis R. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. J Alzheimers Dis 2010;20:253-260.
  • Mulder SD, Hack CE, van der Flier WM, Scheltens P, Blankenstein MA, Veerhuis R. Evaluation of intrathecal serum amyloid P (SAP) and C-reactive protein (CRP) synthesis in Alzheimer’s disease with the use of index values. J Alzheimers Dis 2010;22:1073-1079.
  • Oosterman JM, Vogels RLC, van Harten B, Gouw AA, Poggesi A, Scheltens P, Kessels RPC, Scherder EJA. Assessing mental flexibility: neuroanatomical and neuropsychological correlates of the trail making test in elderly people. Clin Neuropsychol 2010;24:203-219.
  • Petzold A, Verwey NA, van Uffelen K, Blankenstein MA, Teunissen C. Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration. J Neurosci Methods 2010;193:296-299.
  • Petzold A, Chapman MD, Schraen S, Verwey NA, Pasquier F, Bombois S, Brettschneider J, Fox NC, von Arnim CAF, Teunissen C, Pijnenburg Y, Riepe MW, Otto M, Tumani H, Scheltens P, Buee L, Rosso MN. An unbiased, staged, multi-center, validation strategy for Alzheimer’s disease CSF tau levels. Exp Neurol 2010;223:432-438.
  • Polvikoski TM, van Straaten ECW, Barkhof F, Sulkava R, Aronen HJ, Niinistö L, Oinas M, Scheltens P, Erkinjuntti T, Kalaria RN. Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. Neurology 2010;75:2071-2078.
  • Prins ND, van Swieten JC. Alzheimer disease: MRI and CSF biomarkers in AD-accuracy and temporal change. Nat Rev Neurol 2010:6:650-651.
  • Prins ND, Visser PJ, Scheltens P. Can novel therapeutics halt the amyloid cascade? Alzheimers Res Ther 2010;2(2):5.
  • Ramakers IHGB, Visser PJ, Aalten P, Kester A, Jolles J, Verhey FRJ. Affective symptoms as predictors of Alzheimer’s disease in subjects with mild cognitive impairment: a 10-year follow-up study.  Psychol Med 2010;40:1193-1201.
  • Ramakers IHGB, Visser PJ, Aalten P, Maes HL, Lansdaal HGM, Meijs CJC, Jolles J, Verhey FR. The predictive value of memory strategies for Alzheimer’s disease in subjects with mild cognitive impairment. Arch Clin Neuropsychol 2010;25:71-77.
  • Reesink FE, Lemstra AW, van Dijk KD, Berendse HW, van de Berg WDJ, Klein M, Blankenstein MA, Scheltens P, Verbeek MM, van der Flier WM. CSF α-synuclein does not discriminate dementia with lewy bodies from Alzheimer’s disease. J Alzheimers Dis 2010;22:87-95.
  • Richard E, Gouw AA, Scheltens P, van Gool WA. Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI. The evaluation of vascular care in Alzheimer’s disease (EVA) study. Stroke 2010;41:554-556.
  • Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, de Liano SR, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-372.
  • Rohrer JD, Ridgway GR, Modat M, Ourselin S, Mead S, Fox NC, Rossor MN, Warren JD. Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. Neuroimage 2010;53:1070-1076.
  • Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. Lancet Neurol 2010;9:793-806.
  • van Rossum IA, ten Houten R. Alledaagse symptomen als uiting van MELAS. Ned Tijdschr Geneeskd 2010;154:A2168.
  • van Rossum IA, Vos S, Handels R, Visser PJ. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J Alzheimers Dis 2010;20:881-891.
  • Salloway SP, Black R, Sperling R, Fox N, Gilman S, Schenk D, Griundman Ml.  Reply from the authors: A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2010;74(24):2026-2027.
  • Sanz-Arigita EJ, Schoonheim MM, Damoiseaux JS, Rombouts SARB, Maris E, Barkhof F, Scheltens P, Stam CJ. Loss of ‘small-world’ networks in Alzheimer’s disease: graph analysis of FMRI resting-state functional connectivity. PLoS One 2010;5(11):e13788.
  • Scheltens P, Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM,  Wurtman RJ,  Wilkinson D, Twisk JWR, Kurz A. Efficacy of a medical food in mild Alzheimer’s disease: a randomized, controlled trial. Alzheimers Dement  2010;6:1-10
  • Schmidt R, Ropele S, Ferro J, Madureira S, Verdelho A, Petrovic K, Gouw A, van der Flier WM, Enzinger C, Pantoni L, Inzitari D, Erkinjuntti T, Scheltens P, Wahlund LO, Waldemar G, Rostrup E, Wallin A, Barkhof F, Fazekas F, on behalf of the LADIS study group. Diffusion-weighted imaging and cognition in the leukoariosis and disability in the elderly study.  Stroke 2010;41:e402-e408.
  • Schneider LS, Kennedy RE, Cutter GR, and the Alzheimer’s Disease Neuroimaging Initiative. (waaronder Fox N.)Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement 2010;6:367-377.
  • Schott JM, Bartlett JW, Fox NC, Barnes J, for the Alzheimer’s Disease Neuroimaging Initiative Investigators. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Ann Neurol 2010;68:825-834.
  • Schott JM, Bartlett JW, Barnes J, Leung KK, Ourselin S, Fox NC, for the Alzheimer’s Disease Neuroimaging Initiative Investigators. Reduced sample sizes for atrophy outcomes in Alzheimer’s disease trials: baseline adjustment. Neurobiol Aging 2010;31:1452-1462.
  • Schott JM, Frost C, Macmanus DG, Ibrahim F, Waldman AD, Fox NC. Short echo time proton magnetic resonance spectroscopy in Alzheimer’s disease: a longitudinal multiple time point study. Brain 2010;133:3315-3322.
  • Schuitemaker A, Dik MG, Veerhuis R, Scheltens P, Schoonenboom NSM, Hack CE, Blankenstein MA, Jonker C. Inflammatory markers in AD and MCI patients with different biomarker profiles-interpretation of serum and CSF levels. Neurobiol Aging 2010;31:1655.
  • Shen L, Kim S, Risacher SL, Nho K, Swaminathan S, West JD, Foroud T, Pankratz N, Moore JH, Sloan CD, Huentelman MJ, Craig DW, Dechairo BM, Potkin SG, Jack CR Jr, Weiner MW, Saykin AJ and the Alzheimer’s Disease Neuroimaging Initiative.( waaronder Fox N ). Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage 2010;53:1051-1063.
  • Sikkes SAM, van den Berg MT, Knol DL, de Lange-de Klerk ESM, Scheltens P, Uitdehaag BMJ, Klein M, Pijnenburg YAL. How useful Is the IQCODE for discriminating between Alzheimer’s disease, mild cognitive impairment and subjective memory complaints? Dement Geriatr Cogn Disord 2010;30:411-416.
  • Slats D, Spies PE, Sjögren MJC, Visser PJ, Verbeek MM, Rikkert MGM, Kehoe PG. CSF biomarker utilisation and ethical considerations of biomarker assisted diagnosis and research in dementia: perspectives from within the European Alzheimer’s Disease Consortium (EADC). J Neurol Neurosurg Psychiatry 2010;81:124-125.
  • Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, van der Flier WM, Scheltens P. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging 2010;31:758-764.
  • Smits LL, Liedorp M, Koene T, Roos-Reuling IEW, Lemstra AW, Scheltens P, Stam CJ, van der Flier WM. EEG abnormalities are associated with different cognitive profiles in Alzheimer’s disease. Dement Geriatr Cogn Disord 2010;31:1-6.
  • Staekenborg SS, Su T, van Straaten ECW, Lane R, Scheltens P, Barkhof F, van der Flier WM. Behavioural and psychological symptoms in vascular dementia; differences between small and large vessel disease. J Neurol Neurosurg Psychiatry 2010;81:547-551.
  • Staekenborg SS, de Waal H, Admiraal-Behloul F, Barkhof F, Reiber JHC, Scheltens P, Pijnenburg YAL, Vrenken H, van der Flier WM. Neurological signs in relation to white matter hyperintensity volumes in memory clinic patients.  Dement Geriatr Cogn Disord 2010;29:301-308.
  • Teodorczuk A, Firbank MJ, Pantoni L, Poggesi A, Erkinjuntti T, Wallin A, Wahlund L-O, Scheltens P, Waldemar G, Schrotter G, Ferro JM, Chabriat H, Bazner H, Visser M, Inzitari D, O’Brien JT, on behalf of the LADIS Group. Relationship between baseline white-matter changes and development of late-life depressive symptoms: 3-year results from the LADIS study. Psychol Med 2010;40:603-610.
  • Teunissen CE, Verwey NA, Kester MI, van Uffelen K, Blankenstein MA. Standardization of assay procedures for analysis of the CSF biomarkers amyloid β(1-42)), tau, and phosphorylated tau in Alzheimer’s disease: report of an International workshop.
  • Int J Alzheimers Dis 2010; Article ID 635053:1-6.
  • Tolboom N, Koedam ELGE, Schott JM, Yaqub M, Blankenstein MA, Barkhof F, Pijnenburg YAL, Lammertsma AA, Scheltens P, van Berckel BNM. Dementia mimicking Alzheimer’s disease owing to a tau mutation: CSF and PET findings.  Alzheimer Dis Assoc Disord 2010;24:303-307.
  • Tolboom N, van der Flier WM, Boverhoff J, Yaqub M, Wattjes MP, Raijmakers PG, Barkhof F, Scheltens P, Herholz K, Lammertsma AA, van Berckel BNM. Molecular imaging in the diagnosis of Alzheimer’s disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. J Neurol Neurosurg Psychiatry 2010;81:882-884.
  • Tsolaki M, Papaliagkas V, Anogianakis G, Bernabei R, Emre M, Frolich L, Visser PJ, Michel J-P, Pirttila T, Olde Rikkert M, Soininen H, Sobow T, Vellas B, Verhey F, Winblad B and the European Alzheimer’s Disease Consortium. Consensus statement on dementia education and training in Europe. J Nutr Health Aging 2010;14:131-135.
  • Verdelho A, Madureira S, Moleiro C, Ferro JM, Santos CO, Erkinjuntti T, Pantoni L, Fazekas F, Visser M, Waldemar G, Wallin A, Hennerici M, Inzitari D, on behalf of the LADIS Study. White matter changes and diabetes predict cognitive decline in the elderly: The LADIS Study. Neurology 2010;75:160-167.
  • Verwey NA, Kester MI, van der Flier WM, Veerhuis R, Berkhof H, Twaalfhoven H, Blankenstein MA, Scheltens P, Pijnenburg YAL. Additional value of CSF amyloid-β40 levels in the differentiation between FTLD and control subjects. J Alzheimers Dis 2010;20:445-452.
  • VITATOPS Trial Study Group (waaronder Eikelenboom JW, Koedam E). B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial.  Lancet Neurol 2010;9:855-865.
  • Vounou M, Nichols TE, Montana G and the  Alzheimer’s Disease Neuroimaging Initiative (waaronder Fox N). Discovering genetic associations with high-dimensional neuroimaging phenotypes: A sparse reduced-rank regression approach. Neuroimage 2010;53:1147-1159.
  • Wild EJ, Henley SMD, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi SJ. Rate and acceleration of whole-brain atrophy in premanifest and early Huntington’s disease. Mov Disord 2010;25:888-895.
  • Wolk DA, Dickerson BC and the Alzheimer’s Disease Neuroimaging Initiative, (waaronder Fox NC) Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer’s disease. Proc Natl Acad Sci U S A 2010;107:10256-10261.
  • Yaqub M, Tolboom N, van Berckel BNM, Scheltens P, Lammertsma AA, Boellaard R. Simplified parametric methods for [18F]FDDNP studies. Neuroimage 2010;49:433-441.
  • Boer ME de, Hertogh C.MPM, Dröes RM, Jonker C, Eefsting JA. Advance directives in dementia: issues on validity and effectiveness. International Psychogeriatrics, 2010 Mar;22(2):201-8.
  • Boer ME, Dröes RM, Jonker C, Eefsting JA, Hertogh CM. Advance directives for euthanasia in dementia: Do law-based opportunities lead to more euthanasia? Health Policy 2010;98:256-262.
  • Bouman AIE, Ettema TP, Wetzels RB, Beek APA. van, de Lange J, Dröes RM. Qualidem: Evaluation of a Dementia-specific Quality of Life Instrument for Persons with Dementia in residential settings; Scalability and Reliability of Subscales used in four Dutch Field Surveys. International Journal of Geriatric Psychiatry 2011 Jul;26(7):711-22.
  • Dröes RM. Mierlo LD van, Roest HG van der, Meiland FJM. Focus and effectiveness of psychosocial interventions for people with dementia in institutional care settings from the perspective of coping with the disease. Non-pharmacological therapies in dementia, 2010;1(2):139-161.
  • Meiland FJM, Reinersmann A, Sävenstedt S, Bergvall-Kåreborn B, Hettinga M, Craig D, Andersson AL, Dröes RM. User-participatory development of assistive technology for people with dementia – from needs to functional requirements. First results of the COGKNOW project. Non-pharmacological therapies in dementia 2010;1(1):71-91.
  • Roest HG van der, Meiland FJ, Jonker C, Dröes RM. User evaluation of the DEM-DISC. Aging and Mental Health, 2010;14(4):461-70.
  • Van Mierlo LD, Van der Roest HG, Meiland FJM, Dröes RM. Personalized Dementia Care; proven effectiveness of psychosocial interventions in subgroups. Ageing Res Rev. 2010 Apr;9(2):163-83.

Boek(hoofdstukken) en vakpublicaties:

  • Boss HM, van den Berg-Vos RM, Scheltens P, Weinstein HC.  Stand van zaken. Vasculaire cognitieve beperking.Ned Tijdschr Geneeskd 2010;154:A1907
  • Gouw, A.A. Proefschriftbespreking: Schade aan kleine hersenvaten op MRI: klinische uitingen en onderligende pathologie.  Tschr Neurol Neurochir 2010;111:180-182.
  • Keulen MA, Uijterwaal MH, Engels MAH, Koene T, Scheltens Ph, Pijnenburg YAL. Taaldiagnostiek bij patiënten met semantische dementie en progressieve niet-vloeiende afasie. Stem-,Spraak- en Taalpathologie 2010;16:239-254.
  • Lemstra E, Eikelenboom P, van Gool P. Cholinerge deficiëtie en cognitie.
  • In: van der Mast R, Heeren T, Kat M, et al. (red.), Handboek ouderen-psychiatrie; 3e dr. Utrecht, de Tijdstroom,2010:511-518.
  • Scheltens Ph. Nog steeds geen pil voor Alzheimer. Ned Tijdschr Geneeskd 2010;154:A1885.
  • Boer ME de, Dröes RM, Jonker C, Eefsting JA, Hertogh CMPM. De beleving van beginnende dementie en het gevreesde lijden. Tijdschrift voor Gerontologie en Geriatrie 2010; 41(5): 194-203.
  • Craig D, Meiland FJM, Passmore AP, Dröes RM. Prevalence and clinical features of dementia. In: Mulvenna MD, Nugent CD. (Eds.), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010, Chapter 2, 15-22.
  • Dröes RM. Omgaan met dementie het psychosociale perspectief. Tijdschrift voor Ouderen-geneeskunde, 2010, 35(5)197-199.
  • Dröes RM. Omgaan met dementie het psychosociale perspectief. Samenvatting oratie.  CaRe-bulletin CaRré, aug 2010.
  • Dröes RM, Bentvelzen SCL, Meiland F, Craig D. Dementia-related and other factors to be taken into account when developing ICT-support for people with dementia – Lessons from field trials, In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 8, 113-130.
  • Gerritsen DL, Dröes RM, Ettema TP, Boelens E, Bos J, Meihuizen L, de Lange J, Schölzel-Dorenbos CJ, Hoogeveen F. Quality of life in dementia, opinions among people with dementia, their professional caregivers, and in literature. Tijdschr Gerontol Geriatr. 2010 Dec;41(6):241-55.
  • Lauriks S, Reinersmann A, Roest H.G. van der, Meiland FJM, Davies RJ, Moelaert F, Mulvenna MD, Nugent CD, Dröes RM. Review of ICT-based services for identified unmet needs in people with dementia, In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 4, 37-62.
  • Martin S, Bengtsson JE, Dröes RM. Assistive technologies and issues relating to privacy, ethics and security. In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 5, 63-78.
  • Meiland F, Dröes RM, Sävenstedt S, Bergvall-Kåreborn B, Andersson AL. Identifying User Needs and the Participative Design Process, In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 6, 79-100.
  • Meiland F, Dröes RM, Sävenstedt S. Measuring the impact of Cognitive Prosthetics on the daily life of people with dementia and their carers In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 14, 207-220.
  • Mierlo L. & Dröes RM. Dementelcoach; telefonische ondersteuning voor mantelzorgers van mensen met dementie. Vita Valley, Nieuwsbrief, juli 2011.
  • Mulvenna MD, Nugent C, Moelaert F, Craig D, Dröes RM, Bengtsson J. Supporting People with Dementia Using Pervasive Healthcare Technologies, In: Mulvenna MD, Nugent, CD. (Eds.), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 1, 3-14.
  • Mulvenna MD, Moelaert F, Meiland F, Sävenstedt S, Hettinga M, Craig D, Bengtsson JE, Dröes RM, Martin S. Designing and Evaluating a Cognitive Prosthetic for People with Mild Dementia. In: Brinkman WP, Neerincx M, (Eds), Caring Technology for the Future: Proceedings of the European Conference on Cognitive Ergonomics, 389 pp, Mediamatica, 2010;11-18.
  • Roest HG van der, Meiland FJM, Dröes RM. Proefschrift: Zorgbehoeften bij dementie en digitale, gepersonaliseerde informatievoorziening voor dementiezorg. Verpleegkunde 2010;(3):25-31
  • Sävenstedt S, Meiland F, Dröes RM, Moelaert F. Evaluation of Cognitive Prosthetics In: Mulvenna MD, Nugent CD. (Eds.), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag 2010, Chapter 13, 197-206.

Dissertaties:

  • Altena E. Mapping insomnia: brain structure, function and sleep intervention.
  • Vrije Universiteit Amsterdam 17 maart 2010
  • promotoren: EJW van Someren, DF Swaab, copromotoren: YD van der Werf, Ph Scheltens
  • Tolboom N. Imaging Alzheimer’s disease pathology in vivo: towards an early diagnosis.
  • Vrije Universiteit Amsterdam 12 februari 2010
  • promotoren: Ph Scheltens, AA Lammertsma. copromotoren: BNM van Berckel, WM van der Flier
  • Verwey NA. Biochemical markers in dementia: from mice to men.
  • Vrije Universiteit Amsterdam 16 april 2010
  • promotoren: Ph Scheltens, MA Blankenstein. copromotoren: WM van der Flier, R Veerhuis
Top
Volg ons via